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ABSTRACT 
Snake venom is a critical evolutionary innovation enabling venomous snakes to 
become successful limbless predators; it is therefore vital that snakes possess a 
highly efficient venom production system to maintain their predatory arsenal. The 
dynamics of venom synthesis and the regulatory mechanisms by which the 
expression of venom protein-encoding genes is controlled are little understood. The 
overarching aim of the work described in this thesis was to investigate the dynamics 
of venom synthesis in terms of the production of venom in juvenile snakes from birth 
and in the immediate replenishment of depleted venom stores using the African Puff 
Adder (Bitis arietans) as a model viperid species. We also aimed to investigate the 
underlying control mechanisms which regulate venom production 
Initial studies revealed a remarkable degree of intra-species variation in the protein 
profile, immunoreactivity and enzyme activity of venom between B. arietans 
specimens originating from different geographical origins across sub-Saharan Africa 
and Arabia, and within the same geographical origin. Variation was most evident in 
the snake venom metalloproteinases (SVMPs); toxins with a primary role in the 
haemorrhagic and tissue-necrotic pathologies suffered by envenomed victims. Our 
findings are of therapeutic importance as observations could translate into variations 
in the clinical manifestation of B. arietans envenoming and affect the patient 
response to antivenom treatment. 
To monitor the synthesis of venom proteins, we exploited the unusual stability of 
messenger RNA in lyophilised snake venoms as an alternative source of 
transcriptionally active mRNA to venom gland tissues, thus avoiding the requirement 
to sacrifice specimens for transcriptome analysis. Our optimised approach was used 
to quantitatively track changes in expression of venom protein-encoding genes. Our 
results showed that the gene expression, protein composition and functional activity 
of juvenile B. arietans venom did not appear to significantly change over time from 
birth to four years indicating that some aspects of venom are genetically hard-coded. 
We also showed that venom resynthesis triggered by venom expulsion peaked 
between days 3-7 following depletion of venom, with different protein families 
expressed in parallel. It appeared that venom production in both adult and juvenile 
specimens occurs very rapidly, presumably to ensure that venomous snakes retain 
their ability to efficiently predate and remain defended from predators.  
Our findings suggest that highly regulated mechanisms may be in place to ensure the 
rapid synthesis of venom. As it appeared that different venom protein families shared 
similar expression levels during venom replenishment, we investigated whether 
venom genes also showed similarities in their genomic location, organisation and 
structure, and regulatory elements responsible for controlling expression levels. We 
have taken the first steps to begin to investigate the genomic structure and 
organisation of genes encoding venom protein families expressed in B. arietans 
venom. 
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1. INTRODUCTION 
This PhD project aimed to explore and understand how the toxic array of proteins in 
snake venom are synthesised and regulated by the venom production system of 
venomous snakes. It is clearly important that this work is viewed in the context of 
our current knowledge of snakes and the biology of their venoms. The purpose of 
this introduction is to outline the taxonomy, medical importance, 
distribution/diversity of venomous snakes, evolution of the venom toxic arsenal, 
venom gland delivery system, structure/function of venom proteins, venom 
synthesis, the venom glandular microenvironment, the approaches used to analyse 
venom composition, reports of variation in venom composition and the aims of this 
work. 
 
1.1. Taxonomy and global distribution of venomous snakes 
The Serpentes (Ophidia) comprises approximately 2,800 snake species, categorised 
into three superfamilies and 16-20 families (O'Shea, 2005). All venomous snakes 
(advanced snakes) belong to the Colubroidea (or Caenophidia) superfamily. The 
Colubroidea has been traditionally subdivided into four families; Colubridae, 
Atractaspididae, Elapidae and Viperidae. The Colubridae are the largest and diverse 
family containing around 1,700 species distributed worldwide and the classification 
of this group is subsequently undergoing continual evaluation. The colubrids do not 
naturally form a monophyletic group, as many species are more closely related to 
other groups, such as elapids, than to each other (Lawson et al., 2005). While many 
are considered non-venomous, some colubrids such as the African Boomslang 
(Dispholidus typus) which produces hemotoxic venom, are medically important to 
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humans. The Atractaspididae contain around 30 species which are distributed across 
Africa and Arabia. Although venomous, atractaspidids (e.g. burrowing asps) are not 
associated with causing a significant number of human fatalities primarily due to 
their small size. The Elapidae consists of around 351 species which are widely 
distributed across the Americas, Africa, the Middle East, Asia and Australasia. There 
are two recognized sub-families; the Elapinae (coral snakes, cobras, mambas and 
kraits) and the Hydrophiinae (sea snakes). The elapids are front-fanged snakes, most 
of which produce highly potent neurotoxic venom, and are of significant medical 
importance to humans. The Viperidae contains around 311 species and have a 
worldwide distribution (except Australasia), occupying a range of terrestrial habitats 
across the Americas, Africa, Europe and Asia. The Viperidae contains two main sub-
families; the Viperinae (pit-less vipers e.g. Bitis, Cerastes, Echis and Vipera genera) 
and the Crotalinae (pitvipers e.g. Agkistrodon, Bothrops and Crotalus genera). 
Viperids are also front-fanged snakes capable of producing highly potent hemotoxic 
venom and are responsible for a significant number or human fatalities worldwide 
(O'Shea, 2005). 
 
1.2. Medical importance of snakebite 
Envenoming following snakebite is largely a neglected threat to public health, yet 
causes considerable morbidity and mortality throughout the world. There are up to 
1.8 million incidences of snakebite worldwide per year leading to up to 94,000 
deaths, the majority of which occur in sub-Saharan Africa, South and Southeast Asia 
and Latin America (Kasturiratne et al., 2008). In Africa, a recent meta-analytical 
survey indicated that 95% of snakebites and 97% of deaths caused by snakebite 
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Figure 1.1 Global medical importance of snakebite: The global distribution of the 
annual estimates of snakebite-induced deaths. Darker colours denote the highest 
numbers of snakebite mortality (Kasturiratne et al., 2008). 
occurred in rural environments (Chippaux, 2011). Those most at risk of 
death/morbidity from snakebite are subsistence farmers, agricultural workers and 
children, where the threat of snakebite is a daily occupational hazard and access to 
health services is poor. In addition to the risk of mortality, many victims of snakebite 
are also left with permanent disabilities and sequelae due to severe tissue necrosis. 
The morbidity of snakebite in Africa is reflected in the high incidence of amputations 
of the affected limb (5,900-14,600 per year) (Chippaux, 2011) demonstrating that 
snakebite may also have a considerable economic impact. A strong correlation 
between snakebite-induced mortality and poverty has been demonstrated through 
mapping the global distribution of snakebite with economic factors such as gross 
domestic product (GDP) and per capita government expenditure on health, 
illustrating that snakebite is a significant health issue of the rural poor (Figure 1.1) 
(Harrison et al., 2009). 
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Antivenom is the only effective treatment for snakebite. Antivenoms are produced by 
immunising animals (most commonly horses) with either a single venom to produce 
monospecific antivenoms, or a mixture of venoms to produce polyspecific 
antivenoms, with increasing doses over several months. The venom-neutralising 
antibodies (IgG) produced by the immunised animal are collected and purified, 
resulting in antivenom (Lalloo and Theakston, 2003). Although effective, safe and 
affordable antivenoms are available, the lack of a coordinated and constructive 
strategy for the delivery of antivenoms in the developing world has resulted in a 
global antivenom crisis (Williams et al., 2011). The Global Snakebite initiative is a 
worldwide, rational approach developed by toxinologists which aims to reduce the 
incidence of death and morbidity due to snakebite through a combination of 
community education, surveillance of snakebite, clinical research, medical 
management, rehabilitation and implementation of government health policies 
(Williams et al., 2010). In current research, there are several strategies which aim to 
improve the efficiency and specificity of antivenom treatment and to address the 
safety issues with some current antivenoms by improving the dose, purity and 
geographic/species efficacy of antivenom (Harrison et al., 2011). One strategy 
includes the use of IgGs from alternative venom-immunised animals (e.g. camelids). 
Camelid IgGs are less immunogenic and therefore lower the risk of activating 
complement, thus reducing the incidence of adverse effects and improving the safety 
of antivenom treatment (Herrera et al., 2005). Current research has provided 
encouraging support for the potential use of camelid IgG in antivenom production 
(Cook et al., 2010a, Cook et al., 2010b, Cook et al., 2010c). Another strategy 
involves the research into the design of toxin-specific epitopes, directed to target 
only venom components causing the most severe venom-induced pathologies and 
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thus improving the dose-efficacy of antivenom is also providing promising results 
(Wagstaff et al., 2006). In combination, these approaches aim to significantly 
improve the treatment and management of snakebite worldwide. 
 
1.3. Origin and evolution of the venom arsenal 
Venom delivery systems have evolved independently several times throughout 
nature, including in the Cnidaria (jellyfish and anemones) (Bloom et al., 1998), 
Gastropoda (cone snails) (Olivera et al., 2002), Hymenoptera (bees and wasps), 
Arachnida (spiders and scorpions) (Escoubas et al., 2006), Chordata (fish), Reptilia 
(snakes and lizards) (Fry et al., 2006) and Mammalia (platypus) (Whittington et al., 
2009). Arguably, one of the most sophisticated, diverse and efficient venom systems 
exist among the venomous snakes. 
The Colubroidea encompass around 80% of the ~2,900 species of snakes (Vidal et 
al., 2007). The Colubroids form a clade with the closely related Iguania and 
Anguimorphs, known collectively as the Toxicofera. Members of this group share a 
number of basal protein families that were recruited into the venom delivery system 
prior to the divergence of these lineages (Fry et al., 2009). Although evidence 
supports the presence of venom as a basal evolutionary characteristic in the 
Serpentes (Fry et al., 2006), it is currently thought that only ~450 venomous species 
of medical importance exist, which are found exclusively within the Colubroidea, 
thus, venomous dependency appears to have been lost over time. The families of 
venomous snakes which are the most medically important to humans are the 
Viperidae, Elapidae and to a lesser extent, the Atractaspididae, each of which 
represent an independent, monophyletic lineage within the Colubroidea.  
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Snake venom has evolved into a highly complex mixture of several hundred unique 
constituents including enzymatic and non-enzymatic proteins and peptides, 
carbohydrates, lipids, metal ions and organic compounds (Aird, 2002).While the 
composition and toxicity of venoms can vary widely between snake taxa, the primary 
evolutionary function of venom is to ensure the rapid and efficient immobilisation 
and killing of a diverse range of prey species (Kordiš et al., 2002). Venoms may also 
serve in a defensive role as a deterrent to predators/aggressors. 
Venom toxins have been recruited into the venom arsenal from normal, non-toxic 
physiological proteins by adaptive evolution (Fry, 2005). The rapid explosion of 
multiple gene duplication and diversification, selective expression in the venom 
gland and subsequent structural and functional divergence from non-toxin 
homologues has resulted in the formation of multi-isoform, multi-domain protein 
families in snake venoms (Fry, 2005, Fry et al., 2009). The first protein families 
recruited into a venomous role prior to the divergence of the Colubroidea include the 
cysteine-rich secretory proteins, hyaluronidase, kallikrein enzymes and nerve growth 
factor (Figure 1.2). Newly recruited toxin groups have evolved to form large, multi-
gene families via the ‘birth-and-death’ model (Fry et al., 2003). This involves the 
creation of gene families as a result of repeated gene duplication events and rapid 
structural and functional diversifications of genes to form evolutionarily related but 
functionally distinct genes; a key process in the process of adaptive evolution. Where 
some genes are retained in the genome, over time, other genes are subsequently 
deleted from the genome or become non-functional giving rise to pseudogenes (Nei 
et al., 1997).  
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Figure 1.2 Cladogram of evolutionary relationships of the Toxicofera showing 
the recruitment timing of different protein-scaffold types for use as toxins: Blue 
X shows independent evolution of hollow front-fanged, high-pressure venom 
delivery systems and red lines indicate a toxin recruitment event. 3FTX = three 
finger toxin, C3/CVF=ComplementC3/Cobra Venom Factor, CRISP=Cysteine-rich 
secretory protein, NGF=Nerve Growth Factor, SVMP = snake venom 
metalloproteinase, VEGF = vascular endothelial growth factor (Fry et al., 2009). 
  
Snake venom toxins are continually subjected to adaptive evolutionary pressures, 
resulting in the rapid evolutionary explosion of very diverse venoms. The distinct 
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Figure 1.3 The viper venom delivery system. 
substrate specificities and consequent diverse pathologies of venoms generate great 
interest in both biological and therapeutic research. 
 
1.4. The venom delivery apparatus 
          1.4.1. Morphological adaptations of venomous snakes 
The highly complex and functionally diverse mixture of proteins present in venom is 
synthesised by venom glands which are modified parotid glands with an elongated 
and specialised structure. Front-fanged venomous snakes (viperids, elapids and 
atractaspidids) possess a large post-orbital venom-producing apparatus lying along 
the upper jaw, whereas the venom glands of venomous lizards run along the lower 
jaw and glands along the upper jaw have been apparently lost. The venom delivery 
system of venomous snakes comprises of the specialised secretory glands, a toxic 
venom arsenal, compressor muscles, fangs and a predatory behaviour (Kardong, 
1980, Kochva, 1987, Jackson, 2003) (Figure 1.3).  
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In front-fanged venomous snakes, the venom gland apparatus is a highly pressurized, 
closed system which employs extremely efficient mechanisms to result in the rapid 
expulsion and injection of venom into the envenomed prey tissues. The venom gland 
structure consists of four discrete regions; the main glandular lumen, the accessory 
gland, the primary duct and the secondary duct. Venom is synthesised and stored in 
the main glandular lumen. During expulsion, venom is transported, via the ducts, 
from the lumen to the tubular fangs which inject venom into the envenomed prey. 
However, the structural features of glands can vary between different families of 
snakes (Kardong, 1980, Kochva, 1987, Weinstein et al., 2010). The Viperidae family 
possess the most morphologically specialised and efficient venom delivery systems 
of all venomous snakes. Figure 1.4 shows the detailed structure of the viperid venom 
glands. Viperid venom glands have a complex tubular structure with a highly folded 
glandular secretory epithelium divided into several ductules enabling maximal 
venom synthesis and storage (Jackson, 2003). Viper venom glands also have 
capacious glandular lumen enabling storage of significant volumes of venom 
resulting in the accumulation of potentially large quantities of venom that can be 
injected into the victim following snakebite. The glandular lumen is connected, via 
the primary duct, to the accessory gland, a separate region of the apparatus which 
may contribute to venom composition. The secondary duct connects the accessory 
gland to the fangs which inject the venom. Venom glands of elapid snakes share 
similarities to those of viperids but have a more simplified structure with a smaller 
lumen consisting of branching tubules converging into the accessory gland and 
primary/secondary ducts. The venom glands of atractaspidid snakes differ from those 
of both vipers and elapids in that their glands have an elongated, cylindrical structure 
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Figure 1.4 Fine structure of the viperid venom gland: Venom glandular structure 
showing compartmental sections and features of the glands including the secretory 
epithelium, main lumen, ducts and accessory gland. Figure adapted from Mackessey 
and Baxter (Mackessy and Baxter, 2006).  
with characteristic unbranched tubules and do not possess a distinct, discrete 
accessory gland (Kochva, 1987). 
 
 
 
 
 
 
          1.4.2. Fang dentition 
The dentition of fangs/teeth in non-venomous and venomous snakes varies greatly 
between different families of snakes (Jackson, 2002, Jackson, 2003, Jackson, 2007). 
Aglyphous snakes, such as pythons, are mostly non-venomous and have teeth lacking 
any specialisation (e.g. grooves). Opisthoglyphous snakes (Colubridae) are rear-
fanged snakes possessing rear-grooved elongate fangs at the back of the mouth. Most 
opisthoglyphous snakes are considered non-venomous or weakly venomous and 
therefore harmless to humans due to their inefficient venom delivery systems, with 
exceptions including the Boomslang (Dispholidus typus) which are capable of 
delivering haemotoxic venom following snakebite. Proteroglyphous snakes 
(Elapidae) are front-fanged snakes possessing deeply grooved fangs forming a 
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Figure 1.5 Fang dentition of venomous snake families: Variation in fang dentition 
of the most medically important front-fanged venomous snakes A) Viperidae and B) 
Elapidae in comparison to the rear-fanged Colubridae (C). (Photographs courtesy of 
Juan M. Renjifo).  
channel through which venom is directed. Proteroglyphous fangs are relatively short, 
and therefore elapids are required to maintain contact with their prey during injection 
of venom. Solenoglyphous snakes (Viperidae) are front-fanged snakes with hollow, 
tubular hyperextendable fangs resembling hypodermic needles. Solenoglyphs 
possess the most efficient venom delivery systems as the fangs are connected to a 
moveable maxillary bone allowing for maximal fang length. Their incredibly long 
fangs are indicative of the manner by which they predate, typically adopting a ‘strike 
and release’ behaviour whereby large quantities of venom can be injected deep into 
the prey tissues to exert rapid pharmacological effects. Figure 1.5 shows variation in 
fang dentition between the most clinically important families of venomous snakes, 
the viperids and elapids, in comparison to the predominantly non-venomous family, 
the colubrids, of lesser medical importance. 
 
          1.4.3. Cellular structure of the venom gland 
Venom glands comprise of a highly folded secretory epithelium consisting of several 
distinct cell types including secretory, mitochondria-rich, horizontal and ‘dark’ cells 
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(Oron and Bdolah, 1978, Mackessy, 1991, Mackessy and Baxter, 2006). An 
abundance of glandular secretory cells (79% of the proportion of cells in the 
epithelium) are required to synthesise and secrete venom proteins and other 
components including physiological proteins, mucus and saliva into the glandular 
lumen. In lower abundance (10%) are horizontal cells, interdigitating between the 
basement membrane and base of the secretory cells, which function to phagocytose 
cellular debris and replace dead secretory cells. ‘Dark’ cells (9%) possess long 
dendritic processes which interdigitate between secretory cells and may play a role in 
cellular communication between cells. Mitochondria-rich cells (2%), which are 
densely packed with mitochondria, are thought to sustain the high energetic costs of 
venom production by the venom gland (Mackessy, 1991). The venom gland 
epithelium is basally supported by a connective tissue capsule through which pass a 
network of capillaries and nerves processes. The venom gland is surrounded by 
compressor muscle tissue which contracts during venom extraction in order to expel 
the venom glandular contents in a highly pressurized system. 
 
          1.4.4. The accessory gland 
Currently, very little is known about the characteristics and function of the accessory 
glands in the venom delivery system. In viperids, the accessory glands are separate 
from but connected to the main gland via the primary duct. In contrast, in elapids, the 
accessory gland surrounds the duct. There is currently little understanding of the 
input of accessory gland secretions to the main venom bolus. Although there have 
been no significant biochemical or toxic contribution detected, it is thought that 
accessory gland secretions may play a role in activating latent venom enzymes 
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expelled from the main gland before release into the secondary duct and fang to be 
injected into prey tissue during envenomation (Mackessy and Baxter, 2006), but this 
is yet to be confirmed by experimental data. 
 
1.5. The venom arsenal: Protein families 
Snake venom proteins have been extensively studied and characterised. Studies have 
shown significant structural and functional diversity among proteins, but the majority 
of toxin isoforms belong to a few key protein groups. A description of the structure, 
biological function and pathological role of the key components of snake venoms 
(categorised as enzymatic or non-enzymatic) are outlined as follows: 
 
Enzymatic components: 
          1.5.1. Snake venom metalloproteinases (SVMPs) 
Zinc-dependent metalloproteinases in snake venom are members of the M12 
reprolysin subfamily of metalloproteinases, which also contains the ADAMs (a 
disintegrin and metalloproteinase) group of proteins which share some structural 
features such as the homologous metalloproteinase domain (Takeda et al., 2012). The 
snake venom metalloproteinases (SVMPs) are a group of enzymes which 
demonstrate relatively broad proteolytic specificity and have been the focus of much 
research due to their association with severe pathologies including local and systemic 
haemorrhage (Gutiérrez et al., 2005b). The structure and function of the SVMPs 
shows a significant level of diversity resulting in a complex, multi-isoform family. 
The SVMPs can be sub-divided into four classes based on their domain structure and 
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Figure 1.6 Structural classifications of the snake venom metalloproteinases: 
Schematic diagram to show the domain structure of each class of SVMPs ranging 
from PI to PIIID/PIV with examples of SVMPs purified from snake venoms (right). 
Figure taken from Fox and Serrano (Fox and Serrano, 2008). P = signal peptide, Pro 
= prodomain, S = spacer domain.  
function, ranging from PI class to the more complex and multi domain-containing 
PIV SVMPs shown in Figure 1.6 (Fox and Serrano, 2008). The domain structure of 
SVMPs is described in detail by Fox and Serrano (Fox and Serrano, 2008).  
 
The PI class SVMPs represent the structurally simplest form and consist only of the 
propeptide and metalloproteinase domains in the nascent form. In the mature 
enzyme, the propeptide is proteolytically processed. All SVMPs share the highly 
conserved metalloproteinase domain characterized by a canonical zinc-binding motif 
(HEX box). The PII class SVMPs contain an additional disintegrin domain. There 
are five sub-classifications of PII SVMPs. Firstly, the PIIa class in which the 
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disintegrin domain (usually characterised by the presence of an RGD motif) is 
proteolytically cleaved from the metalloproteinase domain, giving rise to a ‘free’ 
disintegrin. In the PIIb class, the disintegrin domain is also proteolytically processed 
but remains part of the enzyme structure. The PIIc SVMPs represent a dimeric form 
of the PIIb class. The PIId and PIIe classes are precursor enzyme forms which give 
rise to homodimeric and heterodimeric RGD-containing disintegrins.  
The sub-classifications of PIII SVMPs all contain additional disintegrin-like and 
cysteine-rich domains in their nascent form (Fox and Serrano, 2005, Fox and 
Serrano, 2008). The disintegrin domain here shares some sequence homology to the 
disintegrin domains of PII SVMPs but is said to be structurally distinct due to 
differences in the sequence homology of the RGD integrin-binding site. In the PIIIa 
subclass, the disintegrin-like and cysteine-rich domains are not proteolytically 
processed from the metalloproteinase domain, whereas in the PIIIb subclass, 
proteolytic processing occurs. The PIIIc subclass represents a dimeric form of the 
PIIIa. The PIV (recently classified as PIIId) SVMPs contain, in addition to the 
domains described for PIII SVMPs, disulphide-bonded CTL-like domains (Fox and 
Serrano, 2005, Fox and Serrano, 2008). 
SVMPs have been shown to exhibit a diverse array of biological activities. The 
proteolytic activities of the SVMPs are largely associated with the metalloproteinase 
domain and characteristically include haemorrhage, apoptosis, myonecrosis, 
proteolysis, fibrinolysis, inhibition of platelet aggregation and activation of 
coagulation factors such as prothrombin, extensive  tissue necrosis, oedema and 
inflammation (Baramova et al., 1989, Gutiérrez and Rucavado, 2000, Gutiérrez et al., 
2005b, Kamiguti et al., 1996). This is due to the wide range of cellular targets of 
SVMPs including extracellular matrix proteins, connective tissue, platelets and 
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coagulation factors (Escalante et al., 2006, Franceschi et al., 2000, Rucavado et al., 
1998). The non-proteolytic activities of the SVMPs are mostly associated with the 
disintegrin and cysteine-rich domains contained in the PII and PIII classes.  
SVMPs are one of the most abundant enzyme families in viper venoms. Recent 
transcriptomic and proteomic investigations have estimated that the SVMP 
composition of most viperid venoms is at least 32%, (Bazaa et al., 2005, Juárez et al., 
2006, Sanz et al., 2008), with the most SVMP-rich venom identified from the saw-
scaled viper, Echis ocellatus of which SVMPs account for approximately 67% of the 
total protein composition (Wagstaff et al., 2009), whereas SVMPs constitute very 
little of the composition of elapid venoms (Li et al., 2004a, Nawarak et al., 2003). 
The high proportion of SVMPs in venoms, and their broad range of highly 
destructive toxic properties, gives an indication of the functional and pathological 
importance of this group of enzymes during viper envenomation.  
 
          1.5.2. Serine proteases 
Snake venom serine proteases (SPs) are a group of enzymes present in snake venoms 
which affect reactions involved in the blood coagulation cascade. SPs can be 
categorised into thrombin-like or kallikrein-like proteases. The thrombin-like 
subgroup contains enzymes functionally related to thrombin, defined by their ability 
to cleave fibrinogen, releasing fibrinopeptides following cleavage the Arg-Lys bonds 
on the α- and β-chains of fibrinogen, and subsequently converting fibrinogen to 
fibrin (Pirkle, 1998). Many thrombin-like SPs in venoms mimic other catalytic 
properties of thrombin such as activating several components of the blood 
 17 
 
coagulation cascade involved in platelet aggregation (e.g. factor V) (Siigur et al., 
1999). 
Kallikrein-like SPs in snake venoms are similar to the mammalian kallikrein 
enzymes which initiate the release of bradykinin through the proteolytic cleavage of 
kininogen (Matsui et al., 2000). Bradykinin is a potent vasodilator which increases 
vascular permeability, resulting in hypotensive symptoms in victims following 
envenomation with venom containing kallikrein-like SPs (Warrell, 2010). Some SPs 
in venom show both kallikrein-like and thrombin-like protease activities such as the 
SPs halytase isolated from Agkistrodon halys blomhoffii (Matsui et al., 1998). 
Halytase showed sequence homology to thrombin-like snake venom SPs (66-72%), 
mammalian tissue kallikrein enzymes (42%) and thrombin (26%) and was shown to 
specifically cleave both fibrinogen and kininogen, although this enzyme appeared to 
be devoid of coagulant activity (Matsui et al., 1998). Other enzymes such as 
crotalase, also show both kinin-releasing and coagulant activities (Markland, 1976). 
In addition to the SVMPs, SPs are also highly pathologically important in viper 
envenoming. The abundance of SPs in viper venom ranges from 2 to 31% of the total 
protein composition of venom (Gutiérrez et al., 2009). Although SPs in snake venom 
exert a wide range of biological activities affecting the coagulation cascade and 
haemostatic system, individual SPs usually catalyse a specific reaction in the 
coagulation cascade with macromolecular specificity to their protein target 
(Markland, 1998). 
 
 18 
 
          1.5.3. Phospholipase A2s (PLA2s) 
Phospholipase A2s (PLA2s) are esterolytic enzymes and are occur abundantly in 
nature. Snake venoms are also a rich source of PLA2s. The primary action of these 
enzymes is in the hydrolysis glycerophospholipids at the sn-2 position of the glycerol 
backbone. Snake venom PLA2s can be classified into two groups based on amino 
acid sequence, three-dimensional structure and disulphide bond patterns. Group I 
PLA2s are found in the mammalian pancreas and in the venoms of elapid and 
colubrid snakes. Group I PLA2s are typically 115-120 amino acid residues in length 
with 7 disulphide bridges. Elapid venom PLA2s contain a characteristic loop that 
connects the catalytic α-helix and the β-wing known as the elapid loop, whereas 
mammalian PLA2s contain an additional extension of 5 amino acids, called the 
pancreatic loop. Group II PLA2s enzymes are present in viper venoms and typically 
contain 120-125 amino acid residues with 7 disulphide bridges. This group lack the 
pancreatic or elapid loop which is characteristic of group I PLA2s, but contain an 
additional C-terminal extension. Group II PLA2s can be further divided into groups 
based on the amino acid residue at the 49
th
 position. Those with an aspartic acid 
residue are known as D49 enzymes; aspartic acid plays an important role in catalysis 
and is therefore conserved in most group II PLA2s (Scott et al., 1990). Amino acid 
substitutions at the 49
th
 position can occur; where the amino acid residue is replaced 
by lysine, serine, asparagine or arginine, enzymes are identified as K49 (Maraganore 
et al., 1984), S49 (Polgár et al., 1996), N49 (Tsai et al., 2004) or R49 (Chijiwa et al., 
2006). Enzymes in which the aspartic acid residue has been substituted show low or 
no hydrolytic activity as substitution interrupts the binding of cofactor Ca
2+
 to the 
Ca
2+
 binding loop (Maraganore and Heinrikson, 1985). Neurotoxic PLA2s produced 
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by elapids predominantly responsible for the cause of death by paralysis of prey and 
are therefore vital for the envenomation strategy of this family of venomous snakes. 
Snake venom PLA2s show remarkable functional diversity and can exert a wide 
variety of pharmacological effects including pre- and post-synaptic neurotoxicity, 
myotoxicity, cardiotoxicity, coagulopathy, hypotension, haemolysis and 
proinflammatory, in addition to the potential role they play in digestion of prey (Kini, 
2003, Kini, 2006, Montecucco et al., 2008). Some PLA2s exhibit pre- or post-
synaptic neurotoxicity. These enzymes belong to the group I PLA2s and are abundant 
components of elapid venoms. Pre-synaptic PLA2s disrupt neurotransmitter release at 
the neuromuscular junction, the effects of which are irreversible. Pre-synaptic 
neurotoxins have been shown to specifically target voltage-sensitive K
+
 channels 
(e.g. β-bungarotoxin (Black et al., 1988)), brain synaptic membrane proteins (e.g. 
ammodytin (Kriz a  et al.,    5)) and neuronal Ca2+ binding proteins (e.g. taipoxin 
(Kirkpatrick et al., 2000)). Post-synaptic neurotoxins extracellularly target the 
neuromuscular junction by competitively blocking acetylcholine receptors, the 
effects of which can be reversed by antivenom treatment. 
Viper venoms primarily contain group II PLA2s. Some group II PLA2s such as 
crotoxin and notexin have myotoxic properties and can induce myonecrosis or 
system myotoxicity (Gopalakrishnakone et al., 1984, Mebs and Ownby, 1990). 
Others have been demonstrated to evoke inflammatory events such the PLA2 isolated 
from Naja naja atra venom which promotes inflammatory cell infiltration (Zhang 
and Gopalakrishnakone, 1999) and Asp49 and Lys49 PLA2s from Bothrops asper 
venom which stimulate the phagocytic activity of macrophages (Zuliani et al., 2005). 
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          1.5.4. L-amino acid oxidases (LAOs) 
L-amino acid oxidases (LAOs) are homodimeric flavoenzymes which catalyse the 
oxidative deamination of L-amino acids to form α-ketoacids, in addition to the 
production of ammonia and hydrogen peroxidase. LAOs occur frequently in nature 
and are present in the venom of most snakes, occurring most abundantly in the 
venom of Crotaline snakes. The proportion of LAO in venoms as a percentage of the 
total weight of dried venoms ranges from 1-4% up to 30% in venom from the 
Malayan pitviper, Calloselasma rhodostoma (Ponnudurai et al., 1994). The venoms 
from mambas and sea kraits contain trace amounts of LAO and colubrid venoms also 
appear to be devoid of LAO activity (Mackessy, 2002). 
Several LAOs have been shown to affect platelet aggregation. LAOs purified from 
the venoms of Naja naja kaouthia (Tan and Swaminathan, 1992) and Agkistrodon 
halys blomhoffii (Takatsuka et al., 2001) demonstrated platelet aggregating inhibiting 
properties, whereas LAOs from the venoms of Ophiophagus hannah (Ahn et al., 
1997) and Eristocophis macmahoni (Ali et al., 2000) cause an induction of platelet 
aggregation. Other LAOs show additional effects including haemolysis and oedema-
induction (e.g. Trimeresurus flavoviridis (Abe et al., 1998) and E. macmahoni venom 
LAOs (Ali et al., 2000)). Other venom LAOs have been reported to demonstrate 
cytotoxic effects (e.g. O. hannah (Ahn et al., 1997)) or antibacterial properties (Stiles 
et al., 1991, Stábeli et al., 2004, Izidoro et al., 2006). LAOs from snake venoms have 
been reported to show moderate lethal toxicity and are therefore not thought to be a 
major pathological component of snake venom (Tan and Saifuddin, 1989). 
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          1.5.5. Hyaluronidase 
Hyaluronidase is an enzyme which specifically degrades hyaluronan, a ubiquitous 
component of the extracellular matrix which is essential in maintaining the structure 
and viscosity of the extracellular matrix. Hyaluronan has also been implicated in 
many biological processes such as wound healing and inflammation (Kreil, 1995, 
Stern and Jedrzejas, 2006). Although hyaluronidases are not thought to be toxic 
themselves, the resultant effect of hyaluronidase activity leads to an increased 
permeability of the extracellular matrix (Kudo and Tu, 2001). This facilitates the 
diffusion of toxins into tissues of the envenomed prey and assists the entry of more 
destructive venom enzymes such as proteases into the haemostatic system, therefore 
contributing to the local and systemic effects of envenomation (Pukrittayakamee et 
al., 1988). Thus, hyaluronidase has been termed the ‘venom spreading factor’.  
Hyaluronidase is a highly conserved constituent component which is ubiquitously 
expressed in all snake venoms. Despite its important role in snake envenomation, 
hyaluronidase remains a relatively unstudied venom toxin as the rapid autolysis of 
this protein has inhibited its chromatographic isolation preliminary to functional 
studies. Hyaluronidases have been isolated and purified from the venoms of 
Deinagkistrodon acutus (Xu et al., 1982), Agkistrodon contortrix (Kudo and Tu, 
2001) and the Indian Cobra, Naja naja (Girish et al., 2004). A study by Harrison et al 
determined the nucleotide sequence of hyaluronidase from several viperid species 
(Echis ocellatus, Echis pyramidum leakeyi, Cerastes cerastes cerastes and Bitis 
arietans), demonstrating a high level of sequence homology between species (over 
95%) (Figure 1.7) (Harrison et al., 2007). This study, for the first time, determined 
the sequence structure of a snake venom hyaluronidase which has five conserved N-
linked glycosylation sites and conserved residues in the catalytic, positional and 
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Figure 1.7 Snake venom hyaluronidase sequence analysis: Alignment of inferred 
full length hyaluronidase venom gland cDNA sequences from Echis ocellatus, 
Cerastes cerastes, Echis pyramidum leakeyi, Bitis arietans, Echis carinatus 
sochureki with EST sequences from Agkistrodon acutus and Lachesis muta from 
Harrison et al 2007 (Harrison et al., 2007). The conserved catalytic and positional 
residues are identified by the solid and open triangles respectively. 
cysteine scaffold regions with a predicted molecular mass of over 50 kDa (Harrison 
et al., 2007).  
 
 
Hyaluronidase activity facilitates the diffusion of venom proteins into prey tissues 
and therefore results in the rapid influx of target-specific venom toxins into the 
circulating blood system and thus, is an essential component of all snake venoms. It 
is also thought that hyaluronidase is also involved in the symptoms of extensive local 
tissue destruction observed following snakebite. Current antivenoms are unable to 
neutralise the local symptoms and so the resultant uncontrollable tissue destruction 
remains a complex and unresolved clinical issue. As hyaluronidase degrades 
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hyaluronan, a key structural component of the extracellular matrix, it is thought that 
hyaluronidase may be one of several factors involved in causing severe tissue 
damage as it has been demonstrated that the inhibition of hyaluronidase presents 
local tissue destruction (Yingprasertchai et al., 2003). In addition, the inhibition of 
hyaluronidase by injection of inhibitors following envenomation can delay the time 
to death (Girish and Kemparaju, 2006) which also implicates the potential 
therapeutic use of hyaluronidase inhibitors in the treatment of snakebite. 
 
          1.5.6. Acetylcholinesterase (AChE) 
Acetylcholinesterase (AChE) is present in all vertebrates and plays a functional role 
in the cholinergic system in the rapid hydrolysis and subsequent inactivation of the 
neurotransmitter, acetylcholine at the neuromuscular junction (Tougu, 2001). AChE 
has been detected at high levels in most elapid venoms, with the exception of the 
genus Dendroaspis which instead contains fasciculins, potent inhibitors of AChE 
(Karlsson et al., 1984, Cousin and Bon, 1997, Frobert et al., 1997). Studies analysed 
the AChE activity of 45 snake venoms and detected an absence of AChE activity in 
viperid and crotalid venoms (Frobert et al., 1997). In this study, a variation in the 
stability of AChEs among elapid venoms was apparent; AChE isolated from 
Bungarus venoms was much more stable than AChE isolated from venoms of 
Hemachatus, Ophiophagus and Naja species (Frobert et al., 1997). Venoms from 
Bungarus species were also shown to have the richest source of AChE activity with 
over twice as much activity as Naja venoms (Frobert et al., 1997). Despite the 
common occurrence of AChE in venoms, the biological function of AChE during 
envenomation remains unclear. 
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          1.5.7. Nucleases, nucleotidases and phosphomonoesterases  
Hydrolytic enzymes, such as nucleases (DNase, RNase and phosphodiesterase), 
nucleotidases (5’ nucleotidase, ATPase and ADPase) and phosphomonoesterases 
(acid and alkaline phosphomonoesterases) have been found in venoms.  
Nucleases are enzymes which act on nucleic acids (DNA/RNA). Venoms have been 
shown to contain both endonucleases which degrade either DNA or RNA 
specifically, and exonucleases which degrade both DNA and RNA. Currently, there 
have been very few studies investigating venom nucleases and so the occurrence, 
distribution and function are not fully understood. RNases have been identified from 
the venoms of Naja naja oxiana (Vasilenko and Ryte, 1975) and Naja naja 
(Mahalakshmi and Pandit, 1987, Mahalakshmi et al., 2000), and DNases have only 
been identified from Bothrops atrox venom (Georgatsos and Laskowski, 1962). 
Phosphodiesterases (PDEs) catalyse the phosphodiester bonds in polynucleotides 
acting on DNA, rRNA and tRNA. Unlike DNases/RNases, PDEs have been found 
ubiquitously in snake venoms across a wide range of taxa including colubrids, 
elapids and viperids (Aird, 2002, Aird, 2005, Mackessy, 2002) although few studies 
have attributed a biological function to this enzyme group.  
Nucleotidases act upon nucleic acid derivative and nucleic acid-related substrates 
(e.g. ATP and ADP). 5’ nucleotidases catalyse the hydrolysis of phosphate from the 
sugar moiety. These enzymes have also been found ubiquitously in snake venoms 
with viper venoms showing a greater 5’ nucleotidase activity than elapids (Aird, 
2005). There is, again, a lack of information about the biological role of 5’ 
nucleotidases in snake venoms, although 5’ nucleotidases in the venoms from 
Deinagkistrodon acutus (Ouyang and Huang, 1986) and Trimeresurus gramineus 
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(Ouyang and Huang, 1983) were shown to inhibit platelet aggregation either induced 
by ADP, collagen, sodium arachidonate, ionophore A-23187 in platelet-rich plasma 
and thrombin in platelet poor plasma. More recently, 5’ nucleotidases in the venom 
of Naja naja have been shown to be involved in the anticoagulant effect of this 
venom by interacting with anticoagulant factors (Dhananjaya et al., 2006). 
ATPases and ADPases catalyse the hydrolysis of ATP and ADP respectively. 
ATPase and ADPase activity have been observed in several snake venoms (Kini and 
Gouda, 1982a, Kini and Gouda, 1982b, Sales and Santoro, 2008). As the ATPases 
from venoms have not been purified, little is known about their biological role in 
venom. The ADPases, for example in D. acutus venom, have been shown to have 
platelet aggregation inhibiting properties (Ouyang and Huang, 1986). 
Phosphomonoesterases catalyse non-specific hydrolysis of phosphate esters. Acid 
phosphomonoesterases are most active at pH 5.0 whereas alkaline 
phosphomonoesterases are most active at pH 9.5. Both acid and alkaline 
phosphomonoesterases have been found in venoms, although the alkaline enzymes 
appear more widespread and abundant, appearing in venoms from a range of snake 
taxa (Mackessy, 2002, Aird, 2002). However, phosphomonoesterases in venoms are 
yet to be characterised or assigned a biological role. 
 
Non-enzymatic components: 
          1.5.8. C-type lectins (CTLs) 
C-type lectins (CTLs) are non-enzymatic proteins found in many animals which bind 
in a Ca
2+
-dependent fashion to mono- and oligosaccharides. In snake venoms, there 
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are two types of CTLs; CTL-like proteins (CLPs) and the classic sugar binding snake 
lectins. CLPs are found only in snake venoms and show a level of sequence 
homology with classic CTLs, but lack the Ca
2+
 binding loop which recognises 
carbohydrates (Ogawa et al., 2005). The basic structure of snake CTLs is a 
homodimeric form, whereas CLPs are heterodimers composed of homologous α- and 
β-subunits, interacting with a loop linked by a disulphide bond. 
Sugar binding CTLs are not highly toxic components of snake venoms. They have 
been shown to initiate various immunological processes including adhesion, 
endocytosis and pathogen neutralisation (Weis et al., 1998). They have also 
demonstrated the ability to inhibit tumour cell lines and endothelial cell growth (de 
Carvalho et al., 2001), thus their role in snake venom is currently not fully 
understood. CLPs, on the other hand, show a diverse array of pharmacological 
activities affecting coagulation factors, platelets, haemostasis and thrombosis and can 
be divided into three subgroups based on biological activity; these are coagulant 
proteins, platelet aggregation agonists and platelet aggregation antagonists (Morita, 
2005, Ogawa et al., 2005).  
Firstly, anticoagulant proteins, which target the coagulation factors X and factor IX, 
have been isolated from several venoms. These bind to the γ-carboxyglutamic acid 
(Gla) domain of factor X and IX in the presence of Ca
2+
 (Atoda et al., 1994). 
Anticoagulant CTLs have been identified from the venoms of Bothrops jararaca 
(Sekiya et al., 1993), Trimeresurus flavoviridis (Atoda et al., 1994), Echis carinatus 
leucogaster (Chen and Tsai, 1996), Deinagkistrodon acutus (Atoda et al., 1998) and 
Agkistrodon halys brevicaudus (Koo et al., 2002). Secondly, platelet aggregation 
agonists, which have been isolated from the venoms of Trimeresurus albolabris 
(Andrews et al., 1996), Crotalus durissus terrificus (Polgár et al., 1997), 
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Calloselasma rhodostoma (Shin and Morita, 1998) and Ophiophagus hannah (Du et 
al., 2002). These activate platelet aggregation by binding to the platelet glycoproteins 
(GP) which facilitate the binding of fibrinogen to integrin αIIbβ3 and mediate the 
adherence of platelets to collagen. Other platelet aggregation agonists bind directly to 
von Willibrand Factor (vWF), forming an active complex which induces platelet 
aggregation by interacting with GPIb receptor. These include botrocetin from B. 
jararaca venom (Read et al., 1989) and bitiscetin from B. arietans venom (Hamako 
et al., 1996). In contrast, several CLPs act as platelet aggregation antagonists by 
interacting directly with GPIb receptor, thus blocking the binding of vWF and 
inhibiting platelet aggregation. These include agkicetin from Agkistrodon acutus 
venom (Chen and Tsai, 1995), mamushigin from Agkistrodon halys blomhoffii 
(Sakurai et al., 1998), CHH-A/B from Crotalus horridus horridus venom (Andrews 
et al., 1996) and echicetin from Echis carinatus venom (Peng et al., 1993). 
  
          1.5.9. Disintegrins 
Disintegrins are present in snake venoms as a result of the proteolytic processing of 
multi-domain class II or class III venom metalloproteinases. Disintegrins are a family 
of small (40-100 amino acids), cysteine-rich polypeptides which can be divided into 
five different groups based on their length and number of disulphide bonds in the 
polypeptide (Calvete, 2005, Calvete et al., 2005). The sequence alignments of several 
different venom disintegrins from each group are shown in Figure 1.8. Short 
disintegrins are composed of 41-51 residues and four disulphide bonds, medium 
disintegrins contain around 70 residues with six disulphide bonds and long 
disintegrins are composed of an 84 residue polypeptides cross-linked by seven 
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Figure 1.8 Snake venom disintegrin sequence analysis: Alignment of selected 
polypeptide sequences of the different disintegrin subfamilies including short, 
dimeric, medium, long and PIII-derived disintegrins. Cysteine residues are 
highlighted in grey, missing cysteines are highlighted in green, the extra cysteine in 
bilitoxin is shown in red, the RGD tripeptide is shown in yellow and non-RGD 
integrin binding tripeptides in blue (Calvete et al., 2005). 
disulphide bonds (Calvete et al., 2005, Calvete et al., 2003). Short, medium and long 
disintegrins contain an RGD tripeptide, the binding motif of RGD-dependent 
integrins. The fourth group of disintegrins are derived from PIII SVMPs and contain 
100 amino acids with 16 residues involved in the formation of eight disulphide bonds 
and the fifth group is composed of homo- and hetero-dimeric disintegrins (Calvete et 
al., 2003). 
 
Snake venom disintegrins were first described as potent inhibitors of platelet 
aggregation by Huang et al in 1987 and were shown to act through selectively 
blocking the binding of fibrinogen to the integrin αIIbβ3 receptor (Huang et al., 1987). 
The disintegrins have evolved numerous integrin-binding motifs including RGD 
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which blocks the α8β1, α5β1, αvβ1, αvβ3 and αIIbβ3 integrins, MLD blocks the α4β1, 
α4β7, α3β1, α6β1, α7β1 and α9β1 integrins, VGD and MGD block the α5β1 integrin, 
KGD block the αIIbβ3 integrin, WGD α5β1, αvβ3 and αIIbβ3 (and is as potent in its 
inhibitory action as the RGD motif) and KTS/RTS block α1β1 integrins (Calvete, 
2005, Calvete et al., 2005). 
 
          1.5.10. Bradykinin potentiating peptides (BPPs) 
BPPs are short chain pyroglutamyl proline-rich oligopeptides expressed from within 
larger precursor components, typically encoding numerous distinct BPPs flanked by 
conserved spacer regions and C-terminal C-type natriuretic peptides (CNP). BPPs, 
were originally isolated and characterised from B. jararaca venom (Ferreira et al., 
1970a, Ferreira et al., 1970b) and can have profound effects on the cardiovascular 
system of the envenomed victim. They act through inhibiting angiotensin-converting 
enzyme and potentiating the action of bradykinin and are therefore thought to 
contribute to the symptoms of hypotension experienced as a consequence of 
envenoming by some viperid species (Hayashi and Camargo, 2005). 
 
          1.5.11. Inhibitory peptides (QKW tripeptides) 
Following a transcriptomic survey of the venom gland from E. ocellatus, a group of 
endogenous inhibitors of the SVMPs was discovered (Wagstaff and Harrison, 2006). 
Proline-rich, C-type natriuretic peptide-containing transcripts characterised by a 
QKW tripeptide repeat were identified in the transcriptome, which were highly 
homologous to the bradykinin potentiating peptides in B. jararaca venom (Figure 
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Figure 1.9 Sequence analyses of QKW tripeptides from viper venoms: 
Comparison of polypeptides encoded by novel transcripts isolated from the venom 
glands of two viperids, Echis ocellatus and Cerastes cerastes venom glands. QKW 
tripeptide repeats are indicated by open square brackets. The pHpG tract and CNP 
precursors in E. ocellatus sequences are denoted by solid bars (Wagstaff et al., 
2008). 
1.9)(Wagstaff et al., 2008). As previously described, BPPs in venom induce 
hypotension in the envenomed victim; as E. ocellatus venom rarely causes symptoms 
of hypotensive in victims following envenoming, the presence of this unusual cluster 
of transcripts was examined in further detail. The findings of this study provided the 
first characterisation of novel genes encoding QKW tri-peptides with inhibitory 
properties including the inhibition of SVMP catalytic activity and venom-induced 
haemorrhagic activity (Wagstaff et al., 2008). 
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          1.5.12. Kunitz serine proteinase inhibitors 
Snake venom kunitz serine proteinase inhibitors (KTI) belong to the bovine 
pancreatic trypsin inhibitor (BPTI) gene family. KTI/BPTI inhibitors can be divided 
into two groups; the non-neurotoxic trypsin and chymotrypsin inhibitors, and the 
neurotoxic KTI/BPTI group. The latter group are homologs of trypsin/chymotrypsin 
inhibitors which have lost their proteinase inhibitory function and act as K
+
 and Ca
2+
 
channel blockers such as dendrotoxin, a neurotoxic KTI/BPTI which has been 
isolated and characterised from mamba (Dendroaspis) venoms (Harvey and 
Karlsson, 1980, Smith et al., 1993). Snake venom KTI/BPTI proteinase inhibitors 
belong to a functionally diverse, multi-gene family and have been isolated from the 
venoms of several viper and elapid species (Župunski et al., 2003).  
 
          1.5.13. Vascular endothelial growth factors (VEGFs) and nerve growth 
factor (NGFs) 
The protein family of vascular endothelial growth factors (VEGFs) are regulators of 
neovascularization and angiogenesis (Olsson et al., 2006). There are currently seven 
members of this protein family including tissue type VEGF (VEGF-A), VEGF-B, 
placenta growth factor (PlGF), VEGF-C, VEGF-D, viral VEGF (VEGF-E) and snake 
venom VEGF (svVEGF) and, although diversity within sub-types exists, all 
members of the family are structurally homologous (Olsson et al., 2006) (Yamazaki 
and Morita, 2006) (Figure 1.10). VEGF was first characterised from the venom of 
Vipera aspis aspis following the isolation and purification of a heparin-binding 
dimeric hypotensive factor with 45% sequence homology to tissue type VEGF 
(Komori et al., 1999). VEGFs have also been characterised from Bothrops insularis 
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Figure 1.10 The VEGF protein family and receptor selectivity: Interaction of 
several VEGF ligands with their receptors. The ligand binding domain for each 
receptor is shaded black (Yamazaki and Morita, 2006). 
(de Azevedo et al., 2001), Trimeresurus flavoviridis (Takahashi et al., 2004), 
Agkistrodon piscivorus piscivorus (Yamazaki et al., 2005) and Bitis arietans 
(Yamazaki et al., 2009) venom glands. Although tissue type VEGFs are highly 
conserved throughout vertebrates, including snakes, svVEGFs expressed are highly 
diversified in structure, particularly in the functionally important regions including 
receptor-binding loops and C-terminal co-receptor binding regions (Yamazaki et al., 
2009). Some svVEGFs have been shown to induce strong vascular permeability with 
similar activity to VEGF-A (Takahashi et al., 2004), but the receptor selectivity of 
svVEGFs has not yet been fully explored and therefore the specific functions of 
svVEGFs in envenoming are not completely understood.  
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Nerve growth factors (NGFs) are members of the neurotrophin family of proteins 
which are responsible for the maintenance and survival of neuronal cells and the 
stimulation of nerve growth. NGFs were first isolated from the venom of 
Agkistrodon piscivorus and Crotalus adamanteus (Cohen and Levi-Montalcini, 
1956) and have since been isolated from venoms of several species of vipers and 
elapids including Daboia russellii (Koyama et al., 1992), Vipera lebetina (Siigur et 
al., 1985), Vipera berus berus (Siigur et al., 1986), Echis carinatus (Siigur et al., 
1987), Naja naja (Hogue-Angeletti et al., 1976) and Gloydius halys (Siigur et al., 
1987). Snake venom NGFs have been shown to display around 65% sequence 
homology to mammalian NGFs and may have similar biological activities (Kostiza 
and Meier, 1996) but the relevance of NGFs in envenoming is currently little 
understood. 
 
          1.5.14. Cysteine rich secretory proteins (CRISPs) 
Cysteine rich secretory proteins (CRISPs) have been isolated and characterized from 
most reptile venoms, including all three families of venomous snakes (colubrids, 
viperids and elapids) (Fry et al., 2006, Hill and Mackessy, 2000, Yamazaki and 
Morita, 2004). Venom CRISPs have been shown to demonstrate a wide range of 
biological effects including blockage of cyclic nucleotide-gated ion channels in 
elapid venom (Yamazaki et al., 2002a), blockage of calcium-activated potassium 
channels in elapid venom (Wang et al., 2005), blockage of smooth muscle 
contraction in viper venom (Yamazaki et al., 2002b) and proteolysis in cone snail 
venom (Milne et al., 2003). The CRISP isolated from the venomous lizard species, 
Heloderma horridum, (helothermine) is of particular interest as it exhibits a diversity 
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of functions including the blockage of potassium currents (Nobile et al., 1994) and 
calcium channels in neurons (Nobile et al., 1996) and the potential induction of 
hypothermia in prey (Mochca-Morales et al., 1990). 
 
          1.5.15. Purine and pyrimidine nucleosides 
Purine and pyrimidine nucleosides are present in most elapid and viperid venoms, 
although appear to be absent from crotalid venoms (Aird, 2005). Nucleosides are 
multifunctional toxins acting on all cell types. It has been suggested that purines 
(adenosine, inosine and guanosine) contribute to the immobilization (through 
hypotension or paralysis) and digestion of prey (Aird, 2002). Adenosine has been 
shown to assist in the immobilization of prey by activating neuronal adenosine A1 
receptors leading to the induction of sedative effects (Dunwiddie and Worth, 1982) 
and alterations in cognitive functioning (Winksy and Harvey, 1986). Adenoside and 
inosine have been shown to promote inflammation (Walker et al., 1997, Fan and 
Jamal Mustafa, 2006), the activation of mast cell A2 receptors (Ramkumar et al., 
1993) and, at high concentrations, induce apoptosis (Tanaka et al., 1994, Abbracchio 
et al., 1995) (Saitoh et al., 2004). Pyrimidine nucleosides (cytidine and uridine) have 
also been found in most elapid and viperid snake venoms (Aird, 2005). The function 
of purines and pyrimidines in envenomation is currently unclear but is has suggested 
that these components play a role in the envenomation strategies of advanced snakes, 
such as the ‘strike and release’ (viper) and the ‘seize and grasp’ (elapid) approaches, 
in enabling the rapid immobilization of prey (Aird, 2005). 
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Figure 1.11 Secretory cycle of the venom gland during venom synthesis: 
Microscopic examination of the venom glandular secretory epithelium during the 
cycle of venom synthesis to show changes in the size of secretory cells with levels of 
activity. Figure modified from Oron, U. and Bdoloh (Oron and Bdolah, 1978). 
1.6. Venom protein synthesis and storage 
The cycle of transcriptional activity of secretory cells is thought to be initiated 
through the act of venom expulsion either by snake bite or manual extraction 
(Mackessy, 1991). Morphological observations of the venom gland epithelium 
following manual extraction of venom showed that the secretory cells change from a 
short, cuboidal shape during the inactive (atrophic) state to a long columnar shape  
(hypertrophic) following activation initiated by depletion of the venom gland 
contents (Oron and Bdolah, 1978) (Figure 1.11). Newly synthesised venom proteins 
are secreted into the large central lumen and smaller tubular ductules of the venom 
gland via exocrine transportation, or can be stored in microvesicles (Carneiro et al., 
2007), or granules within the secretory cells of the glandular epithelium (Oron and 
Bdolah, 1978).  
 
 
 
 
 
 
The activity of mRNA and the rate of protein accumulation in the venom gland are 
thought to change throughout the course of venom synthesis as cells cycle. Previous 
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literature using immunohistochemistry methodologies indicates that total RNA 
activity occurs at day 3 post venom extraction and translation of amino acids 
incorporated into proteins reaches maximal levels following a short lag period 
between 4 to 8 days post venom extraction (Paine et al., 1992). Protein synthesis is 
thought to be maintained at a high rate until completion on day 16 but studies have 
suggested that secretory cells can remain active for up to 30 to 60 days post venom 
extraction indicating that the complete cycle of venom synthesis may be longer than 
expected (Carneiro et al., 2002). The organization and regulation of venom protein 
production is not yet fully understood. There is some evidence to suggest that the 
regeneration of depleted venom proteins following venom gland expulsion may be 
asynchronous (Oron and Bdolah, 1973, Oron et al., 1978). Although secretory cells 
have the capacity to synthesise and secrete the complete range of venom proteins, it 
is thought that each toxin group has a rate of production independent of other 
components synthesised by the glands. A study on Vipera ammodytes venom glands 
demonstrated that the glands may synthesise a greater proportion of molecules 
without an obvious predatory function immediately after venom extraction and a 
higher percentage of toxic components are synthesised later in the cycle on day 8 
post-milking (Oron and Bdolah, 1973). This study noted that on the first day 
following venom extraction, only 25% of newly synthesised proteins could be 
precipitated by antivenom in comparison to venom synthesised at 8 days post-venom 
extraction where 80% of proteins were precipitated by antivenom (Oron and Bdolah, 
1973). These results could be interpreted to suggest that the venom gland may 
synthesise non-toxic venom proteins, such as structural or inhibitory/stabilising 
components, prior to the synthesis of toxic venom proteins. It could be suggested that 
the physiological proteins with inhibitory functions may function to prepare and 
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protect the glandular epithelium for the storage of toxins. Asynchrony in venom 
synthesis was further investigated in a study by Oron et al (Oron et al., 1978) 
whereby venom of Vipera palaestinae was analysed following injection of animals 
with [
3
H] Leucine. The incorporation of [
3
H] Leucine into venom components in the 
venom glands was compared between snakes injected 2 and 4 days after milking. 
Considerable variability in the incorporation of several proteins was evident, 
however, more stability and less variability were observed in the synthesis of 
neurotoxins: enzymes which are essential enabling prey immobilisation. It has been 
suggested that non-parallel synthesis of some venom proteins may be related to the 
importance of their toxic or physiological role in venom in that the expression of 
components most vital in envenoming is more stable and less variable than those less 
fundamentally important in the pathology of snakebite (Oron et al., 1978). 
 
1.7. The venom glandular environment; protecting against self-proteolysis  
The venom gland provides a unique natural microenvironment which synthesises and 
stores a highly biologically active and volatile combination of toxic components. 
Despite the presence of potent enzymes, the venom gland provides conditions that 
stabilise these and other proteins during long-term storage of venom. Several 
biological, chemical and physical properties have been shown to influence venom 
protein stability and may contribute to the maintenance of a stable glandular 
environment.  
Biochemical factors such as pH, metal ions chelators and endogenous inhibitors may 
act to ensure stabilisation of venom components and prevent self-autolysis of venom 
constituents. Previous studies have demonstrated that the venom gland contents are 
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acidic (Mackessy and Baxter, 2006). The acidic pH is thought to be achieved by the 
mitochondria-rich cells in the glandular epithelium which are morphologically 
similar to the parietal cells of the gastric pits in mammalian stomach lining. In the 
stomach, parietal cells function to activate digestive enzymes following the 
acidification of stomach contents. However, in venom, the acidic environment may 
serve to inhibit the function of venom enzymes (Mackessy and Baxter, 2006). 
Studies have shown that the pH of the venom gland may influence the activity of 
venom enzymes. Sousa et al (Sousa et al., 2001) investigated the stability of venom 
under different pH conditions. Thus, following incubation at room temperature for 48 
hours, the naturally occurring proteolytic action of venom upon its own components 
was seen to be significantly reduced or absent in venom incubated in the acidic 
environment (pH 5.0) when compared to venom maintained at in alkaline conditions 
(pH 8.5) illustrating the proteolytic-inhibiting properties of an acidic environment. In 
addition, some biological properties of venom such as haemagglutinating activity 
was drastically decreased and many high molecular weight proteins degraded under 
alkaline conditions, supporting evidence that that venom is significantly more stable 
at a weakly acidic pH (Sousa et al., 2001).  
There may also be non-proteinaceous components of venom that specifically inhibit 
venom toxicity during glandular storage. Studies have demonstrated that citrate is 
present in snake venoms and is thought to chelate divalent metal cations resulting in 
the inactivation of cation-reliant enzymes such as Zn
2+
-dependent SVMPs and Ca
2+
-
dependent PLA2s. Studies therefore suggest that citrate may act as a complete 
(Francis and Kaiser, 1993) or partial inhibitor of snake venom enzymes (Odell et al., 
1998). The presence of citrate as a major component of venom has been documented 
in the study of the venom of several Vipers including Bothrops asper, Crotalus 
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atrox, Crotalus viridis viridis, Crotalus adamanteus, Sistrurus miliarius barbouri, 
Crotalus horridus horridus, Agkistrodon contortrix mokasen, Agkistrodon contortrix 
contortrix, Agkistrodon piscivorus piscivorus (Frietas et al., 1992). Francis et al 
found citrate levels ranged from 95 to 150mM across venom from four different 
species; Agkistrodon contortrix contortrix, Bothrops asper, Bitis caudalis and Vipera 
ammodytes (Francis et al., 1992). The potential function of citrate as an enzyme 
inhibitor may explain the high levels of citrate reported in these venoms. 
Toxic-specific inhibitory peptides may be present in abundance in venom which 
could be responsible for subduing the toxic effects of venom components. A study by 
Wagstaff et al (Wagstaff et al., 2008) identified and characterised a group of tri-
peptides present in abundance in the venom of the saw-scaled viper, E. ocellatus, and 
the puff adder, B. arietans. These peptides were shown to act to specifically to inhibit 
the in vitro and in vivo activity of SVMPs. It is currently unknown as to whether 
peptides acting to specifically inhibit the activity of other venom toxins are 
synthesised by the venom glands.  
 
1.8. Analysis of venom composition; venomics and transcriptomics 
Studies of snake venom gland transcriptomes aim to examine the expression levels of 
all mRNAs encoding venom proteins in cells of the venom glandular epithelium. The 
resultant transcriptome reflects all of the genes which are actively expressed by the 
venom gland at any given time and provides a comprehensive picture of the 
abundance and diversity of all of the transcripts encoding venom proteins. The 
venom gland transcriptome has been produced and extensively studied for several 
medically important species of vipers including Bitis gabonica (Francischetti et al., 
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2004), E. ocellatus (Wagstaff et al., 2009, Casewell et al., 2009), Bothrops species 
(Cidade et al., 2006, Kashima et al., 2004, Neiva et al., 2009), Sistrurus catenatus 
edwardsii (Pahari et al., 2007) and Deinagkistrodon acutus (Zhang et al., 2006) and 
elapids including Bungarus flaviceps (Siang et al., 2010), Bungarus multicinctus and 
Naja atra (Jiang et al., 2011) and Micrurus altirostris and M. corallinus (Corrêa-
Netto et al., 2011). The ability to generate an accurate representation of all venom 
proteins transcribed by the venom glands of snakes through transcriptomic surveys is 
vital for venom research. From a clinical perspective, transcriptomic studies have 
improved our understanding of the toxic composition of venom and thus greatly 
aided in our ability to characterise envenomation profiles and in the strategies to 
improve the treatment of snakebite such as in the design of toxin-specific 
antivenoms. From a biological view, transcriptomic studies aiming to generate a full 
catalogue of transcripts encoded by snake venom glands could reveal novel or 
unusual components of snake venom of interest for drug discovery and in addressing 
unanswered fundamental biological questions. However, it is also vital that venom 
gland transcriptomes are analysed in combination with the venom proteome or 
‘venome’. Although the transcriptome can be viewed as a precursor of the proteome, 
small transcriptional and post-translational processes may significantly influence the 
overall protein composition of venom. A study by Wagstaff et al revealed differences 
between the transcriptome and proteome of E. ocellatus venom glands and 
demonstrated that some venom proteins such as hyaluronidase and nerve growth 
factors which were predicted by the transcriptome, could not be detected in the 
proteome (Wagstaff et al., 2009). Such studies emphasise the importance of 
combined transcriptomic and proteomic approaches to analysing venom composition. 
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1.9. Variation in venom composition 
Variation in venom has been well documented on several taxonomic levels including 
inter-family, inter-genus and inter- or intra-species variation in venom (Chippaux et 
al., 1991). Many studies investigating the levels of venom variation have attributed 
their findings to factors such as dietary, geographical, ontogenetic and gender 
associated changes.  
Diet has been demonstrated as one of the most important factors influencing 
variation in venom composition. Intra-species variation in venom composition was 
first correlated with diet by Daltry et al who investigated variation in venom from the 
Malayan pitviper, Calloselasma rhodostoma. Studies provided evidence that 
variation in venom protein composition and biological activity was most strongly 
associated with diet, rather than geographic proximity or phylogenetic relationships 
between populations of C. rhodostoma across Southeast Asia (Daltry et al., 1996a, 
Daltry et al., 1996b). These studies suggested that natural selection of venom toxins 
most adapted to immobilize, kill and digest local prey items has resulted in variable 
venom protein patterns in this species (Daltry et al., 1996b). Variation in the venom 
protein composition between closely related subspecies of Sistrurus rattlesnakes 
(Sanz et al., 2006) and Echis species (Barlow et al., 2009) have been correlated with 
the recruitment of different toxins into the proteome of species with predominantly 
mammalian or varied diets. In a transcriptomic approach, findings of a recent study 
demonstrated significant intra-family variation in the venom transcriptomes of Echis 
species (Casewell et al., 2009) where changes in toxin isoform diversity and 
expression levels could be correlated with prey specificity.  
Ontogenetic variation in the composition and activity of venom has been 
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demonstrated in several species. It is thought that ontogenetic shifts in venom 
composition and function are related to dietary and habitat shifts from juvenile to 
adult snakes. The first observations of ontogenetic variation in venom were 
demonstrated by Reid and Theakston who identified changes in the coagulant 
activity of Crotalus atrox venom as snakes age (Reid and Theakston, 1978). This 
study concluded that the venom of juvenile snakes was more lethal (indicated by 
LD50) and showed greater ability to induce platelet aggregation (indicated by in vitro 
platelet aggregation assays) and emphasises the importance of understanding 
ontogenetic variation in venom from a clinical perspective as different venom 
activities could explain conflicting reports of snakebite envenoming symptoms. 
Further studies illustrating ontogenetic variation in venom composition and toxicity 
are described in detail in Chapter 5, however, the general consensus conclusions for 
the majority these studies indicate that juvenile venoms, overall, exert a distinct 
pathology to adult venoms, particularly in the coagulant activity of venom. Gender 
associated variations in venom composition and activity have also been demonstrated 
in B. jararaca (Furtado et al., 2006, Menezes et al., 2006, Pimenta et al., 2007), 
Boiga irregularis (Mackessy et al., 2006) and Deinagkistrodon acutus (Gao et al., 
2011). These studies indicated that differences in the protein composition and 
various toxic properties of venom between males and females could be observed. 
The study of variation in venom composition and function is important for 
therapeutic, biological and evolutionary purposes. Variation in venom could affect 
the clinical presentation of venom-induced pathology following envenomation. This 
could subsequently lead to variations in the efficacy of antivenom treatment in 
patients, particularly in those treated with antivenoms which are in use over wide 
geographical areas. Such antivenoms may not incorporate the complete species 
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diversity of venom composition and therefore vary in their ability to neutralise 
venom toxicity.  
 
1.10. Aims of this work 
Presently, there are several aspects of fundamental venom biology which are yet to 
be resolved. These include the dynamics of venom protein synthesis and the 
mechanisms by which protein synthesis by the venom gland is controlled and 
regulated. In past years, many areas of venom research have experienced significant 
benefit from the recent advances in proteomic and transcriptomic technologies 
leading to a greater understanding of snake venoms. However, we currently still have 
little understanding of how venom is synthesised, regulated and maintained by snake 
venom glands. The major aim of this work was to elucidate the real-time time scale 
for the replenishment of venom proteins during venom synthesis and to investigate 
how venom synthesis is controlled and coordinated using advanced high throughput 
techniques. 
The initial aim of this thesis was to gain a greater understanding of the composition 
of venom of the African Puff Adder, B. arietans. This viperid species is a member of 
the sub-family Viperinae and is the most medically important species of the genus 
Bitis. The genus also incorporates other species of lesser medical importance 
including the Gaboon viper (B. gabonica), the Horned Puff adder (B. caudalis), the 
Rhinoceros viper (B. nasicornis) and the Dwarf adder (B. schneideri). With an 
average size of around 1m in length, this stout and powerful snake is one of the most 
common venomous snakes in Africa. There are currently two recognised sub-species 
of B. arietans. These are the pan-African sub-species B. arietans arietans and the 
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Somali Puff Adder (B. arietans somalica) which is found exclusively in Somalia and 
Northern Kenya. B. arietans exhibits a diverse and extensive pan-African 
geographical distribution occupying a range of varied habitats throughout sub-
Saharan Africa and the Arabian Peninsula. The venom from B. arietans is highly 
toxic, containing an abundance of haemotoxic proteases and other enzymes. Toxins 
in B. arietans venom typically interfere with the haemostatic system and are 
responsible for causing the characteristic symptoms of B. arietans envenoming such 
as severe local and systemic effects including swelling, haemorrhage and tissue 
necrosis (Warrell et al., 1975). Without antivenom treatment, B. arietans 
envenoming can have fatal consequences (Warrell et al., 1975). Due to (i) its 
extensive co-distribution in areas of high human density, (ii) highly potent venom 
and (iii) potentially large quantities of venom which can be injected per bite, B. 
arietans is considered one of the most medically important species of venomous 
snake in Africa. In addition to the saw-scaled viper (E. ocellatus) and the spitting 
cobra (Naja nigricollis), the Puff Adder is therefore thought to be responsible for a 
high proportion deaths resulting from snakebite in sub-Saharan Africa. These 
characteristics also make this species an ideal candidate to investigate occurrence of 
intra-species variation in venom. In a study including proteomics, immunological 
and venom enzyme activity analyses, we aimed to evaluate the levels of intra-species 
variation in the venom proteome, immunoreactivity and enzyme function of this 
species. Specifically, we aimed to determine the degree of variation between B. 
arietans specimens from both different and the same geographical origins across sub-
Saharan African and Arabia. The overall outcome of this work aimed to gain a 
greater understanding of the venom of this clinically and biologically important 
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species of venomous snake; the resultant findings of this study could therefore have 
both biological and therapeutic implications. 
The second aim of this work was to develop and optimise novel protocols to 
efficiently and quantitatively track changes in the gene expression of specific venom 
proteins, including venom toxins and less toxic physiological proteins, during the 
course of venom production. The experimental limitations of current methodologies 
render the study of real-time gene expression analyses extremely difficult as they 
rely upon the extraction of transcriptionally active messenger RNA from venom 
gland tissues, therefore requiring the sacrifice of snakes. Consequently, we elected to 
conduct a novel approach enabling the analysis of venom gene expression using non-
invasive experimental techniques, circumventing the requirement to sacrifice snakes 
for venom glandular dissection. This unique approach aimed to utilise and exploit the 
unusual presence and stability of messenger RNA in lyophilised venom samples in a 
stringently optimised quantitative PCR protocol, as an alternative source of 
messenger RNA for gene expression and transcription analyses. 
Our fully optimised experimental approach would be applied to quantitatively 
monitor the levels of expression of venom protein-encoding genes using quantitative 
PCR. We aimed to track changes in gene expression during venom synthesis, both in 
terms of the production of venom in juvenile snakes from birth to maturity, and in 
the replenishment of depletion venom stores by adult specimens, using B. arietans as 
a model species. After gaining a greater understanding of the dynamics of venom 
protein expression during venom synthesis, we subsequently aimed to investigate and 
characterise the genomic structure and organisation of venom protein-encoding genes 
and subsequently identify gene regulatory regions (e.g. promoters and transcription 
factors) responsible for controlling venom synthesis. 
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Figure 2.1. Venom extracted from an adult Bitis arietans specimen. 
2. MATERIALS AND METHODS 
Recipes for buffers and stock solutions used during the course of this experimental 
work can be found in appendix I. 
 
2.1. Venom extraction, preparation and storage 
All venoms used in this work were extracted by Paul Rowley and Dr Rob Harrison 
from snakes maintained under identical climatic and dietary conditions in the 
herpetarium at the Alistair Reid Venom Research Unit in the Liverpool School of 
Tropical Medicine. During venom extraction, venom glands were massaged to 
ensure maximal quantities of venom were obtained (Figure 2.1). Following 
extraction, venom samples were immediately transferred into glass bijoux bottles 
using a sterile pipette, weighed and frozen at -20°C for 24 hours. Venoms were then 
freeze-dried using a mini Lyotrap lyophilizer (LTE Scientific Ltd, UK) for 3-4 hours 
before storage at 4°C until analysis. Following reconstitution of lyophilised venom, 
samples were stored at -80°C. 
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PROTEIN ANALYSIS 
2.2. One dimensional sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (1D SDS-PAGE) 
          2.2.1. Venom sample preparation for SDS-PAGE 
Unless otherwise stated, lyophilised venom samples were reconstituted in 1X 
phosphate-buffered saline (1X PBS) at a concentration of 10mg/ml. Venom samples 
were diluted to a final concentration of 1mg/ml in 2X protein loading buffer (2X 
PLOB). To prepare reduced 2X PLOB, a reducing agent, β-mercaptoethanol, was 
added to non-reduced loading buffer at a proportion of 15% v/v (e.g. 150µl β-
mercaptoethanol per 850µl non-reduced 2X PLOB). For non-reduced 2X PLOB, the 
reducing agent was substituted for the same volume of distilled water (dH2O). 
Venom samples for both non-reduced and reduced SDS-PAGE were heated to 95°C 
for 5 min prior to electrophoretic analysis to promote protein denaturation. The 
addition of the reducing agent, β-mercaptoethanol, acted to further denature proteins 
by disrupting intra and inter molecular disulphide bridges. 
 
          2.2.2. SDS-PAGE gel preparation and electrophoresis 
1D SDS-PAGE was used to separate venom samples into their constituent protein 
components based on molecular mass. 1mm glass plates were assembled using the 
mini-Protean electrophoresis system (BioRad, UK) according to the manufacturer’s 
instructions. 1mm or 7.5mm 15% polyacrylamide resolving gels (for 4 gels: 7.5ml 
dH2O, 5ml 1.5M Tris pH 8.8, 7.5ml 40% Bis Acrylamide, 200µl 10% SDS, 120µl 
10% ammonium persulphate (APS) and 14µl TEMED) were prepared, poured into 
the glass plates, overlaid with dH2O to remove bubbles and prevent drying and 
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allowed to polymerize for 45 min. Acrylamide concentration was adapted to prepare 
10 or 12% gels if further separation of proteins was required. Following 
polymerisation, dH2O was removed and the stacking gel mixture (for 4 gels: 5ml 
dH2O, 2ml 0.5 M Tris pH 6.8, 350µl 40% Bis Acrylamide, 30µl 10% APS and 5µl 
TEMED) was poured on top of the polymerised resolving gel and a 15-well 1mm 
comb was inserted into the plate. The stacking gel was allowed to polymerise for a 
further 45 min. Electrophoresis was carried out using a mini-Protean cell (BioRad, 
UK) at 200V for 45 min to 1 hour in 1X Tris-glycine-SDS (TGS) running buffer. A 
standard broad range molecular weight protein marker ranging from 10 to 225kDa 
(Promega, UK) (7µl) was run alongside 10µl venom samples in order to give an 
indication of the molecular weight of venom proteins in the sample. Gels were then 
stained with Coomassie Blue R-250 overnight and destained with coomassie destain 
solution until clear. Where increased sensitivity in gel-staining was required, for 
example when analysing venom samples of a low protein concentration or to 
visualise proteins of low abundance in venom samples, a silver staining kit 
(PageSilver
TM
 silver staining kit, Fermentas, UK) or the rapid staining protocol 
adapted from Nesterenko et al (Nesterenko et al., 1994) which is described in table 
2.1 was used. 
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Table 2.1. Rapid silver staining protocol for staining SDS-PAGE protein gels: 
Protocol adapted from Nesterenko et al (Nesterenko et al., 1994). Volumes of 
solutions used are suitable for staining one 7.5mm mini gel.  
 
2.3. Immunoblotting 
Immunoblotting was used to detect specific venom proteins which were 
immunoreactive to antivenoms or toxin-specific antibodies. 1D SDS-PAGE 
separation of venom samples was conducted as previously described in section 2.2.2. 
Following electrophoresis, the polyacrylamide gel was sandwiched together with a 
0.45µm nitrocellulose membrane (BioRad, UK) between two double layers of filter 
paper and foam padding. The sandwich was inserted into a cassette and placed into 
an immunoblotting transfer tank (BioRad, UK) containing immunotransfer buffer. 
Electro-transfer of proteins from the SDS-PAGE gel onto the nitrocellulose 
membrane was achieved following electrophoresis of proteins for 1 hour at 100V, 
mixing continually with a magnetic stirrer. An ice block was inserted into the 
 Step: Solution/per gel: Incubation 
time: 
1 Fixation 60ml 50% acetone, 1.5ml 50% trichloroacetic 
acid, 25 µl 37% formaldehyde (HCHO). 
5 min 
2 Rinse dH2O 3 x 5 sec 
3 Wash dH2O 5 min 
4 Rinse dH2O 3 x 5 sec 
5 Pre-treat 60ml 50% acetone 5 min 
6 Pre-treat 100µl 10% Na2S2O3·5H2O in 60ml dH2O 1 min 
7 Rinse dH2O 3 x 5 sec 
8 Impregnate 0.8ml 20% AgNO3, 0.6ml 37% HCHO in 60ml 
dH2O  
12-15 min 
9 Rinse dH2O 2 x 5 sec 
10 Develop 1.2g Na2CO3, 25µl 37% HCHO, 25µl 10% 
Na2S2O3·5H2O in 60 ml dH2O 
10-20 sec 
11 Stop 1% glacial acetic acid in 60ml dH2O  
12 Rinse/store dH2O  
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transfer tank to prevent the buffer from overheating during electro-transfer. Once 
complete, transferred proteins were temporarily visualised using 1X Ponceau S dye 
to check the efficiency of electro-transfer and to enable labelling of markers and 
sample well lanes. Membranes were thoroughly rinsed in 1X Tris-buffered saline 
Tween-20 (TBST) to remove the Ponceau S dye. Membrane protein binding sites 
were blocked overnight in 5% non-fat milk (Marvel) in TBST to reduce non-specific 
protein binding. Primary antibodies were diluted in 5% non-fat milk at a 
concentration ranging from 1/1000 for antivenoms to 1/200 for toxin-specific 
antibodies. For negative controls, normal animal sera (e.g. horse or mouse sera) were 
used. Membranes were incubated with the primary antibodies for 5 hours. 
Membranes were washed by conducting three 10 min washes in TBST. Horseradish 
peroxidase-conjugated secondary antibodies (e.g. anti-horse or anti-mouse) (Sigma, 
UK) were diluted in 5% non-fat milk at a concentration of 1/1000. Membranes were 
incubated with the secondary antibody for 2 hours followed by a final three 10 min 
TBST washes. Blots were developed using a 3,3'-Diaminobenzidine peroxidase 
(DAB) solution for approximately 2 min. 
 
2.4. Substrate zymography 
          2.4.1. Venom sample preparation for substrate zymography 
The proteolytic activity of venom proteins was assessed by addition of substrates into 
SDS-PAGE gels and subsequent examination of lysis. Reconstituted venom samples 
were prepared at a concentration of 1mg/ml in non-reduced 2X PLOB as described in 
section 2.2.1. For zymography, samples were not denatured by heating to 95°C.  
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          2.4.2. Zymogram gel preparation, electrophoresis and activation  
0.75mm gels were prepared using BioRad equipment. The resolving gel was 
prepared by co-polymerising molten gelatin or fibrinogen with polyacrylamide (for 4 
gels 5ml dH2O, 5ml 1.5M Tris pH 8.8, 5ml 40% Bis Acrylamide, 5ml of 10mg/ml 
molten gelatin or fibrinogen in dH2O, 100µl 10% SDS, 300µl 10% APS and 15µl 
TEMED), poured into the glass plates and overlaid with dH2O before allowing to 
polymerise for 45 min. The stacking gel was prepared as previously described for 1D 
SDS-PAGE, poured with a 15-well 0.75mm comb and left to polymerise for a further 
45 min. Electrophoresis of venom samples was carried out at 200V for 45 min in 1X 
TGE running buffer. Following electrophoresis, gels were incubated at room 
temperature for 30 min in enzyme re-naturing buffer (2.5% Triton X-100 solution) 
with gentle agitation. Gels were then washed three times with dH2O before 
incubating overnight at 37°C in developing buffer. Gels were then stained with 
Coomassie Blue R-250 for 2-3 hours and destained briefly for 1-2 min until clear 
areas indicating degradation of substrate by venom enzymes were visible. 
 
2.5. Mass spectrometry:  
          2.5.1. In-gel trypsin digestion 
In-gel trypsin digestion of protein bands was performed using protocols adapted from 
Hayter et al (Hayter et al., 2003). Coomassie stained protein bands which were 
clearly distinguishable as single bands on 1D SDS-PAGE gels were excised using a 
clean scalpel and transferred into a 1.5ml eppendorf tube. Gel bands were destained 
to remove all traces of Coomassie Blue by incubating at 37°C for 10 min in 20-50µl 
destaining solution containing 50mM Ammonium bicarbonate/50% acetonitrile 
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(AmBic/ACN). Destaining was repeated at least three times by replacing the solution 
with fresh destain solution each time in order to remove all traces of Coomassie 
Blue. Once destained, proteins were reduced by incubating with 20µl DTT at 37°C 
for 30 min and alkylated by incubating with 20µl IAN at 37°C for 30 min in the dark. 
The gel bands were then dehydrated by adding 10µl of 100% ACN and incubating at 
37°C for 15 min – after which time the gel band turned white. The solvent was 
carefully removed and the remaining acetonitrile was left to evaporate at 37°C for 10 
min. The trypsin solution required to digest proteins was prepared by re-suspending 
25µg proteomics grade trypsin (Sigma, UK) in 250µl of 50mM acetic acid. The 
trypsin stock solution was diluted 1:10 in 50mM AmBic/50%ACN (giving a final 
concentration of 0.1µg/µl) and 10µl of the final solution was added to the gel band 
and incubated for 1 hour at 37°C. A further 10µl of the trypsin solution was added 
and incubated overnight at 37°C. Enzymatic digestion was terminated by adding 2µl 
2.6M formic acid. Digests were dried using a Speed Vac and could be stored at -
20°C until mass spectrometry analysis. Prior to LC-MS, 50µl high performance 
liquid chromatography (HPLC)-grade water was added to each gel band, sonicated 
for 10 min and centrifuged for 20 min at 13,000rpm. 
 
          2.5.2. HPLC – tandem mass spectrometry (HPLC-MS/MS) and protein 
identification using bioinformatics tools 
In order to analyse the protein composition of venom fractions, whole venom 
samples (5mg/ml solution in 0.1% formic acid mobile phase buffer) were centrifuged 
at 13,000rpm for 20 min. Samples were fractionated in the first dimension via an ion-
exchange 2mm x 50mm ProPac ® SCX-10G column over a gradient (600-900mM 
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NaCl in 0.1% formic acid, pH 2.3) at a flow rate of 60µl/min using an Ultimate 3000 
system (Dionex, UK). Following this, the fractions generated (20 per sample) were 
subjected to second dimension fractionation over a gradient (2-90% acetonitrile in 
0.1% formic acid over 50 min) at a flow rate of 300nl/min using a 300μm I.D. x 
15cm capillary LC ion exchange column packed with 3μm PepMap™ C 8 stationary 
phase. Eluted peptides were analysed on a LCQ Deca XP Plus Mass Spectrometer 
(ThermoFisher, UK), operating on a ‘triple play’ mode (zoom scan followed by 
MS/MS). Proteins were identified by screening LC-MS sequence data against 
Uniprot databases and a B. arietans venom gland EST database using Proteome 
Discoverer 1.0.0 (ThermoScientific) software incorporating both Sequest 
(ThermoScientific (Yates et al., 1996) and Mascot (Matrix Science Ltd, UK (Perkins 
et al., 1999) search algorithms. A parent mass tolerance of 1.5Da and fragment mass 
tolerance of 1Da were used, allowing for 1 missed cleavage. Carbamidomethylation 
of cysteine and oxidation of methionine were the fixed and variable modifications 
respectively. For Sequest, high confidence peptide matches were filtered with an 
XCorr cut-off (+1>1.5, +2>2 and +3>2.5) and for Mascot, an Exp value of less than 
0.01 indicated a confident peptide match. 
 
MOLECULAR BIOLOGY 
2.6. Extraction of Poly(A) mRNA from venom using oligo (dT) magnetic 
Dynabeads® 
Poly adenylated messenger RNA (poly(A) mRNA) was extracted from lyophilised 
venom samples using Dynabeads® mRNA DIRECT™ Kit (Dynal, Invitrogen) 
following a protocol adapted from Chen et al (Chen et al., 2002)(Figure 2.2). 
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Messenger RNA was isolated from venom following hybridization and capture by 
magnetic oligo (dT)25 coated beads. 2mg lyophilised venom was reconstituted in 
300µl lysis/binding buffer (100mM Tris-HCl, pH 7.5, 500mM LiCl, 10mM EDTA, 
pH 8, 1% LiDS and 5mM DTT). 50µl Dynabeads were washed in an equal volume 
of lysis/binding buffer before removing buffer after separation of beads on a magnet. 
Washed beads were incubated with the lysed venom sample by inverting at room 
temperature for 10 min. Unbound material was removed by placing on the magnet 
for 2 min. Beads were then washed twice using 600µl washing buffer A (10mM Tris-
HCl pH 7.5, 0.15 M LiCl, 1mM EDTA and 1% LiDS) and once with 300µl washing 
buffer B (10mM Tris-HCl pH 7.5, 0.15M LiCl, 1mM EDTA). Poly(A) mRNA was 
eluted in 10µl Tris-HCl (10mM, pH 7.5) at 65-80°C for 2 min. Following the first 
elution of mRNA, unbound material was transferred back to the pre-washed 
magnetic beads and the mRNA isolation protocol was repeated once to ensure 
complete capture of mRNA from venom. Absorbance at 260/280nm and 
concentration of eluted mRNA was determined using the Nanodrop 1000 (ND-1000) 
Spectrophotometer and software (version 3.2.1). Messenger RNA was placed on ice 
and used immediately in first strand cDNA synthesis. 
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Figure 2.2 Extraction of poly(A) mRNA from venom using Dynabeads®: Flow 
diagram to show a direct approach for the extraction and PCR-amplification of 
mRNAs from snake venom and other biological materials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.7. First strand complementary DNA (cDNA) synthesis 
cDNA synthesis was performed from mRNA previously extracted from venom using 
first strand Superscript III cDNA synthesis kit (Invitrogen, UK). 8µl 2-5ng/µl mRNA 
was added to each reaction tube containing 1µl primer (50µM oligo dT) and 1µl 
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10mM dNTP mix. Samples were incubated for 5 min at 65°C and placed on ice for 1 
min. The cDNA synthesis master mix was prepared as follows (per reaction): 2µl 
10x RT buffer, 4µl 25mM MgCl2, 2µl 0.1M DTT, 1µl RNaseOUT (40U/µl), 1µl 
Superscript III RT (200U/µl). 10µl of the master mix was added to each reaction, 
gently mixed and incubated for 50 min at 50°C. The reaction was terminated 
following incubation at 85°C for 5 min. 1µl RNase H was added to each reaction and 
incubated at 37°C for 20 min. Confirmation and concentration of cDNA was 
performed using the ND-1000 Spectrophotometer. cDNA was used immediately in 
PCR or was stored at -20°C until required. 
 
2.8. Plasmid purification of venom gland library cDNA for PCR positive control 
A previously constructed B. arietans venom gland cDNA library using methods 
described in Wagstaff et al (Wagstaff and Harrison, 2006) was used as a positive 
control in polymerase chain reaction (PCR) experiments. 3ml sterile LB broth was 
inoculated with 2 x 200µl aliquots of the B. arietans venom gland cDNA library and 
incubated overnight at 37°C with vigorous agitation. Venom gland plasmid DNA 
was purified using the QIAprep Spin Miniprep kit (Qiagen, UK). All buffers were 
provided in the kit. 1.5ml of each culture was transferred to a 1.5ml eppendorf tube 
and centrifuged at 13,000rpm at 22°C for 1 min. Supernatant was discarded and 
250µl E. coli resuspension buffer (P1 and RNase A) was added to re-suspend the 
bacterial pellet. 250µl E. coli lysis buffer (P2) was added and mixed well by 
inversion for 5 min to lyse bacterial cells. 350µl neutralisation buffer (N3) was added 
and mixed immediately by inverting the tube for 2 min. The mixture was centrifuged 
at 13,000rpm at 22°C for 10 min to pellet protein and genomic DNA. The 
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supernatant was applied to the QIA prep spin column, incubated at room temperature 
for 1 min and centrifuged at 13,000rpm at 22°C for 1 min. The flow-through was 
discarded. The column was washed with 0.5ml wash buffer PB and centrifuged for 
30-60 seconds. Flow-though was discarded. A second wash with 750µl wash buffer 
PE was carried out, centrifuged for 1 min and the flow-through was discarded before 
repeating the wash with buffer PE. A dry spin was performed in order to remove any 
residual wash buffer and dry the column. To elute DNA, the spin column was 
inserted into a new 1.5ml eppendorf tube. 50µl MilliQ ultrapure water (Merck 
Millipore, UK) was pipetted directly onto the surface of the spin column and 
incubated at room temperature for 1 min. The column was centrifuged at 13,000rpm 
at 22°C for 1 min and plasmid DNA was placed on ice or stored at -20°C until use 
for PCR. 
 
2.9. Polymerase chain reaction (PCR) 
          2.9.1. PCR primer design 
PCR primers were designed to amplify a range of venom protein-encoding gene 
targets with varied representation in the Bitis arietans venom gland EST database. 
Primer design is discussed in greater detail in Section 4.3.4 in Chapter 4. 
 
          2.9.2. Conventional PCR 
The GoTaq® PCR Core system I (Promega, UK) was used to perform conventional 
PCR. PCR master mixes were prepared per reaction as follows: 10µl 5 x PCR buffer, 
4µl MgCl2,  µl dNTPs, 2.5µl 5’ primer, 2.5µl 3’ primer, 0.25µl Taq polymerase, 
 58 
 
28.75µl MilliQ ultrapure water (Merck Millipore, UK). 49µl of the master mix was 
added to 1µl venom gland cDNA in 0.2ml thin-walled eppendorf tubes. Following 
successful amplification of gene targets from venom gland cDNA, identical reactions 
were performed from venom cDNA. In this instance, 2µl of venom cDNA per PCR 
reaction was used (volume of MilliQ ultrapure water per reaction was adjusted to 
27.75µl). Samples were mixed thoroughly before initially undergoing the following 
amplification programme:  
- Step 1: Denaturation 94°C, 5 min. 
- Step 2: Denaturation 94°C, 1 min; annealing step 55°C, 1 min; extension 72°C, 1 
min. Repeat for 35 cycles. 
- Step 3: Final extension 72°C, 7 min. Maintained at 4°C. 
As all primer pairs were designed with similar melting and annealing temperatures, 
PCR amplification was carried out using an annealing temperature of 55°C. 
Following initial PCR amplification as described above, we observed several non-
specific PCR products. To optimise the PCR amplification and improve specificity, 
we elected to perform a touch-down PCR programme. Touch-down PCR was used to 
facilitate the binding of primers to specific sequences and avoid non-specific 
binding. A touch-down PCR programme was designed, beginning with a high 
annealing temperature (i.e. near to the primer melting temperature) to ensure highly 
specific annealing of primers sequences. The temperature was gradually decreased to 
a lower temperature which would be more tolerable to non-specific binding and 
therefore increase the overall yield of the amplicon. 
A touch-down programme was employed as follows: 
- Step 1: Denaturation 94°C, 5 min. 
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- Step 2: Denaturation 94°C, 1 min; annealing step 66-55 °C, 1 min; extension 
72°C, 1 min. Repeat for 35 cycles. 
- Step 3: Final extension 72°C, 7 min. Maintained at 4°C.  
Agarose-ethidium bromide (Agarose-EtBr) gels were prepared by melting a solution 
of 1% agarose in 1X Tris-Acetate-EDTA (TAE) buffer for 2-3 min or until agarose 
was completely dissolved. The molten agarose was cooled to ~50-55°C and 10-20µl 
ethidium bromide was added. The solution was gently mixed and poured into the gel 
casing containing the appropriate size well comb and left to solidify for 1 hour. To 
analyse the amplicon, 5µl of the PCR reaction was added to 5µl dH2O and 2µl 6X 
DNA loading buffer. The PCR reaction mixture was run on the 1% agarose-EtBr gel 
for 1 hour-90 min at 100V alongside 5µl marker (Benchtop DNA ladder, Promega, 
UK) in an electrophoresis tank filled with 1X TAE buffer. PCR products were 
visualised on the gel using a UV light box or transilluminator. 
 
          2.9.3. Purification of PCR products 
Amplicons from conventional PCR experiments were purified and tested as a 
standard for subsequent quantitative PCR (qPCR) experiments. Firstly, 45µl of each 
product was run on a 1% agarose-EtBr gel for 1 hour. Bands were visualised using 
the UV transilluminator and excised using a clean scalpel blade. Excised bands were 
cut into small pieces and transferred into an eppendorf tube and weighed. The 
Wizard PCR clean-up system (Promega, UK) was used to purify products and all 
solutions/reagents used were provided in the kit. Firstly, 10µl of the membrane 
binding solution was added per 10mg gel slice. The gel band was dissolved by 
incubating at 60°C for 2 min and mixing by vortex for a few seconds; this process 
 60 
 
was repeated until the gel band was completely dissolved. A mini-column was 
inserted into a collection tube and the molten gel solution was transferred onto the 
column. Following incubation at room temperature for 1 min, the mixture was 
centrifuged for 1 min at 16,000 x g. The flow-through was discarded and the mini-
column was re-inserted into the collection tube. To wash the column, 700µl 
membrane wash solution was added, centrifuged for 1 min at 16,000 x g and the 
flow-through discarded. A further 500µl membrane wash solution was added and 
centrifuged for 5 min at 16,000 x g. The collection tube was emptied and re-
centrifuged for 1 min with the inner centrifuge lid removed to allow evaporation of 
excess ethanol in the membrane wash solution which could affect subsequent 
analysis of DNA. Following the final wash, the mini-column was transferred into a 
clean 1.5ml eppendorf tube, 50µl nuclease-free water was added directly onto the 
mini-column filter surface and incubated at room temperature for 1 min. A final 
centrifuge at 16,000 x g for 1 min was carried out. The mini-column was then 
discarded and DNA collected in the eppendorf tube was stored at -20°C until further 
use.     
 
          2.9.4. Quantitative PCR (qPCR) 
The KAPA SYBR® FAST qPCR Kit (KAPA Biosystems, AnaChem) containing 2X 
qPCR master mix (DNA polymerase, SYBR green fluorescent dye, MgCl2, dNTPs 
and stabilisers) was used for all qPCR experiments. Briefly, 11µl PCR reactions were 
prepared by adding 10µl master mix (containing 0.22µl forward primer (10µM), 
0.22µl reverse primer (10µM), 5.5µl KAPA SYBR green dye and 4.06µl ultrapure 
water) to 1µg of each cDNA sample in a 1µl volume. QPCR reactions were 
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performed using the BioRad CFX 384 real-time PCR system using a two-step PCR 
program and data was analysed using the CFX manager software. Detailed 
descriptions of the optimisation and standardisation of qPCR experiments can be 
found in Chapter 4. 
 
2.10. Isolation and characterisation of venom-encoding genes by genome 
walking protocols 
          2.10.1. Genomic DNA isolation 
Liver tissue was harvested from an adult B. arietans specimen in 2006 and 
immediately frozen in liquid nitrogen. 25mg frozen tissue was gently ground in 
liquid nitrogen and transferred to a 1.5ml eppendorf tube. Genomic DNA was 
isolated according to the DNeasy Blood and tissue Kit (Qiagen, UK). 180µl of buffer 
ATL and 20µl Proteinase K was added to the tissue sample, mixed thoroughly by 
vortexing and incubated at 56°C until tissue was completely lysed. 200µl buffer AL 
was added to the sample and mixed thoroughly by vortexing. 200µl absolute ethanol 
was added to the sample and immediately mixed thoroughly by vortexing in order to 
yield a homogenous solution. The solution (including any precipitate) was pipetted 
onto the DNeasy Mini Spin column placed in a 2ml collection tube and centrifuged 
at 8000rpm for 1 min. The spin column was placed in a new collection tube, 500µl 
buffer AW1 was added and centrifuged 8000rpm for 1 min. The spin column was 
placed in a new collection tube and 500µl buffer AW2 was added and centrifuged at 
13,000rpm for 3 min to dry the membrane to ensure that no residual ethanol 
remained on the membrane. The spin column was placed into a clean 1.5ml 
eppendorf tube, 200µl buffer AE was pipetted directly onto the surface of the 
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membrane and incubated at room temperature for 1 min then centrifuged at 8000rpm 
for 1 min for elute genomic DNA. Elution of DNA was repeated for a second time 
using a new eppendorf tube to increase the overall yield of DNA. Genomic DNA at a 
concentration of approximately 0.1µg/µl was eluted and stored at -20°C until further 
use. 
 
          2.10.2. Quality assessment of genomic DNA 
0.1-10µg genomic DNA isolated from B. arietans liver tissue was analysed on a 
0.6% agarose-EtBr gel alongside 1µg human control genomic DNA to assess the 
quality of genomic DNA. Genomic DNA purity was assessed by performing DraI 
digestion. 0.1µg-10µg B. arietans genomic DNA was added to 1.6µl DraI 
(10units/µl), 2µl 10X DraI restriction buffer and 11.4µl MilliQ ultrapure water 
(Merck Millipore, UK). An identical reaction was also prepared using 1µg human 
control genomic DNA and negative controls where DraI enzyme was substituted for 
water. Reactions were gently mixed and incubated overnight at 37°C. 5µl of each 
reaction was analysed on a 0.6% agarose-EtBr gel alongside undigested genomic 
DNA to visualise DNA smearing following digestion. 
 
          2.10.3. Genomic library construction using GenomeWalker
TM
 Kit 
Genome walking experiments were performed using the GenomeWalker
TM
 Universal 
kit (ClonTech, UK). Four digestion reactions containing B. arietans genomic DNA 
were set up – one for each of the restriction digestion enzymes included in the library 
construction kit; DraI, EcoRV, PvuII and StuI creating four DNA libraries (DL1-4). 
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Additionally, one PvuII digestion of human genomic DNA was set up as a positive 
control. 25µl of genomic DNA at a concentration of 0.1µg/µl was transferred to a 
labelled eppendorf tube. 8µl of restriction enzyme (10 units/µl), 10µl 10X restriction 
buffer and 57µl dH2O was added and mixed gently. Digestion reactions were 
incubated at 37°C for 2 hours. Each reaction was gently vortexed for 5-10 seconds 
and returned to 37°C for overnight incubation. Following digestion, 5µl of each 
reaction was removed and analysed on a 0.6% agarose-EtBr gel to determine whether 
digestion was complete. Digested genomic DNA was then purified. Firstly, 95µl of 
phenol was added to each DNA digest and mixed by gently vortexing for 5-10 
seconds. The mixture was briefly centrifuged to separate aqueous and organic 
phases. The upper aqueous phase was transferred into a new 1.5ml eppendorf tube 
and the lower organic layer was discarded. To each tube 95µl chloroform was added 
and mixed by gently vortexing for 5-10 seconds. The mixture was briefly centrifuged 
to separate aqueous and organic phases. The upper aqueous phase was transferred 
into a new 1.5ml eppendorf tube and the lower organic layer was discarded. To each 
tube, 190µl ice cold 95% ethanol, 9.5µl 3M NaOAc (pH 4.5) and 20µg glycogen was 
added and mixed by gently vortexing for 5-10 seconds. The mixture was centrifuged 
at 13,000rpm for 15 min at 4°C. The supernatant was discarded and the pellet was 
washed in 100µl of ice cold 80% ethanol. The mixture was centrifuged at 13,000rpm 
for 10 min. The supernatant was discarded and the pellet was air dried. The pellet 
was dissolved in 20µl TE 10/0.1 (10mM Tris, 0.1mM EDTA pH 7.5) by gently 
vortexing for 5-10 seconds. From each reaction, 1µl was removed and visualised on 
a 0.6% agarose-EtBr gel to confirm DNA. The GenomeWalker
TM
 adaptor (shown in 
Figure 2.3) was ligated onto the four blunt-end digestions of B. arietans genomic 
DNA and one positive control (restriction-digested human genomic DNA). 4 µl 
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Figure 2.3 The GenomeWalker adaptor: Structure of the GenomeWalker
TM
 
adaptor which was ligated to both ends of the genomic DNA fragments to create 
genome walker libraries. The amine group on the lower strand of the adaptor blocks 
extension of the 3’ end of the adaptor-ligated genomic fragments, thus preventing 
formation of an adaptor primer 1 (AP1) binding site of the general population of 
fragments. 
digested and purified DNA was transferred into a fresh 0.5ml eppendorf tube into 
which 1.9µl GenomeWalker adaptor (25µM), 1.6µl 10X ligation buffer and 0.5µl T4 
DNA ligase buffer (6 units/µl) was added and incubated at 16°C overnight. To stop 
the reactions, tubes were incubated at 70°C for 5 min. To each tube 72µl TE 10/1 
(10mM Tris, 1mM EDTA pH 7.5) and mixed by gently vortexing for 10-15 seconds. 
   
        2.10.4. Genome walking PCR primer design 
PCR primers were designed to amplify a region of genomic DNA upstream of the 
transcription start site with the aim of obtaining sequences containing regulatory 
elements. For each gene of interest, two gene-specific reverse primers were designed; 
one for primary PCR and one for secondary (nested) PCR. The primary gene-specific 
primer was designed to be positioned as close to the 5’ end of the coding region of 
the gene as possible. Primer pairs were designed to anneal to the highly conserved 
regions of the signal peptide of each venom protein group target including SVMP, 
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SP, CTL, LAO, VEGF, KTI, QKW and PDI. Primers were 28 nucleotides in length, 
aimed to have a GC% content of approximately 40% and similar melt temperatures 
of 65-70°C. The secondary gene-specific primer was designed to anneal to sequences 
beyond the 3’ end of the primary primer and avoid overlapping of primary and 
secondary sequences. Forward primers, which were designed specifically to bind to 
the adaptor sequence ligated onto genomic DNA during genome library construction, 
were provided in the GenomeWalker
TM
 Universal kit (ClonTech, UK). Primer 
sequences are shown in Table 7.1 in Section 7.3.4 of Chapter 7.  
 
          2.10.5. Long range PCR amplification of genomic DNA and purification of 
PCR products 
Amplification from genome walker libraries was carried out using the Advantage 2 
PCR kit (ClonTech, UK). Positive controls included amplification of human tissue-
type plasminogen activator (tPA) from a human PvuII genome walker library and a 
pre-constructed human genome walker library provided in the kit A master mix 
containing 5µl 10X Advantage 2 PCR buffer, 1µl GSP1 (10µM), 1µl AP1 (10µM), 
1µl 50X dNTP mix (10mM), 1µl 50X Advantage 2 Polymerase mix and 40µl PCR 
grade water per reaction was added to 1µl of each genomic DNA library (DL1-4). 
The following thermocycling protocol was conducted: 7 cycles; 94°C 25 seconds, 
72°C for 3 min, 32 cycles; 94°C for 25 seconds, 67°C for 3 min followed by 
extension for 7 min at 67°C. 5µl of the PCR reaction was visualised on a 1% 
agarose-EtBr gel. For secondary PCR, 1µl primary PCR amplicon was diluted in 
49µl PCR-grade water and 1µl was added to a master mix (containing 5µl 10X 
Advantage 2 PCR buffer, 1µl GSP2 (10µM), 1µl AP2 (10µM), 1µl 50X dNTP mix 
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(10mM), 1µl 50X Advantage 2 Polymerase mix and 40µl PCR grade water per 
reaction). The following thermocycling protocol was conducted: 5 cycles; 94°C for 
25 seconds, 72°C for 3 min, 20 cycles; 94°C for 25 seconds, 67°C for 3 min, 
followed by extension at 67°C for 7 min. 5µl of the PCR reaction was visualised on a 
1% agarose-EtBr gel.  
For cloning, PCR products were purified according to recommendations from the 
TOPO XL PCR cloning kit (Invitrogen) using the S.N.A.P
TM
 purification columns 
provided in the kit. 40µl of selected products was added to 8µl 6 x crystal violet 
loading buffer and separated on a 0.8% agarose gel containing 80µg crystal violet 
dye at 80V until the dye had migrated approximately ¼ of the way towards the 
negative terminal and thin blue bands of PCR product are visible. The gel was placed 
on a light box and single-band products were excised. The gel band was placed on 
parafilm, chopped up into small pieces and transferred into a 1.5ml eppendorf tube. 
The volume of the gel was estimated by weight (1mg = approx. 1µl). 2.5 times the 
gel volume of 6.6M sodium iodine was added to the gel and mixed well by 
vortexing. The gel was incubated at 42-50°C and mixed periodically by vortexing 
until completely dissolved. At room temperature, 1.5 times volume of binding buffer 
was added and mixed well by vortexing. The S.N.A.P
TM
 column was assembled in 
the collection tube. All of the dissolved gel mixture was added onto the column and 
centrifuged at 5600rpm for 30 seconds. The liquid collected in the tube was poured 
back onto the column and centrifuged again. The liquid from the collection tube was 
transferred back onto the column and centrifuged for a third and final time. The 
liquid in the collection tube was discarded. 400µl 1 x final wash buffer was added to 
the column and centrifuged at 5600rpm for 30 seconds. The liquid from the 
collection tube was transferred back onto the column and centrifuged. Liquid was 
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discarded and the column was centrifuged at 10,000rpm for 1 min to dry the column. 
The column was transferred to a clean 1.5ml eppendorf tube. 40µl TE buffer was 
added directly onto the column and incubated at room temperature for 1 min. To 
elute DNA bound to the column, the column was centrifuged at 10,000rpm for 1 min. 
DNA concentration was measured using the ND-1000 spectrophotometer, in 
addition, 10µl DNA was run on a 1% agarose-EtBr gel to visualise DNA.   
 
          2.10.6. Sub-cloning and transformation of E. coli with purified genomic 
PCR products  
Sub-cloning of PCR products was performed using the TOPO® XL PCR cloning kit 
(Invitrogen, UK). Two cloning reactions for each PCR product were set up in order 
to optimise the efficiency of cloning. The first reaction contained 2µl purified PCR 
product, 1µl pCR XL TOPO vector and 2µl MilliQ ultrapure water (Merck 
Millipore, UK). The second reaction contained 4µl purified PCR product and 1µl 
pCR XL TOPO vector. Ligation reactions were mixed gently and incubated at room 
temperature. The incubation time was increased to 1 hour in order to improve the 
efficiency of cloning long PCR products. Following incubation, ligation reactions 
were terminated by adding 1µl 6X TOPO cloning stop solution and mixed at room 
temperature. Reactions were placed on ice. One vial of OneShot TOP 10 chemically 
competent E. coli cells (50µl) per ligation reaction was gently thawed on ice. 5µl 
TOPO cloning reaction was added to the vial of E. coli cells and mixed gently by 
inverting the tube. Tubes were incubated for 30 min on ice. This was followed by a 
heat shock at 42°C for 30 seconds, after which tubes were immediately placed on ice 
for 2 min. 250µl of SOC medium was added to each transformation tube and 
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incubated at 37°C for 1 hour while shaking horizontally. Two volumes of 
transformed cells (75µl and 230µl) of each transformation reaction was spread onto 
an IPTG/Xgal/Kanamycin impregnated agar plate and incubated overnight at 37°C to 
optimise bacterial growth. 
 
          2.10.7. Selection and amplification of recombinant E. coli colonies 
Following overnight incubation, the ratio of blue: white (non-recombinant: 
recombinant) colonies of E. coli was recorded to assess the efficiency of ligation. For 
each plate, a sample of 5 white colonies was taken and transferred into a falcon tube 
containing 2ml of LB Kanamycin medium. Recombinant colonies were cultured 
overnight at 37°C with agitation. 
 
          2.10.8. Purification and analysis of recombinant plasmids by restriction 
enzyme digestion 
Plasmid DNA from overnight E. coli cultures was purified using the QIAprep Spin 
Miniprep plasmid purification kit (Qiagen, UK). 1.5ml of each culture was 
transferred to a 1.5ml eppendorf tube and centrifuged at 13,000rpm at 22°C for 1 
min. Supernatant was discarded and the pellet was resuspended in 250µl E. coli 
resuspension buffer. 250µl E. coli lysis buffer was added and mixed well for 5 min to 
lyse bacterial cells. 350µl neutralisation buffer was added and mixed well for 2 min. 
The mixture was centrifuged at 13,000rpm at 22°C for 10 min to pellet genomic 
DNA and protein. The spin column and collection tube was assembled. The 
supernatant was recovered and applied to the spin column, incubated at room 
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temperature for 1 min and centrifuged at 22°C for 1 min. The flow-though was 
discarded. 750µl wash buffer was added onto the spin column and centrifuged at 
13,000 rpm at 22°C for 1 min and the flow-through was discarded before repeating 
the wash. A dry spin was performed in order to remove any residual wash buffer and 
dry the column. The spin column was inserted into a new 1.5ml eppendorf tube. 50µl 
MilliQ ultrapure water (Merck Millipore, UK) was pipetted directly onto the surface 
of the spin column and incubated at room temperature for 1 min. To elute DNA, the 
column was centrifuged at 13,000rpm at 22°C for 1 min and plasmid DNA was 
placed on ice. To determine the presence of inserts in plasmid constructs, restriction 
digestion of DNA was performed. 5µl plasmid DNA was mixed with 0.5µl EcoRI, 
2µl Buffer H, 0.2µl BSA (10µg/µl) and 12.3µl MilliQ ultrapure water (Merck 
Millipore, UK) and incubated at 37°C for 4 hours to overnight. 4µl digests were 
analysed on a 1% agarose-EtBr gel to detect the presence of PCR product inserts. 
 
          2.10.9. Selection and submission of recombinant plasmids for DNA 
sequencing 
A selection of plasmids containing inserts were submitted to Beckman Coulter 
Genomics for Sanger DNA sequencing in both directions using M13 forward and 
M13 reverse sequencing primers.  
 
          2.10.10. Bioinformatics interrogation of genomic DNA sequences 
A bioinformatics pipeline was employed to describe the upstream region of genomic 
DNA and identify and characterise promoters and regulatory sequences of the gene. 
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Sequence data was analysed using DNASTAR. To assemble contigs from multiple 
fragments of the same gene, the forward and reverse sequences for each clone were 
assembled in SeqMan to create a single construct or contig from the sequences. The 
alignments were examined to identify any discrepancies and the nucleotide 
consensus nucleotide sequences were translated. Firstly, the est2genome (Mott, 
1997) program was used to identify the specific gene sequence obtained following 
sub-cloning by screening the genomic sequence against the B. arietans EST 
database. The open reading frame for each contig was identified using the ORF 
finder tool from NCBI (NCBI, 2012b) and analysing each translation to identify the 
correct reading frame. Signal peptides were identified using SignalP server (version 
4.0 (Bendtsen et al., 2004). Sequences were identified by performing a BLAST 
similarity search (NCBI, 2012a) against the nucleotide database. To map intron-exon 
boundaries in gene sequences, Wise2 algorithm (NCBI, 2012c) was used to compare 
translated protein sequences and genomic DNA sequences, allowing for 
frameshifting errors. 
 
2.11. Ethical declaration 
All animal experimentation involving snakes conducted during the course of this 
work was undertaken using protocols approved by The Liverpool School of Tropical 
Medicine Animal Welfare Committee and performed with licenced approval of the 
UK Home Office. 
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3. INTRA-SPECIFIC VARIATION IN VENOM OF THE AFRICAN PUFF 
ADDER (BITIS ARIETANS); DIFFERENTIAL EXPRESSION AND 
ACTIVITY OF THE SNAKE VENOM METALLOPROTEINASES (SVMPs) 
 
The results of most of the work performed in this chapter have been published in 
Toxicon (Currier et al., 2010). 
 
3.1. Abstract 
Bitis arietans is considered one of the most medically significant snakes in Africa, 
primarily due to a combination of its extensive geographical distribution, common 
occurrence throughout sub-Saharan Africa and highly potent haemorrhagic and 
cytotoxic venom. 
Our investigation has revealed a remarkable degree of intra-species variation 
between pooled venom samples from different geographical origins across sub-
Saharan Africa and Arabia, and within a group of individual specimens from the 
same origin in Nigeria as determined by a combination of immunological, 
biochemical and proteomic assays. We demonstrate significant qualitative and 
quantitative differences between B. arietans venom in terms of protein expression, 
immunogenicity and activity of the snake venom metalloproteinases (SVMPs); 
toxins with a primary role in the haemorrhagic and tissue-necrotic pathologies 
suffered by envenomed victims. Specifically, we have identified a processed PII 
SVMP that exhibits striking inter-specimen variability. The findings of this chapter 
illustrate the degree of variation in venom composition from B. arietans, a venomous 
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Figure 3.1 Adult Bitis arietans coloration and geographical distribution: A) An 
adult B. arietans specimen originating from Ghana (photograph courtesy of 
Wolfgang Wuster) and B) the widespread geographical distribution of B. arietans 
throughout sub-Saharan Africa. 
snake of significant medical importance. These results are therefore important to 
therapeutic, biological and evolutionary venom research. 
 
3.2. Introduction 
The Puff adder, B. arietans, occupies a diverse range of habitats throughout the 
savannah areas of sub-Saharan Africa and parts of the Arabian Peninsula, regions 
which are also densely populated with people and livestock (Figure 3.1).  
 
The venom of this species is highly potent and typically interferes with the 
haemostatic system to cause severe local and systemic effects such as swelling, 
haemorrhage and necrosis (Warrell et al., 1975). Without antivenom treatment, B. 
arietans envenoming can have fatal consequences (Warrell et al., 1975). In Africa, it 
is estimated that snakebite accounts for up to 32,000 deaths per year, with many 
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more victims left with permanent disabilities and sequelae (Kasturiratne et al., 2008). 
The Puff Adder (B. arietans), the saw-scaled viper (Echis ocellatus) and the spitting 
cobra (Naja nigricollis) are responsible for the majority of these fatalities in Africa. 
The medical importance of B. arietans and its unusually extensive pan-African 
distribution for a single species make this species an ideal subject to investigate intra-
species venom variation, not only from a biological and evolutionary standpoint, but 
also from the perspective of the possible consequences venom variation may have on 
the clinical symptoms of envenoming and patient response to antivenom.  
Viper venom is a highly complex biologically active mixture typically containing 
numerous enzymatic and non-enzymatic components (Serrano et al., 2005), most of 
which are proteins and peptides enabling the rapid immobilisation, killing and 
digestion of envenomed prey. Variation in venom protein composition has been well 
documented on several taxonomic levels and particularly within species occupying 
wide geographical distributions. Several studies investigating inter-species venom 
variation have attributed their findings to factors such as specimen age, dietary and 
gender associated changes. Firstly, diet has been strongly linked to variation in 
venom protein composition and biological function. Daltry et al correlated variation 
in the protein composition and biological activity of Calloselasma rhodostoma 
venom to geographic location and phylogenetic relationships. Studies presented 
strong evidence for the association between variation in the venom of this species 
and its diet (Daltry et al., 1996a, Daltry et al., 1996b). Variation in venom protein 
composition between closely related subspecies of Sistrurus rattlesnakes determined 
by proteomics (Sanz et al., 2006) and in the venom toxicity of Echis species 
determined by LD50 assays (Barlow et al., 2009) have also been correlated with the 
selection of different toxins into the proteome of species with predominantly 
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mammalian or varied diets. Ontogenetic shifts related to specimen age (and dietary 
shifts in venom-specificity) will be described further in Chapter 5. Differences in 
venom between adult and juvenile venoms with respect to (i) coagulant activity of 
Bothrops atrox and Crotalus atrox venom (Lopez-Lozano et al., 2002) (Reid and 
Theakston, 1978) (ii) PIII to PI SVMPs in B. asper (Alape-Giron et al., 2008), and 
(iii) haemorrhagic and oedema-forming activities both in B. atrox and B. asper 
(Saldarriaga et al., 2003) have been demonstrated. Finally, examples of gender-
specific differences in B. jararaca venom have also been demonstrated (Menezes et 
al., 2006) in respect of fibrinogenolytic and amidolytic properties, differential 
processing of bradykinin-potentiating peptides (Pimenta et al., 2007), and differential 
hyaluronidasic, haemorrhagic, coagulant, phospholipasic and myotoxic properties 
(Furtado et al., 2006). 
While variation in venom composition has been described for members of the Bitis 
genus of less medical significance (e.g. B gabonica gabonica, B. g. rhinoceros, B. 
nasicornis and B. caudalis) (Calvete et al., 2007a, Calvete et al., 2007b), there have 
been no such studies on B. arietans, the most clinically important member of the 
genus. A previous investigation of B. arietans venom demonstrated that the proteome 
may be less complicated than originally predicted, containing proteins belonging to 
only a few major toxin families, the majority of which are SVMPs and to a lesser 
extent, SPs, disintegrins and CTLs (Juárez et al., 2006). The latter proteomic studies, 
in conjunction with our own venom gland transcriptomic results (Wagstaff and 
Harrison, unpublished) indicate that the composition of Bitis venom exhibits 
extensive isoform diversity, potentially within one of the most toxic groups of venom 
proteins, the SVMPs.  
The primary aim of this study was to explore the B. arietans venom proteome and 
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determine the extent of variation between specimens from different or the same 
geographical origins, particularly within the major toxin groups responsible for the 
most significant clinical pathology. As much of the pathology of viper envenoming is 
caused by enzymes and venom is the immunogen used for antivenom preparation, we 
therefore elected to use biochemical assays of enzyme function and immunological 
assays, in addition to the standard proteomic techniques used to characterise venom 
proteome diversity, to produce a more comprehensive understanding of variation in 
B. arietans venom. The results of this work aimed to provide detailed analyses of the 
protein composition of B. arietans venom and gaining an insight into the levels of 
variability in the venom from this species, which we could later correlate with gene 
expression and transcriptomic analyses. 
 
3.3. Materials and Methods: 
          3.3.1 Venom sample extraction and preparation 
Individual venom samples extracted from 12 Nigerian and 6 Ghanaian wild-caught 
adult specimens were analysed. Individual snakes were maintained in the 
herpetarium at the Alistair Reid Venom Unit under identical climatic conditions 
where they were fed the same diet and the technique and frequency of venom 
extraction was identical for all animals. Following manual extraction, venom was 
frozen at -20°C, lyophilised and stored at 4°C until analysis. Following analysis, 
venom extractions from the same specimens were repeated to ensure reproducibility 
of observations. Pooled venom samples from B. arietans specimens originating from 
six different geographical origins across Africa and Western Arabia (Ghana, Nigeria, 
Zimbabwe, Malawi, Tanzania and Saudi Arabia) typically comprised multiple 
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extractions from larger pools (usually tens) of individual specimens had been 
reconstituted in phosphate-buffered saline (PBS) at 10mg/ml and stored at -80°C. To 
compare the levels of intra-species venom variation within groups of different 
viperid species, the protein composition of venom from individual Saw-scaled vipers 
(20 Echis ocellatus, Nigeria) and Desert horned vipers (18 Cerastes cerastes, Egypt) 
specimens was analysed.  
 
          3.3.2. Venom protein composition profiling by 1D SDS-PAGE 
Lyophilised venom samples were reconstituted at 10mg/ml in PBS and diluted to 
1mg/ml in reducing or non-reducing SDS-PAGE sample buffer and separated on 
1mm 15% SDS-PAGE gels as described in Section 2.2 of Chapter 2. 
 
          3.3.3. Antibody cross-reactivity of venoms by immunoblotting 
Gels were electro-blotted to 0.45µm nitrocellulose membranes using the 
manufacturer’s protocols (BioRad) under reducing conditions as described in Section 
2.3 of Chapter 2. Following blocking and washing, blots were incubated for 5 hours 
with the following primary antibodies diluted in blocking buffer; EchiTAb-Plus-ICP 
(an equine IgG polyspecific antivenom prepared against E. ocellatus, B. arietans and 
N. nigricollis venoms; Instituto Clodomiro, University of Costa Rica (Gutiérrez et 
al., 2005a) (1/1000 dilution), rabbits immunised with recombinant E. ocellatus 
SVMP epitope string [E. o α-SVMP-string] (Wagstaff et al., 2006) or sera from mice 
immunised with a DNA-encoding expression plasmid pVaxSec (Wagstaff et al., 
2006) containing E. ocellatus VEGF clone Eo_venom_02G03 (Accession number: 
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DW360875) [E. o α-VEGF] (1/200 dilution). We elected to investigate the 
immunoreactivity of the SVMPs due to their abundance, toxicity and important 
pathological role in viperid envenoming. We also selected to analyse the 
immunoreactivity of VEGF. VEGFs are of interest due to the variation in structure 
and function that exists between different species of venomous snakes. A recent 
publication showed that barietin, a VEGF isolated from B. arietans venom, may be 
unique among the snake venom VEGFs as it is able to bind to heparin with a high 
affinity, despite apparently lacking the heparin binding sites in the C-terminal region 
present in other snake venom VEGFs (Yamazaki et al., 2009). It is therefore thought 
that barietin may demonstrate unique biological properties which require further 
investigation. Although the toxin-specific antibodies used were specific to E. 
ocellatus venom, previous investigation has demonstrated varying degrees of cross-
reactivity with venoms of other viperid species, including B. arietans (Wagstaff et 
al., 2006). Blots were incubated with secondary antibodies, washed and developed as 
described in Section 2.3 of Chapter 2. 
 
          3.3.4. Venom enzyme activity profiling by substrate zymography 
Zymography was carried out using gelatin and fibrinogen substrates to visualise the 
degradative activity of the enzymes present in viper venoms as described in Section 
2.4 of Chapter 2.  
 
          3.3.5. Identification of venom proteins by LC-MS/MS 
In-gel trypsin digestion, LC-MS/MS and protein identification protocols are 
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described in Section 2.5 of Chapter 2. Several protein bands of interest from SDS-
PAGE profiles of individual Nigerian venom samples were excised from the gel as a 
discrete entity (see Figure 3.2 and Table 3.1). Protein bands of interest which were 
expressed in more than one individual viper were excised from all those individuals 
to ensure reproducibility and accuracy of the identification. 
 
3.4. Results: 
          3.4.1. Variation in venom composition between B. arietans specimens from 
different geographical origins: 
Protein profile 
We observed variation in venom protein profiles separated by reducing and non-
reducing SDS-PAGE of pooled venom from B. arietans specimens originating in 
Ghana, Saudi Arabia, Nigeria, Zimbabwe Malawi and Tanzania (Figure 3.2Ai and 
ii). Saudi Arabian venom had the most distinct venom protein profile in comparison 
with the African samples; this was most evident under reducing SDS-PAGE 
conditions as a distinct protein of approximately 22kDa (Figure 3.2Aii
[1]
) present in 
the African venoms was clearly lacking in the Saudi Arabian venom. The variation 
between B. arietans venoms from within Africa was less striking. The Ghanaian, 
Nigerian, Zimbabwean and Malawian venoms showed a relatively similar protein 
profiles but the Tanzanian venom was markedly different; the 22kDa protein present 
in all other African venoms was at a much lower level in Tanzanian venom and this 
venom also contained a highly expressed protein of approximately 12kDa (Figure 
3.2Aii
[2]
) which was either absent or present at a significantly lower level in other 
venoms. 
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Antibody cross-reactivity 
We used toxin-specific antibodies to SVMPs (Wagstaff et al., 2006) and VEGF, 
(Figure 3.2Bi and ii) to further investigate toxin-class specific changes in expression 
between pooled venom samples. With respect to SVMP composition, immunoblot 
analysis, like the SDS-PAGE result, revealed that the Saudi Arabian B. arietans 
venom was substantially different from the African venoms as this sample presented 
very little SVMP reactivity to the antisera. Tanzanian venom also showed a unique, 
intense immunoreactivity with the SVMP antibody to proteins in the lower molecular 
mass region, approximately 14kDa (Figure 3.2Bi
[A]
) – possibly corresponding to a 
fragment of a metalloproteinase domain that underwent autolysis. This was a similar 
molecular mass to the uniquely expressed 12kDa protein (Figure 3.2Aii
[2]
) observed 
in this sample, suggesting that the protein may be a member of this enzyme family, 
although we were unable to obtain a confident LC-MS/MS identification to confirm 
this. The remaining African venoms showed similar SVMP immunoreactivity and all 
venom samples exhibited the same reactivity to the VEGF antibody. However, as the 
antisera used in these experiments were raised against E. ocellatus venom proteins, it 
is possible that some variation in immunoreactivity of venoms may be due to 
differences in antibody specificity, although cross-reactivity between African viper 
venoms has been observed.  
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Figure 3.2 Analysis of pooled B. arietans venom samples from six different 
geographical origins: A) SDS-PAGE under i) non-reducing and ii) reducing 
conditions, B) reduced immunoblotting against i) E. o α-SVMP epitope string and ii) 
E. o α-VEGF antibodies and C) substrate zymography using i) gelatin and ii) 
fibrinogen substrates. Molecular weight markers (kDa) are shown on the left of each 
image. Note that migration on zymograms does not necessarily correspond with 
migration on SDS-PAGE or immunoblots due to differences in sample preparation 
conditions and the presence of substrate in the gels. 
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Enzyme activity 
The substrate-degrading activity of SVMPs present in the B. arietans venoms varied 
significantly between samples from different geographical origins. With gelatin and 
fibrinogen zymography, the extent of substrate degradation by venom enzyme 
activity followed a general pattern of decreasing lytic activity as follows; Nigeria > 
Ghana > Malawi > Tanzania > Zimbabwe > Saudi Arabia (Figure 3.2Ci and ii). 
These activities do not display an obvious geographical trend. For example, B. 
arietans venom from the relatively closely neighbouring countries of Malawi, 
Tanzania and Zimbabwe exhibit varied fibrinogen- and gelatin-degrading activities. 
Similarly, Nigerian venom showed significantly greater gelatin and fibrinogen 
substrate-degrading ability compared to those specimens found in nearby Ghana. 
Saudi Arabian venom showed an unusual pattern of substrate degradation with an 
apparent doublet of weak gelatin-degrading enzyme activity but little detectable no 
fibrinogenolytic activity; a finding also consistent with the relatively low amounts of 
SVMPs in this venom detected by immunoblotting. Tanzanian venom also showed 
unique SVMP activity with a low molecular weight area of fibrinogen degradation 
not observed in other venoms.  
 
          3.4.2. Variation in venom between individual B. arietans specimens from 
the same geographical origin (Nigeria): 
Protein profile 
The extensive venom variation observed between B. arietans specimens from distinct 
geographical origins may have been due to compositional differences in venoms of 
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individual specimens. To address this, we examined the individual venom protein 
profiles of several Nigerian B. arietans specimens. No apparent differences were 
observed in non-reduced SDS-PAGE profiles (Figure 3.3Ai). We observed a 
remarkable variation in SDS-PAGE protein profile under reducing conditions 
between venom samples of individual snakes from the same origin (Figure 3.3Aii). 
There were subtle and more prominent variable components; the generalised profile 
shows significant qualitative differences confined to a molecular mass below 25kDa 
with the majority of high molecular weight proteins being more intra-specifically 
conserved. To ensure reproducibility of these observations, venom samples extracted 
on two different occasions were analysed by identical SDS-PAGE experiments, 
yielding identical results (Figure 3.4). On first observation, the group could be 
equally divided into two clades based on the presence or absence of a 23kDa 
molecular weight protein (Figure 3.3Aii
[1]
), the presence of which was not gender-
specific as it could be observed in both male and female specimens. However, a 
more detailed examination of the low molecular weight components indicates that 
variation between individuals may be much more complex than was initially 
apparent. Thus, specimen BaN61 was noted to have a particularly unique protein 
profile due to the high expression of a protein of approximately 8kDa (Figure 
3.3A
[4]
), which was either absent, or expressed a very low levels in other individuals. 
It is noteworthy that, whilst the pooled venom and individual venoms show broadly 
similar protein profiles on reduced SDS-PAGE gels (with prominent components 
around 50, 20 and 12-15kDa), they may differ in the presence of specific venom 
components. Since pooled venoms contain a more heterogeneous population of 
proteins (in terms of molecular mass and charge variations of isoforms) extracted 
from a larger pool of individuals, resolution of venom components from pooled 
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Figure 3.3 Analysis of individual Nigerian B. arietans venom samples: Ai) non-
reduced SDS-PAGE and ii) reduced SDS-PAGE, B) reduced immunoblotting against 
i) E. o α-SVMP epitope string and ii) E. o α-VEGF and C) substrate zymography 
using i) gelatin and ii) fibrinogen substrates. Number in (Aii) illustrates proteins 1-4 
which were excised and trypsin-digested for LC-MS/MS identification. Molecular 
weight markers (kDa) are shown on the left of each image. Note that migration on 
zymograms does not necessarily correspond with migration on SDS-PAGE or 
immunoblots due to differences in samples preparation conditions and presence of 
substrate in the gels. (F = Female, M = Male specimen) 
venoms is not always comparable with that of individual specimens. 
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Figure 3.4 Reproducibility of venom protein profile of Nigerian Bitis arietans 
specimens: Venom samples extracted from Nigerian specimens on a different 
occasion to venom samples analysed in Figure 3.3Ai were analysed by identical 
SDS-PAGE experiments, yielding identical results. Molecular weight markers (kDa) 
are shown on the left of the image. 
 
 
 
 
 
 
 
Antibody cross-reactivity 
Immunoblotting with the Eo-SVMP string antibody revealed a high degree of 
variation in SVMP venom immunoreactivity (Figure 3.3Bi). We interpret these 
observations as reflecting variation in the expression, and/or differential processing, 
of SVMPs or disintegrins. Firstly, an immunoreactive protein of 23kDa (Figure 
3.3Bi
[A]
) in venoms from six individuals (BaN02, 53, 60, 65, 66 and 72) was 
observed and appeared to correlate with the presence or absence of the variable 
protein of the same molecular mass clearly apparent on reduced SDS-PAGE (Figure 
3.3A
[1]
). These individuals also share a common immunoreactive band of 
approximately 12kDa (Figure 3.3Bi
[B]
), interpreted as indicating the likely presence 
of an additional disintegrin. A variable 25kDa immunoreactive protein (Figure 
3.3Bi
[C]
) was expressed in six individuals but the expression of this protein did not 
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co-vary with either the 12kDa or the 23kDa protein above. Of the high molecular 
weight proteins, an intensely immunopositive protein of approximately 70kDa was 
uniquely expressed in a single individual; BaN61 (Figure 3.3Bi
[D]
). In comparison, 
there was no variation between individuals in immunoreactivity when probed with 
the Eo-VEGF antibody (Figure 3.3Bii), indicating that the expression of this venom 
protein was more constitutive than that of the SVMPs. 
 
Identification of individual venom components 
We identified, by LC-MS/MS of excised protein, bands which were either 
significantly variable between individual B. arietans venoms (Figure 3.3A
[1,4]
) and 
venom proteins whose expression appeared to be highly conserved between 
individual specimens (Figure 3.3A
[2-3]
) (Table 3.1). The functional identity of venom 
proteins showing distinct expression profiles were determined by LC-MS/MS. The 
venom component exhibiting the most marked quantitative differences, a 23kDa 
protein (Figure 3.3A
[1]
), was confidently identified as an SVMP isoform (contig 
BAR00042 in our assembled B. arietans venom gland EST database) (Table 3.1). 
The predicted full-length protein sequence of BAR00042 (Figure 3.5) strongly 
suggests that it belongs with the PII class of SVMPs, containing a C-terminal RGD-
containing disintegrin domain. The predicted molecular weight of the intact enzyme 
was 53kDa which did not correspond to the observed molecular weight of the protein 
band. However, the molecular weight (23kDa) and MS peptide data being 
exclusively recovered from within the catalytic metalloproteinase domain of the 
SVMP (Figure 3.5) indicated that the 23kDa protein was the processed 
metalloproteinase domain of a PII SVMP that lacks the disintegrin domain and not 
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the intact form of the enzyme. We identified further proteins (peptide sequences, ion 
scores, XCorr and probability values summarized in Table 3.1) which appeared to be 
more conservatively expressed throughout Nigerian B. arietans venoms. Firstly, an 
11kDa protein (Figure 3.3A
[2]
), was identified as VEGF-encoding transcript 
BAR00040. A 50kDa protein (Figure 3.3A
[3]
) was identified as an LAO, BAR00017 
(see Figure 3.5 for predicted protein sequences). Following several attempts to 
identify the second variable protein of interest; a unique low molecular weight 
protein clearly detected in the venom of only 1 of 12 B. arietans specimens, (Figure 
3.3A
[4]
), we were unable to produce a confident match against either Uniprot, 
Serpentes or in-house generated B. arietans venom gland EST databases. Thus, this 
component most likely represents a novel, previously un-described snake venom 
protein whose identification remains the focus of further research in our laboratory. 
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                                                                                                                                                                Mascot                   Sequest 
  
Band 
number 
Molecular 
weight on 
gel (kDa) 
MS-derived 
molecular 
weight 
(kDa) 
Snake 
ID 
Cluster Protein 
family 
Accession 
no. 
m/z 
(Da) 
z MS/MS derived 
sequence 
Ion  
score 
Exp  
value Proba
bility 
X 
Corr 
1 23 55 BaN02 BAR00042 PII-SVMP CAJ01682 797.29 +2 SAAVVMNYQPEIDR 47 2.50E-05 
  
 
  
  
  864.30 +2 GLEMWSNGDLCTVTK 43 5.00E-05 
  
 
  
  
  805.24 +2 SAAVVMNYQPEIDR 42 6.20E-05 
  
 
  
  
  864.22 +2 GLEMWSNGDLCTVTK 35 2.90E-04 
  
 
  
  
  597.86 +2 SASDTLHSFAEWRER 18 1.70E-02 
  
 
  
  
  797.29 +2 SAAVVMNYQPEIDR 
  
42.48 3.56 
 
  BaN53 BAR00042 PII-SVMP CAJ01682 856.21 +2 GLEMWSNGDLCTVTK 59 1.40E-06 
  
 
  
  
  797.24 +2 SAAVVMNYQPEIDR 40 1.10E-04 
  
 
  
  
  856.25 +2 GLEMWSNGDLCTVTK 36 2.40E-04 
  
 
  
  
  598.18 +2 SASDTLHSFAEWRER 28 1.80E-03 
  
 
  
  
  797.24 +2 SAAVVMNYQPEIDR 
  
48.42 3.42 
 
  
  
  598.18 +3 SASDTLHSFAEWRER 
  
67.53 2.58 
 
  
 
BAR00220 No sig. hits  664.29 +1 ESDGEK 24 5.90E-03 
  
 
  
 
BAR00133 No sig. hits  500.20 +1 LPGGR 20 9.20E-03 
  
 
  BaN60 BAR00042 PII-SVMP CAJ01682 864.19 +2 GLEMWSNGDLCTVTK 43 4.80E-05 
  
 
  
  
  797.24 +2 SAAVVMNYQPEIDR 43 6.60E-05 
  
 
  
  
  805.17 +2 SAAVVMNYQPEIDR 34 4.00E-04 
  
 
  
  
  856.32 +2 GLEMWSNGDLCTVTK 22 6.90E-03 
  
 
  
  
  797.24 +2 SAAVVMNYQPEIDR 
  
62.17 3.68 
 
  BaN65 BAR00042 PII-SVMP CAJ01682 804.82 +2 SAAVVMNYQPEIDR 40 1.10E-04 
  
 
  
  
  805.16 +2 SAAVVMNYQPEIDR 28 1.70E-03 
  
 
  
  
  797.28 +2 SAAVVMNYQPEIDR 24 4.30E-03 
  
 
  
  
  797.28 +2 SAAVVMNYQPEIDR 
  
50.96 3.07 
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  BaN66 BAR00042 PII-SVMP CAJ01682 796.77 +2 SAAVVMNYQPEIDR 52 6.00E-06 
  
 
  
  
  855.74 +2 GLEMWSNGDLCTVTK 52 6.20E-06 
  
 
  
  
  805.18 +2 SAAVVMNYQPEIDR 39 1.30E-04 
  
 
  
  
  754.16 +2 SASDTLHSFAEWR 39 1.40E-04 
  
 
  
  
  598.14 +3 SASDTLHSFAEWRER 20 9.40E-03 
  
 
  
  
  796.77 +2 SAAVVMNYQPEIDR 
  
64.16 4.06 
 
  
  
  754.16 +2 SASDTLHSFAEWR 
  
51.51 2.83 
 
  
 
BAR00220 No sig. hits  664.28 +1 ESDGEK 25 5.70E-03 
  
 
  BaN72 BAR00042 PII-SVMP CAJ01682 856.16 +2 GLEMWSNGDLCTVTK 51 8.40E-06 
  
 
  
  
  805.21 +2 SAAVVMNYQPEIDR 48 1.50E-05 
  
 
  
  
  864.27 +2 GLEMWSNGDLCTVTK 43 4.80E-05 
  
 
  
  
  598.20 +3 SASDTLHSFAEWRER 25 2.90E-03 
  
2 11 16 BaN11 BAR00040 VEGF ACN22038 695.21 +2 TVELQVMQVTPK 90 1.10E-09 
  
 
  
  
  686.80 +2 TVELQVMQVTPK 44 3.70E-05 
  
 
  
  
  622.16 +3 ETLVSILEEYPDKISK 38 1.40E-04 
  
 
  
  
  695.21 +2 TVELQVMQVTPK 
  
84.43 4.16 
 
  
  
  686.80 +2 TVELQVMQVTPK 
  
32.21 3.63 
3 50 31 BaN53 BAR00017 LAO CAQ72894 611.72 +2 SAGQLYQASLGK 68 1.40E-07 
  
 
  
  
  611.74 +2 SAGQLYQASLGK 40 9.10E-05 
  
 
  
  
  611.72 +2 SAGQLYQASLGK 
  
72.49 3.87 
 
  
  
  611.74 +2 SAGQLYQASLGK 
  
41.74 3.29 
 
  
 
BAR00490 No sig. hits  848.00 +4 
FQEFDDAANLLAANP
DAVTISIDEPTEKPKK 
20 9.40E-03 
  
 
  
 
BAR00220 No sig. hits  664.33 +1 ESDGEK 25 5.50E-03 
  
 
  BaN55 BAR00017 LAO CAQ72894 611.66 +2 SAGQLYQASLGK 49 1.40E-05 
  
 
  
  
  612.05 +2 SAGQLYQASLGK 32 6.40E-04 
  
 
  
  
  611.66 +2 SAGQLYQASLGK 
  
68.97 3.44 
 
  
  
  612.05 +2 SAGQLYQASLGK 
  
23.84 2.48 
 
  
 
BAR00083 Ecto-5’- BAG82602 595.70 +2 MGKVFPAVEGR 34 5.20E-04 
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Table 3.1 LC-MS/MS identification of venom proteins: Variable and conserved venom proteins were excised and trypsin-digested from individual Nigerian 
B. arietans venom samples (Figure 2). The table includes a list of peptide sequences derived by mass spectrometry for each protein of interest, the protein 
family assigned to each protein and the accession number of the protein which corresponds to the closest protein match identified by BLAST search. Ion score 
and E values indicate protein identification by Mascot algorithm and Probability and XCorr correspond to protein identification by Sequest algorithm. 
nucleoti-dase 
 
  
  
  595.70 +2 MGKVFPAVEGR 
  
70.09 2.6 
 
  
 
BAR00535 No sig. hits  586.61 +4 
KSPLETFLPETGSSLQG
ATSHR 
20 9.90E-03 
  
4 <10 N/A BaN61 No confident hits         
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Figure 3.5 Full and partial-length peptide sequences identified by LC-MS/MS 
from adult Bitis arietans specimens: Peptide searches against contigs assembled 
from our B. arietans venom gland EST database were performed to identify protein 
bands of interest (Figure 3.3Aii). Signal peptides predicted using Signal P (Bendtsen 
et al., 2004) are underlined. Peptides identified by LC-MS/MS are indicated by grey 
shaded areas. The RGD-containing disintegrin domain of BAR00042 (identified by 
BLAST search as Bitistatin) is highlighted in red and the metalloproteinase domain 
in blue. The RGD disintegrin tripeptide is boxed. 
>BAR00042_1 Full-length cDNA encoding PII SVMP encoding RGD disintegrin 
MIQVLLVIICLAVFPYQGSSIILESGNINDYEVVHPQKVTALPKGAAKQPEQK
YEDTMQYEFKVNGEPVVLHLEKNKGLFSKDYSETHYSPDGREITTKPPVEDH
CYYHGRIQNDADSTASISACNGLKGHFTLQGETYFIEPLKITDSEAHAVFKYE
NIEKEDEAPKMCGVTQTNWESDVPIKKASQLVATSEQHRSSDPIKYINVIVV
ADQRLVTYYKGELNKITTKVHQYFNTLNEMYRYFYIRPILRGLEMWSNGDL
CTVTKSASDTLHSFAEWRERDLLSRKKHDNAQLFTGAEFDGGIIGIAYVGTM
CDLKRSAAVVMNYQPEIDRAVAAIMAHEMGHNLGIRHDGNQCYCGADACI
MAPHISNPPPMYFSDCSWNDYNRFISTHNPQCIHNQPSRTVIVSPPVCGNKILE
QGEDCDCGSPANCQDRCCNAATCKLTPGSQCNYGECCDQCRFKKAGTVCRI
ARGDWNDDYCTGKSSDCPWNH 
>BAR00040_1 Full-length cDNA encoding VEGF precursor 
MAAYLLAVAILFCIQGWPSGTVQGEVRPFMEVYQRSVCQPRETLVSILEEYP
DKISKIFRPSCVAVLRCGGCCSDESLTCTSVGERTVELQVMQVTPKTLSSKIK
VMKFREHTACECRPRSGSRVNIGKHKRSPEEGEREPSSPLTPGSL 
>BAR00017_1 Full-length cDNA encoding L-amino oxidase 
MNVFFMFSLLFLATLGSCADDKNPLEECFREADYEEFLEIARNGLKKTSNPQ
HVVIVGAGMSGLSAAYVLAGAGHKVTVLEASERVGGRVRTHRNDKEGWY
ANLGPMRLPEKHRIVREYIRKFGLKLNEFVQETENGWYFIKNIRKRVWEVKK
DPGLLKYPVKPSEAGKSAGQLYQASLGKAVEELKRTNCSYMLNKYDTYSTK
EYLIKEGNLSPGAVDMIGDLLNEDSGYYVSFIESPEHDDIFAYEKRFDEIVGG
MDQLPTSMYRAIEKSVHFKA 
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Sequence analysis of the intact PII SVMP isoform BAR00042, identified the 
disintegrin domain as bitistatin isoform D1 (Figure 3.5). Bitistatin D1 has been 
recognised as a major component of B. arietans venom (Juárez et al., 2006) and is 
classed as a long, RGD-containing disintegrin at around 80 residues in length. 
 
Venom enzyme activity 
Variation in the gelatinolytic and fibrinogenolytic activity of venoms between 
individual B. arietans from Nigeria was observed (Figure 3.3Ci and ii). Gelatin 
zymography demonstrated that venoms from most specimens shared a common 
region of substrate degradation. Two individuals showed unique activities. Firstly, 
BaN52 appeared to have significantly lower enzymatic activity compared with 
venoms from other specimens showing relatively little degradation of either gelatin 
or fibrinogen substrates. This could not be attributed to any obvious variable feature 
of the protein profile since other individuals, for example BaN11, BaN55 and 
BaN71, who shared similar SDS-PAGE venom protein profiles with BaN52 (Figure 
3.3Aii), demonstrated higher degradative activities. Secondly, BaN61 showed a 
greater molecular mass range of activity with a clear area of degradation above the 
conserved area of activity in the other individuals. BaN61 also has a more distinctive 
SVMP profile in terms of SDS-PAGE composition and immunoreactivity (Figures 
3.3A and 3.3Bi); it is possible that the unique high molecular weight SVMP solely 
present in the venom of BaN61 (Figure 3.3Bi) may contribute to this unusual 
activity. Notably, a similar region of degradation was observed in both gelatin and 
fibrinogen zymograms raising the possibility that the same, or similar venom 
components, may be responsible for both these activities. Overall, the variation 
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observed in substrate degrading activity profiles did not correlate well with observed 
changes in the venom protein expression profile on SDS-PAGE. This suggests a 
multiplicity of variation in proteins from subunit structure to catalytic 
activity/substrate specificity, and that perhaps some minor components may be 
responsible for highly specific activity. Thus, changes in enzymes expressed at 
relatively low levels, but with a high catalytic activity may not be immediately 
apparent or easily detected when analysing venom using the proteome or 
transcriptome alone. 
 
          3.4.3. Comparison with variation in venom of Ghanaian B. arietans 
We compared the venom profiles of Nigerian B. arietans individuals with those of a 
smaller group of individuals of the same species from Ghana and detected very little 
intra-specimen variation in Ghanaian venom samples, whether examined by SDS-
PAGE, immunoblots or substrate zymogram assays (Figure 3.6). Interestingly, the 
only observed evidence of variation between individual Ghanaian venoms was in the 
intensity of immunological reactivity to the VEGF-specific antibody (Figure 3.6B), 
which contrastingly appears to be conserved among Nigerian specimens (Figure 
3.3Bii). Also, as a group, venoms from the Ghanaian specimens differed from the 
Nigerians in protein profile, with venom components present in Nigerian venom at a 
molecular weight of 33kDa (Figure 3.3Aii) that were absent of expressed at a much 
lower level in Ghanaian venom (Figure 3.6A). Here, it is important to note that the 
smaller group size of Ghanaian individuals used in the study (6 specimens in 
comparison to 12 Nigerian specimens) may be limiting the levels of variation 
observed between individuals and further variation in venom composition may be 
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Figure 3.6 Analysis of individual Ghanaian Bitis arietans venom samples: Ai) 
reduced SDS-PAGE and ii) non-reduced SDS-PAGE, B) reduced immunoblotting 
against E. o α-VEGF and C) substrate zymography using i) gelatin and ii) fibrinogen 
substrates. Molecular weight markers (kDa) are shown on the left of each image. 
Note that migration on zymograms does not necessarily correspond with migration 
on SDS-PAGE or immunoblots due to differences in sample preparation conditions. 
observed by increasing the number of specimens in the study. 
 
 
 
          3.4.4. Comparison with variation in venom of B. arietans with other 
species, Echis ocellatus and Cerastes cerastes 
To assess the extent to which intra-specimen variation in Nigerian B. arietans may 
also be reflected in venoms of other African vipers, we examined individual venom 
profiles of two other African viper species of medical importance; Echis ocellatus 
and Cerastes cerastes, using SDS-PAGE and zymography (Figure 3.7). This analysis 
revealed very little intra-specimen variation in the venom protein profile and enzyme 
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activity of individual E. ocellatus specimens (Figure 3.7Ai and Aii) and minor intra-
specimen variation in the venom protein profile and enzyme activity of individual C. 
cerastes specimens (Figure 3.7Bi and Bii). Thus, the extensive variation reported 
here for Nigerian B. arietans venom is not necessarily reproduced to the same extent 
in the other African viper species examined. Interestingly, all C. cerastes venom 
samples showed a uniquely high molecular weight region of substrate degredation 
that was not apparent in B. arietans or E. ocellatus venoms, which was not reflected 
in the venom protein profile. These findings indicate that some low abundant venom 
components may be responsible for highly specific enzyme activity.
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Figure 3.7 Analysis of other African viper venoms, Nigerian E. ocellatus (A) and Egyptian C. cerastes (B): by reduced SDS-PAGE (Ai, 
Bi) and gelatin zymography (Aii, Bii) illustrate the protein composition and enzyme activity of venoms respectively. Molecular weight markers 
(kDa) are shown on the left of each image. Note that migration on zymograms does not necessarily correspond with migration on SDS-PAGE 
due to differences in samples preparation conditions.  
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Figure 3.8 Immunoreactivity of Bitis arietans venoms to polyspecific antivenom: 
Reduced venom immunoblots probed with commercial pan-African polyspecific 
antivenom developed in Costa Rica (EchiTAb-Plus-ICP) against B. arietans venom 
samples from A) six different geographical origins, B) 12 individual Nigerian 
specimens and C) 6 individual Ghanaian specimens. Molecular weight markers 
(kDa) are shown on the left of each image. 
3.4.5. Variation in immunoreactivity of B. arietans venom towards Pan African 
polyspecific antivenom 
Given the intra-specimen variation in B. arietans venom reported here, we examined 
the immunoreactivity of a polyspecific antivenom (EchiTAb-Plus_ICP, Costa Rica), 
which is currently used to treat B. arietans envenoming, to B. arietans venom pools 
from different geographical origins (Figure 3.8A) and between venoms extracted 
from several individuals from the same origin in Nigeria (Figure 3.8B) or Ghana 
(Figure 3.8C).  
 
 
Whilst the antivenom tested here seems to satisfy the requirements of broad protein 
specificity (assessed by immunoblotting), and has been proven successful in the 
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treatment of B. arietans envenoming (Nasidi, Warrell and Theakston, personal 
communication), antibodies to some rare/unusual transcripts, such as the unidentified 
venom component in Figure 3.3A
[4]
, may be missing from antivenoms. 
 
3.5. Discussion 
Diversity in toxins, and shifts in venom composition and function, are considered a 
consequence of gene duplication and accelerated molecular evolution to recruit new 
proteins into the venom proteome and increase their diversity (Kordiš et al., 2002). 
The evolutionary driving force underpinning this isoform diversity is thought to 
include factors such as habitat, diet, gender or ontogeny. With such sharply 
contrasting expression profiles observed between individual venoms, we consider the 
variation identified here, which is apparently independent of influencing factors 
including environment, age, gender and diet, to be more biologically ‘deliberate’ 
than the gradual shifts expected as a result of random genetic drift. We have 
observed a high degree of qualitative and quantitative variation in several 
characteristics of venom including protein composition, immunoreactivity to toxin-
specific antibodies and polyvalent antivenom and enzyme substrate-degradative 
capacity, leading us to conclude that B. arietans venom varies significantly between 
individuals in terms of its composition, immunogenicity and predicted function of 
perhaps the most pathologically important enzyme group in viper venom; the 
SVMPs. We have observed individual variation in the gelatinolytic and 
fibrinogenolytic activity of venom enzymes which may translate in differential 
symptomologies of envenoming. The most prominent variable component in venom 
composition was in the presence or absence of the BAR00042 isoform, the 
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proteolytically processed metalloproteinase domain of a PII RGD-containing SVMP, 
which was either present in significant quantities, or absent in 50% of individual 
specimens. We suggest several possible scenarios to explain this observed absence of 
this protein in some individual venoms; (i) the PII SVMP is not processed in some 
individuals and is present in the proteome at a higher molecular weight, (ii) the PII 
SVMP is present and processed in all individuals but the metalloproteinase domain 
in some individuals is unstable and cannot be detected, (iii) the PII SVMP is 
completely absent from the venom gland transcriptome in some specimens or iv) the 
PII SVMP is absent from the genome in some specimens. PII class SVMPs comprise 
of a metalloproteinase domain and an additional disintegrin domain which can be 
proteolytically processed from the metalloproteinase domain. Disintegrins, following 
release from the PII metalloproteinase through proteolytic cleavage, are potent 
inhibitors of platelet aggregation and function (Shebuski et al., 1989). RGD-
containing disintegrins such as bitistatin have been shown to act through selectively 
blocking the binding of fibrinogen to the integrin αIIbβ3 receptor (Huang et al., 1987). 
Thus, differences in the proteolytic processing of disintegrins would be predicted to 
lead to an altered mechanism of action of venom. A protein band consistent with the 
predicted mass of bitistatin (8.6kDa) (Shebuski et al., 1989) although not evident on 
15% SDS-PAGE gels, could be observed in all individual venoms separated on 
silver-stained 4-12% gradient gels (Figure 3.9). Overall, our data emphasizes the 
need for further work to characterize the precise bitistatin isoform products in venom 
due to the potential impact such components may have on the clinical effects of 
envenoming. 
The full scale of intra-species variation in B. arietans venom is still not completely 
understood. From our SDS-PAGE, it appears that the presence of novel toxins in the 
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Figure 3.9 Analysis of low molecular weight protein components of Bitis arietans 
venom: A selection of venoms from individual B. arietans specimens originating 
from Nigeria and Ghana were separated by SDS-PAGE using 4-12% Bis-Tris 
gradient gels which were silver stained following protein separation. Low molecular 
weight range markers are shown to the left of the image. 
B. arietans venom proteome, particularly in the low molecular weight region, may be 
very likely and are yet to be identified. Further work is required to fully characterise 
the venom of this species to reveal novel and potentially important toxins which may 
play vital roles in envenoming or endogenous biological processes. 
 
 
 
 
 
 
 
In summary, B. arietans appears to be highly adaptive in terms of venom 
composition and activity and this can be reflected in their adept ability to inhabit a 
range of habitats over a wide geographical distribution throughout sub-Saharan 
Africa. It may be that this species has developed variable venom phenotypes, not 
only between specimens from different geographical regions but within groups 
occupying similar habitats. Our findings illustrate that there appears to be very little 
association between geographic location and similarity or differences in protein 
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expression or activity profiles of venom from B. arietans from different, and also the 
same geographic origin. This suggests that variation observed here may not be a 
simple consequence of pan-African random genetic drift and raises the possibility 
that African B. arietans could be regarded (at least in terms of venom phenotype) as 
a collection of subpopulations that have arisen as a result of differential evolutionary 
pressures such as prey type and availability or habitat (Barlow et al 2012, in 
preparation). Furthermore, such intra-species variation in venom may give rise to 
variability in the clinical manifestation of snakebite and ultimately affect the success 
of antivenom treatment. Although the current antivenom used to treat B. arietans 
envenoming appears to satisfy requirements, our findings emphasise that great care 
should be taken when selecting B. arietans specimens for antivenom production to 
ensure that the complete diversity of venom is considered. 
The high degree of intra-species variation in venom between B. arietans specimens is 
also an important factor to take into consideration when conducting further studies 
including gene expression and transcriptome analyses of B. arietans venom. With 
such significant levels of individual variation in the B. arietans venom proteome, 
immunoreactivity and enzymatic function, we may also expect to observe levels of 
variation in the venom gland transcriptome and gene expression of venom proteins 
between individual specimens. Our observations in this chapter, therefore, highlight 
the requirement to accommodate for potentially high levels of variation in 
subsequent chapters in which aim to characterise the dynamics of gene expression of 
venom proteins. 
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4. OPTIMSATION OF QUANTITATIVE POLYMERASE CHAIN 
REACTION (PCR) PROTOCOLS; EXPLOITING VENOM AS A SOURCE 
OF MESSENGER RNA FOR GENE EXPRESSION ANALYSES. 
 
4.1. Abstract 
Messenger RNA (mRNA) has been demonstrated as a stable component of snake 
venoms. The ability to isolate mRNA encoding venom proteins from venoms 
therefore may provide an alternative source of genetic material for research, 
including real-time gene expression analyses of venom proteins. The objectives of 
this chapter were to optimise protocols for (i) isolating mRNA from Bitis arietans 
venom, (ii) amplifying specific venom protein-encoding transcripts from venom 
mRNA and (iii) detecting mRNA expression levels using a fluorescence-based 
quantitative PCR (qPCR) approach. The resultant optimised protocols would be 
applied to quantitatively track changes in gene expression during venom synthesis. 
Quantitative PCR is an accurate and highly sensitive technique which can be used to 
simultaneously amplify and quantify DNA and has experienced a rapid rise in 
popularity and accessibility in recent years. Experiments require optimisation 
protocols for each new set of primer/DNA target combinations, thus we referred to 
the Minimum Information for publication of Quantitative Real-time PCR 
Experiments (MIQE) guidelines published 2009 which aim to ensure the generation 
of reliable, accurate, easily interpreted and reproducible qPCR experiments. Our 
results demonstrate the ability to detect and quantify gene expression levels of 
venom protein-encoding genes from mRNA extracted from venom in combination 
with fully optimised qPCR protocols. 
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4.2. Introduction 
The overall aim of this work was to elucidate the time scale for the replenishment of 
venom proteins during venom synthesis and to investigate how venom synthesis is 
controlled and coordinated. The dynamics of venom protein gene expression and 
synthesis are currently little understood. This is primarily due to the limitations of 
current conventional methods used to interrogate venom gland transcriptional 
activity which requires sacrificing specimens for dissection of venom glandular 
tissue. Such studies prove difficult or unachievable and require an ethically 
unattractive sacrifice of a large number of snakes. The aim of the following work 
was to develop alternative protocols for investigating gene expression levels of 
venom proteins during venom synthesis. To enable real-time analysis of venom 
replenishment, we decided to exploit observations of previous studies which 
demonstrated an unusual presence and apparent stability of messenger RNA 
(mRNA) in venom and the use of venom as an alternative source of the 
transcriptionally active mRNA. 
Messenger RNA was first shown as a stable component of snake venoms by Chen et 
al who demonstrated that intact mRNA can be recovered, and toxins can be PCR-
amplified and cloned from lyophilised venoms (Chen et al., 2002). This key study 
demonstrated that, using magnetic oligo dT-coated beads, poly(A) mRNA could be 
isolated from the lyophilised venom of the Chinese Copperhead (Deinagkistrodon 
acutus), the black mamba (Dendroaspis polylepsis) and the venomous lizard species, 
Gila monster (Heloderma  suspectum) (Chen et al., 2002). Successful PCR 
amplification and cloning of major toxin groups including an SVMP, PLA2 and 
neurotoxin from mRNAs isolated from the venoms demonstrated that the mRNA 
present in venom appears to be intact and encodes for venom proteins (Chen et al., 
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2002). Subsequent studies by this group demonstrated that mRNA could also be 
isolated from the toxic secretions of the Chinese toad (Bombina maxima) (Chen et 
al., 2003a), the fire-bellied toad (Bombina orientalis) (Chen and Shaw, 2003, Chen et 
al., 2005), and venom from the North African scorpion (Androctonus amoreuxi) 
(Chen et al., 2003b). Currently, very little is known about the properties of mRNA in 
venoms such as its purity, stability or function and whether mRNAs are 
constitutively observed in venoms from snakes of a variety of different taxonomic 
classification. However, the ability to obtain protein-encoding mRNA from venom 
appears to offer a non-evasive alternative approach to explore the transcriptional 
activity and gene expression of venom glands. This alternative technique 
circumvents the requirement to sacrifice specimens for venom gland dissection and 
may therefore have the potential to expand opportunities in venom transcriptomics, 
overcoming limitations of conventional techniques (Kwok et al., 2008). 
To quantitatively track relative changes in venom protein expression, we elected to 
use quantitative PCR (qPCR) which has, in recent years, revolutionised DNA 
detection and analysis due to its high sensitivity, precision, resolution, ease of 
automation, increased dynamic range and minimal post-PCR processing in 
comparison to conventional PCR. Recent years have experienced a significant rise in 
the use of qPCR in many areas of research including gene expression quantitation, 
gene expression profiling, pathogen detection, drug efficacy testing and diagnostic 
applications (Bustin, 2000, Mackay et al., 2002, Bernard and Wittwer, 2002, 
Mackay, 2004, Kubista et al., 2006). The technology uses chemistries based on the 
addition of fluorescent DNA-binding dyes into the reaction, such as SYBR green I, 
which binds all double stranded DNA, and, once bound, emits green light. The 
specialised thermocycler-detector system in qPCR instruments both detects and 
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measures the levels of fluorescence following each successive cycle of PCR 
amplification, which is directly proportional to an exponential increase in the 
concentration of DNA. Whereas conventional (qualitative) PCR produces an 
endpoint DNA amplicon as a result of the total PCR amplification which can be 
visualised on an agarose-EtBr gel, qPCR generates an amplification growth curve 
which illustrates the amplification of DNA in real-time. qPCR can be applied in two 
approaches; absolute or relative DNA quantification. Absolute (or standard curve 
quantification) measures the DNA copy number of an unknown sample based on a 
standard curve which is prepared from a dilution series of a standard DNA template 
of known concentration. This approach is most applicable for use in diagnostics, for 
example, in quantifying pathogen load in an unknown infected sample. Relative 
quantification, which is the most widely used approach, enables the direct 
comparison of expression levels of two or more genes of interest, normalised against 
the expression of reference (housekeeping) genes, and therefore can be used to detect 
up- or down-regulation of the genes of interest, for example, in measuring gene 
response to drug treatment. The Minimum Information for Publication of 
Quantitative Real-time PCR Experiments (MIQE) guidelines (Bustin et al., 2009)) 
were used as a guide throughout our qPCR experiment. The guidelines include 
information on experimental design, RNA sample quality and treatment, nucleic acid 
extraction, reverse transcription, qPCR primer design, thermocycling parameters, 
validation experiments and statistical analysis of data with the aim of producing 
accurate and reproducible qPCR data. By exploiting a combination of venom mRNA 
and highly sensitive qPCR protocols, we aim to develop and optimise non-invasive 
approaches through which we can track, in real-time, expression of venom proteins 
during venom synthesis. 
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4.3. Materials and Methods: 
          4.3.1. Venom sample preparation 
In all PCR optimisation experiments, lyophilised West African Bitis arietans venoms 
extracted and pooled in 2009 and stored in a sealed container at 4°C was used as the 
source of mRNA. 
 
          4.3.2. Extraction of Poly(A) mRNA from venom using Dynabeads® 
For PCR optimisation experiments, mRNA was extracted from 10mg lyophilised 
pooled West African B. arietans venom. Poly(A) mRNA was purified from 
lyophilised venom using Dynabeads® mRNA DIRECT™ Kit (Dynal, Invitrogen) as 
described in Section 2.6 of Chapter 2. To optimise mRNA extraction and determine 
the minimum quantity of mRNA required to yield mRNA amounts sufficient for 
cDNA synthesis and downstream PCR applications (e.g. ~ 10-20µg poly(A) mRNA 
in a volume of 20µl), mRNA was extracted from different quantities of pooled B. 
arietans venom ranging from 2, 10, 20, 50 and 100mg. The presence of DNA 
contamination of mRNA samples was evaluated by reverse transcriptase-negative 
controls and DNase treated mRNA. Alongside reverse transcriptase cDNA synthesis 
reactions, identical reactions were performed in the absence of the reverse 
transcriptase enzyme (referred to as no reverse transcriptase controls). For DNase 
treatment, DNase was added to duplicate mRNA samples and DNase treatment was 
performed prior to reverse transcription. PCR amplification from reverse 
transcriptase-negative and DNase treated controls was performed and products were 
analysed on a 1% agarose-EtBr gel. 
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          4.3.3. Reverse transcription cDNA synthesis 
cDNA synthesis was performed using the Superscript® III first strand synthesis 
system (Invitrogen) as described in Section 2.10 of Chapter 2. 
 
          4.3.4. Design of PCR primer pairs for conventional PCR and quantitative 
PCR reactions 
PCR primers were designed to amplify a range of venom protein-encoding gene 
targets with varied representation in the Bitis arietans venom gland EST database 
(indicated by number of sequences in Table 4.1 and 4.2). These included class II 
snake venom metalloproteinases (SVMP) [BAR00042 and BAR00015], serine 
protease (SP) [BAR00034], phospholipase A2 (PLA2) [BAR00406], C-type lectins 
(CTL) [BAR00002 and BAR00012], L-amino acid oxidase (LAO) [BAR00017], 
vascular endothelial growth factor (VEGF) [BAR00040], Kunitz inhibitor (KTI) 
[BAR00023], disintegrin (DIS) [BAR00155], protein disulphide isomerase (PDI) 
[BAR00008] and QKW inhibitory peptides (QKW) [BAR00003]. Primers pairs were 
designed using Primer Select software (DNASTAR) complimentary to sequences 
within the coding regions of specific genes. Primers were designed to avoid primer 
dimers, secondary structures and hairpin loops, have a GC content of 40-60% and 
have similar melting and annealing temperatures (Tm) (Singh and Kumar, 2001). A 
different set of PCR primers were designed specifically for use in qPCR to amplify 
selected transcripts from the B. arietans venom gland EST database including a class 
II SVMP [BAR00042], SP [BAR00034], PLA2 [BAR00406], CTL [BAR00012], 
LAO [BAR00017], VEGF [BAR00040], KTI [BAR00023], PDI [BAR00008] and 
QKW [BAR00003]. In addition, three housekeeping genes were selected as reference 
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transcripts including β-actin (ACTIN), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and heat shock protein (HEAT SHOCK), which are frequently used in the 
literature (Bustin et al., 2005, Vandesompele et al., 2002). The expression of 
reference genes was used as a baseline to which the expression of target genes was 
normalized. Three references were included to improve accuracy of normalization 
(Vandesompele et al., 2002). Reference gene primer pairs were designed on 
consensus sequences obtained from other snake species including Oxyuranus 
scutellus, Laticauda semifasciata and Echis ocellatus DNA sequences. Primer pairs 
for qPCR were designed to have approximately the same melting temperature to 
enable simultaneous amplification of gene targets, and an amplicon length of less 
than 200 base pairs. Primers were synthesised (Sigma, UK), reconstituted in MilliQ 
Ultrapure water (Merck Millipore, UK) to a concentration of 100µM stock solutions 
according to the manufacturer’s instructions and diluted to  0µM working 
concentration for PCR. 
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Table 4.1 Conventional PCR primer sequences: Sequences of primer pairs used to amplify venom protein targets by conventional PCR. 
 
Cluster ID No. sequences Toxin group Forward primer (5'-3') Reverse primer (5'-3') 
Melting 
temp. °C 
BAR00042 31 PII SVMP ATGAGGCCCCCAAAATGTGT AGCGCCTGTGAATAACTGAGC 
F 55.4 
R 53.7 
BAR00015 90 PII SVMP TCGGCCAGAAATAGATAGTGC TCTCCCCTGTTGTTTAGTGATTC 
F 51.4 
R 51.8 
BAR00406 2 PLA2 TGCTGTTACGGGATAACGGCAGAA CCGTTTTGGGGCCGCACTTA 
F 61.4 
R 61.4 
BAR00034 19 SP CTGCATGCGGTGGGACTTT CTTTGTGCCGGTAATCGTTCATA 
F 55.7 
R 55.8 
BAR00002 4 CTL GGATCCATGGGGCGATTCATCTTC CTCGAGTCAGGGAGCCTTGATCTC 
F 63.2 
R 59.4 
BAR00012 6 CTL GGATCCATGGGGCGATTCATCTTC CTCGAGCTATACCCGGTACTTGCA 
F 63.2 
R 58.6 
BAR00040 14 VEGF GGATCCATGGCTGCGTACCTGCTG CTCGAGTCAAAGGGATCCTGGAGT 
F 65.3 
R 58.7 
BAR00017 14 LAO CTCCCAAGAATTCCCATCCACA GCGCTTTTGCCTGCTTCTGA 
F 57.4 
R 57.9 
BAR00155 2 DIS CCGCATAGCAAGGGGTGAT GCCGATAATTCTGAAAAACTGCTA 
F 54.8 
R 53.9 
BAR00023 4 KTI TGCAGGCAGAACCGTCCAGA TGCAGAACAGAAGGGGTGAAGC 
F 58.8 
R 58.0 
BAR00008 32 PDI TTTTTGTTGCTCGGTCTCTTT CTTCTCTGCCAGCTGTGTATTC 
F 51.1 
R 51.0 
BAR00003 122 QKW GCAAACGCGGCTCGGCTCTGT GGGGGCGCAAAACTCAATCCAACC 
F 65.2 
R 66.7 
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Table 4.2 Quantitative PCR primer sequences: Sequences of primer pairs used in quantitative PCR amplification.* denotes primer sequences 
which were designed based on sequences from other snake species as sequences were unavailable in the B. arietans venom gland EST database. 
 
Cluster ID 
No. 
sequences 
Toxin 
group 
Forward primer (5'-3') Reverse primer (5'-3') 
Melting 
temp. °C 
BAR00042 31 
PII 
SVMP 
ATACTGCGTGGTCTAGAAATGTGG AGCGCCTGTGAATAACTGAGC 
F 54.2 
R 53.7 
BAR00034 19 SP AGGAGGCGAGGAGAAGAGACG TTCCGCCCCATCCCATAATAC 
F 56.5 
R 57.2 
BAR00406 2 PLA2 CGGATAAGTGCGGCCCCAAAAC ATGGGTTTTCGTCTCCGCAGATGA 
F 63.1 
R 62.5 
BAR00012 6 CTL GCTCCGGCTTGCTGGTCGTGTTC GCCCGTCCTTCCCCTGCTTCTTG 
F 65.6 
R 65.5 
BAR00040 14 VEGF GAAGGGGAGCGAGAGCCAAGTT ACCCCCAGCATCAGAAAGAGGAG 
F 59.7 
R 59.5 
BAR00017 14 LAO GGGCCCATGCGTTTACCTG GCGCTTTTGCCTGCTTCTGA 
F 57.4 
R 57.9 
BAR00023 4 KTI GGGCCTATATCCGTTCCTTCTT ATTCCCATAGCATCCACCATAAAA 
F 54.5 
R 55.6 
BAR00008 132 PDI CCCGAATATTCTGGTGGAGT AAATTGTTGGGCGAGTTCTG 
F 50.5 
R 51.8 
BAR00003 122 QKW TGCGCCCCCAAATCCTCCTA TGGCATACGCAGCTGGTTTACTCA 
F 61.0 
R 60.5 
Oxyuranus 
scutellus* 
 ACTIN CTCAGAGTCGCCCCGGAAGAACAT AGAGGCGTACAGGGAGAGCACAGC 
F 63.3 
R 61.8 
Laticauda 
semifasciata* 
 GAPDH GAATATCATCCCAGCATCCACAGG CATCATACTTCGCCGGTTTCTCTA 
F 58.3 
R 56.4 
Echis 
ocellatus* 
 
HEAT 
SHOCK 
AGCCCCCAAGGATGAAGAGAAGC ATCGGGGTTGCGGGTCCAG 
F 60.7 
R 61.4 
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          4.3.5. Amplification of venom transcripts by conventional PCR 
The ability of primer pairs to amplify their specific target genes of interest was tested 
by PCR amplification from venom gland cDNA library as a positive control and 
cDNA synthesised from venom mRNA. Conventional PCR was performed as 
previously described in Section 2.9.2 of Chapter 2 alongside negative water controls. 
The presence of amplified products was confirmed and visualised on a 1% agarose-
EtBr gel. 
 
Optimisation of quantitative PCR (qPCR) protocols 
All qPCR experiments were performed using the BioRad CFX 384 real-time PCR 
system. Optimisation and standardisation of qPCR was performed in accordance with 
the MIQE guidelines (Bustin et al., 2009) (Appendix II). 
 
          4.3.6. Experimental optimisation of annealing temperature for qPCR 
amplification 
qPCR experiments were performed in order to experimentally determine the optimal 
annealing temperature for efficient qPCR amplification of venom components was 
determined, based on the theoretical primer annealing temperatures which were 
calculated by Primer Select software (DNASTAR) during primer design. KAPA 
SYBR® FAST qPCR Kit (KAPA Biosystems, AnaChem) was used as previously 
described in Section 2.9.4 of Chapter 2. The experimental qPCR plate set up and 
reaction parameters are shown in Figure 4.1 with a temperature gradient ranging 
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Figure 4.1 qPCR plate and thermocycling for optimisation of annealing 
temperature: A) Layout of qPCR plate set up using BioRad CFX 384 real-time 
PCR system with a temperature gradient from 65 to 50°C and B) thermocycling 
parameters using a temperature gradient in order to optimise PCR amplification.   
from 50 to 65°C. Amplification was followed by melt curve analysis to ensure 
specific PCR products were amplified. 
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          4.3.7. Optimising cDNA concentration for qPCR 
To optimise the concentration of cDNA per qPCR reaction, cDNA was firstly 
synthesised from mRNA was extracted from 10mg venom. The concentration of total 
cDNA synthesised was 1270ng/µl which was subsequently diluted to 50, 20, 10 and 
5ng/µl aliquots and each sample was performed in duplicate. qPCR amplification 
protocol was performed accordingly; 3 minute enzyme activation at 95°C, 30 
seconds DNA annealing at 55°C for 40 cycles. 
 
          4.3.8. Standard curve analysis to determine the amplification reaction 
efficiency in qPCR 
Standard curve construction is essential for the absolute quantification of DNA in an 
unknown sample with reference to a standard sample of known concentration. 
However, it was also necessary to conduct standard curves during relative 
quantification and gene expression analyses. Here, standard curve analysis was used 
to (i) assess that the optimal starting concentration of cDNA in the venom samples 
was used in order to produce a linear standard curve within the dynamic range for 
each gene target and (ii) to obtain the PCR reaction efficiencies for each gene of 
interest. Standard curves were constructed by plotting the log of the concentration of 
a standard cDNA sample against the Ct value (the cycle number at which exponential 
amplification occurs). To do this, the standard cDNA sample was diluted across a 
range of serial dilutions (between 5-10 different concentrations) and amplified by 
qPCR to generate a standard curve. The amplification efficiency of the PCR reaction 
(E) was calculated from the gradient of the standard curve by the formula E = 10
(-
1/slope)
 and subsequently converted into a percentage; % PCR reaction efficiency = (E-
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1) x 100%. For standard curves, two different templates were used. Firstly, for a 
model standard sample, PCR products amplified by conventional PCR from venom 
cDNA of each gene of interest were excised and purified. Here, we aimed to 
determine the efficiency of qPCR reactions under ideal conditions. Secondly, cDNA 
synthesised from mature B. arietans venom pooled from several individual 
specimens was used as a standard sample. Here, we aimed to determine the PCR 
reaction efficiency values of amplification under more representative conditions 
which would be more relevant in practice and take into consideration the differences 
in abundance/expression level of specific targets. For each standard sample, ten 
doubling dilutions of pooled venom cDNA were carried out to produce a range of 
cDNA concentrations; 1000, 500, 250, 125, 62.50, 31.25, 15.63, 7.81, 3.91 and 
1.95ng/µl. For some genes of interest, the pooled venom cDNA sample concentration 
was subsequently increased in quarter-dilutions in order to enter the linear dynamic 
range as follows; 2000, 1500, 1125, 843.75, 632.81, 474.61, 355.96 and 266.97ng/µl. 
cDNA was added to qPCR KAPA SYBR green reaction master mix as previously 
described. Duplicate samples were amplified by qPCR amplification protocol 
alongside negative controls as previously described. 
 
          4.3.9. Melt curve analysis to determine the specificity of primer pairs in 
qPCR 
Melt curve analysis following qPCR amplification was necessary to assess the 
sensitivity and specificity of PCR primers, and was subsequently performed for each 
gene of interest. Melt curves were constructed by gradually heating the final PCR 
amplicon to 95°C in small increments which melted the double stranded DNA. At 
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the specific melting point of the product, the fluorescently-bound DNA begins to 
dissociate and the levels of fluorescence decrease due to the breakdown of DNA. The 
point at which the loss in fluorescence is maximal is said to be the melting 
temperature of the DNA characterised by a sharp peak on the melt curve. The 
negative of the first derivative of the dissociation curve is plotted which produces a 
peak on the chart which enables a more accurate estimation of the melt temperature. 
The presence of a single peak on the melt curve indicates the presence of a single, 
specific amplicon. Melt curve analysis was performed following qPCR amplification 
as follows; 10 seconds at 95°C, ramping from 50°C to 95°C in 0.5°C increments for 
5 seconds. The plate layout and thermocycling parameters for standard curve and 
melt curve analysis are shown in Figure 4.2. 
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Figure 4.2 qPCR plate and thermocycling for standard and melt curve validation: Layout of qPCR plate set up using BioRad CFX 384 
real-time PCR system for standard curve and melt curve analysis (A) and thermocycling parameters using a temperature gradient (B).   
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4.4. Results: 
          4.4.1. Quantity of mRNA recovered from venom 
To determine the effect of the quantity of venom on the yield of mRNA and cDNA 
from venom, mRNA was extracted from different quantities of lyophilised B. 
arietans venom ranging from 2 to 100mg. The concentration of mRNA eluted from 
venom was measured using the ND-1000 spectrophotometer. Figure 4.3 shows that 
the amount of mRNA eluted from venom increases as the quantity of venom 
increases (Figure 4.3A), thus the concentration of first strand cDNA synthesised 
from mRNA also increased as venom quantity increased (Figure 4.3B). The ND-
1000 spectrophotometer was also used to assess RNA purity. The optical density 
(OD) was measured at 260 and 280nm wavelengths. The ratio of absorbance at 260 
and 280nm (A260/280) gives an indication of the purity of the DNA/RNA sample. The 
A260/280 of pure RNA should be greater than 1.8 (Fleige and Pfaffl, 2006, Becker et 
al., 2010) which is considered suitable for gene expression studies. The average 
260/280 absorbance ratios of the venom mRNA samples was 2.43 ±0.57 indicating 
the absence of proteins, phenol or other contaminating compounds. These results 
demonstrate that potentially large quantities of mRNA can be reproducibly recovered 
from B. arietans venom. A mass of 2mg lyophilised B. arietans venom was 
determined as the minimum mass yielding a quantity of mRNA sufficient for 
downstream applications. 
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Figure 4.3 Identifying the optimal venom quantity for mRNA and cDNA yield: 
Effect of initial weight of lyophilised B. arietans venom (mg) on A) quantity of 
eluted mRNA from venom (ng) and B) quantity of 1
st
 strand cDNA synthesised (µg). 
Results showed that the mRNA yield increased from 50 to over 350ng with 
increasing venom quantity but cDNA yield was less affected. 
 
          4.4.2. Testing the ability of primer pairs to specifically amplify a range of 
venom protein targets from venom gland and venom cDNA 
Electrophoresis of PCR products amplified from the B. arietans venom gland cDNA 
library (positive control) showed that a range of venom components of varied 
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Figure 4.4 Amplification of venom targets from venom vs. venom gland cDNA: 
PCR amplification of a range of venom protein targets from Bitis arietans venom 
gland cDNA library (Ai and Bi) and cDNA synthesised from mRNA extracted from 
venom (Aii and Bii) using full length conventional PCR primers (A) and primer 
pairs designed specifically for quantitative PCR. Molecular weight markers are 
shown to the left of the gel. 
representation in the venom gland transcriptome, indicating that primer pairs were 
sensitive and specific to amplify target transcripts (Figure 4.4Ai). However, the 
PLA2 gene (BAR00406) could not be efficiently amplified from the venom gland 
library. This may be due to the fact that PLA2s are very poorly represented in the B. 
arietans venom gland cDNA library (represented only by three clusters in the B. 
arietans venom gland EST database; BAR00406, BAR00424 and BAR00538).  
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However, using qPCR primers in conventional PCR reactions, the venom gland 
cDNA positive controls showed that amplicons were produced by each protein-
specific primer pair, including the PLA2 (Figure 4.4Bi). The difference in 
amplification of the PLA2 target when using two different primer pairs suggested that 
primer design may have influenced amplification success could be explained by the 
different regions of DNA targeted by the two different primer pairs. The qPCR 
primers may be more efficient in amplifying truncated cDNA due to the fact that 
they are specifically designed to amplify shorter DNA sequences. PCR amplification 
of venom targets from cDNA synthesised from mRNA extracted from venom 
suggested that, of the targets surveyed in this study including those of high (SVMPs) 
and lower representation (PLA2s), a similar spectrum of mRNA can be amplified 
from venom and venom gland cDNA (Figure 4.4Aii and Bii). 
PCR amplification of targets from mRNA extracted from different quantities of 
venom showed that overall, as the amount of venom from which mRNA was 
extracted increased, the apparent amount of amplicon produced by PCR using 
conventional primer pairs and visualised on an agarose-EtBr gel also qualitatively 
increased (Figure 4.5). PCR amplicons were visible following amplification from 
mRNA isolated from 2 mg venom, but products from some targets (PLA2, SP, LAO 
and DIS) were faint due to the reduced sensitivity. Following amplification from 10 
mg venom, the visual appearance of some amplicons became more intense (SP and 
LAO). Subsequently, by increasing venom quantity from 10 to 100mg, PCR products 
became progressively more intense but there did not appear to be an overall 
significant difference in the amount of PCR amplicon produced.  
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Figure 4.5 Amplification of venom targets from different quantities of venom: 
PCR amplification of venom targets from different initial starting weights of 
lyophilised B. arietans venom PCR amplification of venom targets showed very little 
effect on the qualitative amount of PCR amplicon. Molecular weight markers are 
shown to the left of the gel. 
 
          4.4.3. Assessing DNA contamination of mRNA samples 
To assess for the presence of DNA contaminating mRNA samples, two approaches 
were used. Firstly, during reverse transcription of mRNA, duplicate reactions were 
performed whereby the reverse transcriptase enzyme was omitted from the reaction. 
In addition, for qPCR primers, a DNase treatment of mRNA prior to reverse 
transcription was performed. Using conventional PCR primers in the ‘no reverse 
transcriptase’ control we showed that there was no DNA contamination of venom 
sample mRNA (Figure 4.6) to interfere and distort PCR results. For qPCR primer 
pairs, in addition to the ‘no reverse transcriptase’ controls where again no amplicons 
were visible following gel electrophoresis, a DNase treatment of mRNA was 
included. There was no difference in the PCR products amplified between DNase 
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Figure 4.6 Assessing DNA contamination of mRNA samples using reverse 
transcriptase negative controls (conventional PCR primers): A) shows 
amplification of venom protein targets using conventional PCR primer pairs. B) 
shows PCR amplification following omission of reverse transcriptase from cDNA 
synthesis. Absence of products in B indicates that samples were free from DNA 
contamination. Molecular weight markers are shown to the left of the gel. 
Figure 4.7 Assessing DNA contamination of mRNA samples using reverse 
transcriptase negative controls and DNase treatment (qPCR primers): A) and 
B) shows amplification of venom protein targets using qPCR primer pairs including 
and omitting reverse transcriptase respectively. C) and D) show that there was no 
difference in PCR amplification following DNase treatment of mRNA (C) or no 
DNase treatment (D). Molecular weight markers are shown to the left of the gel. 
treated controls and non-treated mRNA indicating that there was no interference 
from DNA contamination (Figure 4.7).  
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          4.4.4. Experimental optimisation of annealing temperature for qPCR 
amplification 
The cycle time (Ct) values (i.e. the cycle time at which the fluorescence level 
exceeded the given threshold) of qPCR amplifications for each gene of interest 
performed across a temperature gradient were analysed (Figure 4.8) (raw qPCR data 
is shown in Appendix III). Overall, we could not identify a specific optimal 
temperature for all primer pairs, alternative to the predicted optimal annealing 
temperature generated by primer design software, which improved the amplification 
of targets. The average difference in cycle time between the maximum and minimum 
Ct value across all genes of interest including reference genes across the temperature 
gradient was only 2.91 cycles (individually the greatest difference in Ct across the 
temperature gradient was observed in amplification of the heat shock protein 
reference gene at a difference of 8.6 cycles). The standard deviation across all target 
genes ranged from between ±0.36 to ±3.09 cycles demonstrating very little effect of 
the temperature gradient on primer annealing. With the exceptions of the SP, PLA2, 
PDI and β-actin primers, which could potentially be more efficient at a lower 
temperature between 50-53.8°C, Ct values following amplification of targets using 
most primers appeared to fluctuate showing no clear trend in efficiency due to 
temperature. These results could not identify a significant difference in the 
amplification growth curves for each gene from 50-65°C and so we were unable to 
experimentally determine a specific optimal annealing temperature for all primers. 
Subsequently, the computational optimal annealing temperatures determined by 
primer design (Primer Select, DNASTAR) were averaged for all primers (55°C) was 
used in PCR to enable ease of amplifying all genes of interest on a single plate. 
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Figure 4.8 Optimisation of annealing temperature for amplification by 
quantitative PCR: Ct value of amplification for each gene of interest across an 
annealing temperature gradient from 50 to 65°C demonstrating very little effect of 
the temperature gradient on primer annealing. 
 
          4.4.5. Optimising cDNA concentration for qPCR amplification 
To optimise the initial starting quantity of venom cDNA per reaction, qPCR 
amplification of all genes of interest was performed on a range of cDNA 
concentrations; 5, 10, 20 and 50ng per reaction. We observed very little difference in 
the cycle time (Ct) in relation to the initial starting quantity of cDNA per PCR 
reaction (standard deviation for all targets ranged from ±0.11 to ±0.75 cycles) 
(Figure 4.9) (Raw qPCR data is shown in Appendix IV). 
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Figure 4.9 Optimisation of initial cDNA concentration for amplification by 
quantitative PCR: Relationship between initial cDNA quantity per qPCR reaction 
and cycle time (Ct) score showed that there appeared to be no direct correlation 
between Ct score and starting cDNA quantity following amplification for all genes 
of interest. 
 
          4.4.6. Standard curve analysis to determine amplification reaction 
efficiency in qPCR 
Standard curves for all genes of interest are shown in Figures 4.10 and 4.11. Raw 
qPCR data from standard and melt curve analysis (Ct values, melt temperature and 
melt peak height) are shown in Appendix V. Firstly to consider standard curves 
generated using purified PCR products as the standard DNA sample; for all targets, 
linear standard curves were produced with PCR reaction efficiencies between 69.8 
and 91.6% were observed. Notably, the Ct values were consistently between 5-15 
cycles with the exception of CTL and GAPDH which took between 20-30 cycles for 
the fluorescence level to reach the threshold. 
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Figure 4.10 Standard curves generated by qPCR using purified PCR products 
as a standard cDNA sample: Panel A) shows amplification growth curve and panel 
B) shows the standard curve. E = % PCR reaction efficiency, x axis = relative 
fluorescence levels (RFU) in panel A or threshold cycle in panel B, y axis = Log 
starting cDNA concentration.  
 126 
 
To consider standard curves generated using pooled, mature venom cDNA as a more 
representative standard sample; for most targets, linear standard curves were 
produced with PCR reaction efficiencies between 63.3 and 100.7%. However, it is 
important to note that the Ct values were around 20-30 cycles; higher that previously 
observed following amplification of purified product standard samples. This may be 
expected as the mature venom cDNA was synthesised from whole venom, thus 
containing numerous cDNA sequences corresponding to up to hundreds of venom 
proteins. For some genes (PLA2, LAO and VEGF), we were unable to generate a 
linear standard curve. There may be several explanations for this; firstly the 
concentration of cDNA used was outside the linear dynamic range for some specific 
genes. Secondly, the low abundance of certain toxins in B. arietans venom (e.g. 
PLA2) may also affect the ability to detect and quantify toxin expression using 
qPCR. Some standard curves which produced poor % reaction efficiencies using a 
cDNA concentration range from 1.95 to 1000ng/µl were significantly improved 
when the cDNA concentration range was increased to 266.97 to 2000ng/µl (e.g. 
SVMP, ACTIN and GAPDH). 
 127 
 
Figure 4.11 Standard curves generated by qPCR using pooled mature venom 
cDNA as a standard cDNA sample: Panel A) shows amplification growth curve 
and panel B) shows the standard curve. E = % PCR reaction efficiency, x axis = 
relative fluorescence levels (RFU) in panel A or threshold cycle in panel B, y axis = 
Log starting cDNA concentration. 
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Table 4.3 Quantitative PCR reaction efficiencies: PCR reaction efficiency values 
for each gene of interest generated by standard curve analysis.  
The qPCR reaction efficiency values following amplification of targets from both 
standard cDNA samples are summarized in Table 4.3. We acknowledge the 
observation that the amplification efficiencies vary and that the amplification of 
some targets is sub-standard, however, we do not consider variation in amplification 
efficiency to be a significant issue. This is because in subsequent chapters we will 
apply standardised techniques to determine changes in the relative gene expression 
levels of targets genes between different samples, following which we will be able to 
correct for differences in PCR reaction efficiencies, therefore accommodating for 
these observations. 
 
 
 
 
 
 
 
 
 
 
 
 PCR reaction efficiency %: 
Gene 
target 
Purified PCR 
product 
Venom cDNA 
standard 
SVMP 78.7 94.0 
SP 87.2 27.7 
PLA2 85.5 N/A 
CTL 91.6 96.9 
LAO 75.1 N/A 
VEGF 76.0 N/A 
KTI 73.1 100.7 
PDI 69.8 122.6 
QKW 73.9 91.2 
ACTIN 75.3 63.3 
GAPDH 91.1 32.1 
HSP 72.9 184.2 
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          4.4.7. Melt curve analysis to determine qPCR primer specificity 
Melt curve analysis was used to determine the ability of primer pairs to specifically 
anneal to and initiate amplification of specific DNA targets. Melt curves following 
qPCR amplification shown in Figure 4.12 and 4.13 indicated the presence of single 
peaks for most genes of interest. The curves, which plot relative fluorescence against 
temperature, showed that as temperature increases, the level of fluorescence 
decreases as double stranded DNA dissociates.  The negative first derivative of DNA 
dissociation generates a melt curve containing a single peak indicating the 
amplification of a single target, and therefore high specificity of PCR primer pairs. 
Melt curves following amplification of targets from purified PCR product standard 
samples showed single peaks for all genes of interest indicating the presence of a 
specific amplicon, as may have been expected here (Figure 4.12). In the case of the 
mature venom cDNA sample, melt curves also showed the amplification of a single 
specific target for most targets of interest (Figure 4.13). The exception was PDI as 
there appeared to be a minor second peak with a melting temperature of 
approximately 6 °C lower than the major peak. This suggests that there may be two 
different amplicons produced as result of non-specific binding by PCR primers. 
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Figure 4.12 Melt curves generated by qPCR following amplification using 
purified PCR products as a standard cDNA sample: Panel A shows the decrease 
in relative fluorescence levels (RFU) during DNA dissociation. Panel B shows the 
melt curve generated from the negative first derivative of RFU. x axis = RFU in 
panel A or the negative first derivative of RFU in panel B, y axis = Temperature °C. 
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Figure 4.13 Melt curves generated by qPCR following amplification using 
mature venom cDNA as a standard cDNA sample: Panel A shows the decrease in 
relative fluorescence levels (RFU) during DNA dissociation. Panel B shows the melt 
curve generated from the negative first derivative of RFU. x axis = RFU in panel A 
or the negative first derivative of RFU in panel B, y axis = Temperature °C. 
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4.6. Discussion 
The results of this chapter illustrate the potential value of our real-time approach, 
utilising venom stocks as a source of mRNA and advanced quantitative PCR 
technologies, as a tool for analysing the transcriptional activity of the venom gland, 
and to monitor expression levels of venom protein-encoding genes. 
The most commonly employed technique used to extract RNA from biological 
samples involves precipitation of total RNA using organic solvent-based extraction 
which results in the co-precipitation of mRNA subpopulations with other RNAs, 
which are more predominant than mRNA (Cheng et al., 1999, de Azevedo et al., 
2001, Guo et al., 2001). Conventional techniques require obtaining venom gland 
tissue from sacrificed snakes as the source of transcriptionally active mRNA, which 
is often a difficult, undesirable and unsustainable approach.  
Organic solvent-based RNA extraction fails to capture reverse transcriptase PCR-
compatible mRNA from lyophilised venoms. As an alternative approach, the capture 
of mRNA using magnetic beads (Dynabeads
TM
) was first described by Chen et al to 
isolate mRNA from the lyophilised venoms from several snakes, lizards, scorpions 
and amphibians (Chen et al., 2002, Chen et al., 2003a, Chen et al., 2003b, Chen and 
Shaw, 2003, Chen et al., 2005, Chen et al., 2006). The use of oligo dT-coated 
magnetic Dynabeads enables the capture of PCR-compatible mRNA from 
lyophilised venoms. 
To optimise mRNA isolation using this technique, we included a longer incubation 
time of the lysed venom sample with oligo dT magnetic beads (increased to 10 min) 
and we also repeated the isolation procedure for each venom sample to increase the 
yield of mRNA. Our results demonstrate that substantial quantities of venom protein-
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encoding mRNAs can be extracted from the venom of Bitis arietans (over 350ng 
from 100mg lyophilised venom). We identified that relatively small quantities of 
lyophilised venom (2mg), which were much lower than those used in previous 
studies (10mg) (Chen et al., 2002) were required to yield substantial quantities of 
mRNA (around 50ng). Total mRNA extracted from 2mg venom samples was 
synthesised into cDNA (around 20µg) which was easily sufficient for downstream 
PCR and qPCR applications. Although the amount of mRNA extracted from venom 
increased as the amount of lyophilised venom increased, the quantity of cDNA 
synthesised from mRNA did not appear to significantly increase. This suggests that 
there may be some limitations in the reverse transcription protocol. Although 
modifications were performed in order to improve the capture of mRNA from 
venom, further work could aim to enhance the cDNA synthesis reaction and 
subsequently improve cDNA yields accordingly. 
We demonstrated that a wide range of venom protein targets could be efficiently 
PCR amplified from venom mRNA, in comparison to previous literature 
demonstrating amplification of single targets of high abundance in venom e.g. 
SVMPs from viper venom and neurotoxin from elapid venom (Chen et al., 2002). 
Here we demonstrated amplification of a range of venom protein targets, including 
pathologically important enzymes such as SVMPs and SPs, and venom components 
thought to play a less toxic role in snakebite envenoming such as inhibitory peptides 
and structural proteins (PDI, QKW peptides). Importantly, PCR results demonstrated 
that a similar spectrum of mRNA could be efficiently amplified from venom as 
venom gland cDNA. This provided encouraging results indicating that the venom 
transcriptome may be an accurate representative of the venom gland transcriptome. 
Although the full diversity, stability and function of mRNAs in lyophilised venom 
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remain uncertain, these observations emphasise that this approach, and specifically 
the utilisation of venom mRNA, could provide a significantly valuable tool in snake 
venom research as an alternative to conventional methods, thus expanding the 
possibilities for gene expression studies and the study of rare/CITES listed venomous 
species. 
This work describes the optimisation of relative qPCR protocols to monitor changes 
in gene expression of venom protein-encoding genes. Standardisation experiments 
included the optimisation of initial cDNA starting quantity and annealing 
temperature required for effective qPCR amplification of targets, and evaluating PCR 
reaction efficiency and specificity of primer binding. These experiments resulted in 
the generation of stringently optimised qPCR protocols which were used in 
subsequent studies aiming to quantitatively compare gene expression levels of 
venom protein targets during the course of venom protein synthesis. 
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5. INVESTIGATION OF VENOM PRODUCTION IN JUVENILE BITIS 
ARIETANS SPECIMENS; ANALYSIS OF GENE EXPRESSION, PROTEIN 
COMPOSITION AND ENZYME ACTIVITY OF VENOM FROM BIRTH TO 
MATURITY. 
 
5.1. Abstract 
Variation in venom composition can be influenced by several factors including diet, 
gender, age and habitat. In this study, we aimed to monitor the maturation of venom 
production by exploring changes in the protein composition, toxin expression and 
enzyme activity of venom from juvenile Bitis arietans siblings from birth.  
Using relative quantitative PCR gene expression analyses, SDS-PAGE, mass 
spectrometry and substrate zymography we showed that gene expression activity, 
protein composition and functional activity of juvenile B. arietans venom did not 
appear to significantly change over time from birth to four years and venom from 
juvenile specimens appeared to be relatively similar to the maternal venom. A key 
difference in the venom protein composition between the captive-bred juvenile 
specimens and maternal adult specimen was notably in the presence of an additional 
PII SVMP, BAR00015, in the maternal venom, although the proteolytic activity of 
juvenile and maternal venoms, indicated by gelatin zymography, was similar. 
In conclusion, we demonstrate that venom of B. arietans appears highly developed 
and enzymatically active immediately from birth. In the light of these results, we 
discuss the potential role of factors, both internal and external, influencing the 
composition and function of venom in this viper species. 
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5.2. Introduction 
Variation in snake venom composition has been documented on several taxonomic 
levels and can be attributed to several factors including diet and age, and less 
influentially by gender. We previously demonstrated high levels of intra-species 
variation in protein composition and biological activity of venoms from groups of 
unrelated, wild caught Bitis arietans specimens (Chapter 3) (Currier et al., 2010). 
This variation appeared to be irrespective of environmental conditions, but could 
have been a result of inter-species individual differences. The aims of this chapter 
were to determine (i) venom production system and (ii) venom composition and 
enzyme activity in a group of sibling, captive-bred juvenile specimens. 
As previously mentioned, differences in diet have been closely associated with 
variation in venom composition and function. This correlation was firstly 
demonstrated by Daltry et al who showed that variation in venom composition and 
activity in the Malayan pitviper, Calloselasma rhodostoma was related to diet, 
suggesting that venom composition may be subject to strong natural selection 
pressures (Daltry et al., 1996b). Variation in the venom protein composition between 
closely related subspecies of Sistrurus rattlesnakes (Sanz et al., 2006) and Echis 
species (Barlow et al., 2009, Casewell et al., 2009) have been correlated with the 
recruitment of different toxins into the proteome of species with predominantly 
mammalian or varied diets. 
Changes in the diet (and size) of venomous snakes may also be related to changes in 
the composition and function of venom from juvenile snakes as they mature, known 
as ontogenetic shifts. The first observations of ontogenetic variation in venom were 
demonstrated by Reid and Theakston who identified changes in the coagulant 
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activity of Crotalus atrox venom as snakes age (Reid and Theakston, 1978). This 
study concluded that the venom of juvenile snakes was more lethal (indicated by 
LD50) and showed greater ability to induce platelet aggregation (indicated by in vitro 
platelet aggregation assays) than venom from adults. This study emphasises the 
importance of understanding ontogenetic variation in venom from a clinical 
perspective as different venom activities could explain conflicting reports of 
snakebite envenoming symptoms (Reid and Theakston, 1978). A study by Furtado et 
al demonstrated variation in venom from Bothrops species and sub-species by 
analysing venom protein content and composition by SDS-PAGE, toxicity by LD50, 
clotting activity by minimum coagulant dose (MCD) and proteolytic activity by 
substrate assays (Furtado et al., 1991). This study showed that venoms from the 
offspring of some species (B. cotiara) had differing coagulant activity to the maternal 
venom and, overall, venoms from offspring were shown to possess higher levels of 
procoagulant activities (Furtado et al., 1991). Another study identified (by SDS-
PAGE, immunoblotting, chromatography, lethality, haemorrhagic, coagulant and 
haemolytic activity assays), a shift in the composition of venom from Bothrops asper 
and B. atrox from predominantly high molecular weight proteins (in specimens <1 
year of age) to low weight proteins as snakes aged (Saldarriaga et al., 2003). This 
study also demonstrated higher lethal, haemorrhagic and coagulant activities in 
juvenile venoms, whereas venoms from older specimens (3 years of age) showed 
higher indirect haemolytic (PLA2) activity, which was more significant in B. asper. 
Further studies on venom from the Brazilian pitviper, Bothrops insularis, indicated 
that venom from juveniles snakes showed higher coagulant activities than adult 
venom, particularly acting on factors X and II (Zelanis et al., 2007). A more recent 
study showed differences in the activity between venoms from juvenile and adult 
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Bothrops jararaca; one of the most medically important vipers in Brazil. Here, 
juvenile venoms showed higher L-amino acid oxidase, hyaluronidase, platelet 
aggregating and procoagulant activities, although adult venoms were showed to be 
more lethal than juvenile venoms (Antunes et al., 2010). Studies have also 
demonstrated that ontogenetic variations in venom may be closely related to diet. A 
study showed that juvenile B. jararaca venom was more toxic to amphibian prey in 
comparison to endothermic prey (mice) than adult venom (indicated by LD50), and 
adult venom was more toxic to endothermic prey than juvenile venom (Andrade and 
Abe, 1999). These observations are reflected in the natural shifts in feeding patterns 
from ectothermic (frogs) to endothermic (mice) prey as snakes mature from juveniles 
to maturity. A recent proteomic study demonstrated fine scale ontogenetic shifts in 
the relative abundance of SVMPs (class I and II) and PLA2 in the venom of Sistrurus 
miliarius barbouri which was distinctly related to changes in diet (Gibbs et al., 
2011). This study identified no substantial changes in the overall composition of 
venom toxin groups, but a decrease in some PIII SVMPs isoforms was observed, 
most evident in mouse-fed juveniles. There was also variation in the abundance of a 
specific PLA2 with a higher percentage in venom from in juveniles with an 
ectothermic diet and lower proportion in the venom from juveniles with endothermic 
diets (Gibbs et al., 2011).  
The consensus conclusions for the majority of studies investigating ontogenetic 
variation in viper venoms indicate that juvenile venoms, overall, exert a distinct 
pathology to adult venoms, particularly in the coagulant activity of venom, and are at 
least equal to, and in some cases more toxic than there adult counterparts. This could 
lead to variations in the clinical manifestation of snakebite and the effectiveness of 
antivenom treatment if the immunising venom used in the manufacture of 
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antivenoms does not incorporate venoms from snakes of different levels of maturity. 
Thus, it is important to characterise levels of ontogenetic venom variation. In this 
chapter, we aimed to monitor variation in venom composition in B. arietans by 
investigating the development of venom in juvenile B. arietans siblings from birth 
across the course of the study (four years) and identify changes in toxin expression, 
venom protein composition and enzyme activity of juvenile specimens as snakes 
mature. 
 
5.3. Materials and Methods: 
          5.3.1. Venom sample collection and preparation 
A gravid wild-caught female specimen was imported to herpetarium in the Alistair 
Reid Venom Unit from Nigeria, and three months later gave birth to 22 B. arietans 
specimens in captivity in July 2008. New born specimens were fed the same murine 
diet and were exposed to the same environmental conditions throughout the course of 
this study. Larger photographs of individual new born B. arietans specimens are 
shown in Appendix VI which show some variation in the coloration and scale 
patterns between related siblings. Venom samples were extracted from individuals on 
the day of their birth and subsequently extracted at regular intervals (approx. 
monthly) until January 2012 (Figure 5.1). At each venom extraction, the following 
were recorded; (i) specimen health, (ii) specimen bodyweight and (iii) wet venom 
weight. Venoms samples were frozen at -20°C for 24 hours and lyophilised for 3-4 
hours. Due to natural attrition, only three specimens remained throughout the course 
of the study. This resulted in a variable number (1-20) of venom samples obtained 
for each individual specimen for analysis at the end of the study.  
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Figure 5.1 Bitis arietans juvenile specimen: Individual juvenile B. arietans 
specimen coloration (A) and venom extraction (B). 
 
 
 
 
 
          5.3.2. Extraction of Poly(A) mRNA from venom using Dynabeads®  
Messenger RNA was extracted from 2mg selected venom samples from three 
specimens using the Dynabeads® mRNA extraction protocol (Section 2.6 of Chapter 
2). We selected one venom sample from each specimen per year across 4 years. For 
individuals BaN58-1, BaN58-3 and BaN58-9, we selected venom samples from 
October 2008 (Year 1), June 2009 (Year 2), November 2010 (Year 3) and November 
2011 (Year 4). To increase n number BaN58-12 and BaN58-19 were also included in 
the study, however, these specimens survived only for 3 years and so venom from 
year 4 was unavailable for these specimens.  
 
          5.3.3. Monitoring gene expression levels using relative quantitative PCR 
(qPCR):  
For relative qPCR experiments, 10µl KAPA SYBR® FAST qPCR master mix 
(containing 0.22µl forward primer (10µM), 0.22µl reverse primer (10µM), 5.5µl 
KAPA SYBR green dye and 4.06µl ultrapure water) (KAPA Biosystems, AnaChem) 
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was added to 1µg cDNA. Samples were prepared in triplicate alongside no template 
controls. PCR amplification of a range of venom protein-encoding gene targets 
(including a class PII SVMP [BAR00042], group II PLA2 [BAR00406], SP 
[BAR00034], CTL [BAR00012], VEGF [BAR00040], LAO [BAR00017], KTI 
[BAR00023], PDI [BAR00008] and QKWs [BAR00003] (Wagstaff et al., 2008)), 
normalised against three reference transcripts (β-actin, GAPDH and heat shock 
protein) was performed using the BioRad CFX 384 real-time PCR system and 
analysed using the BioRad CFX manager software (version 1.5) in gene expression 
mode with an initial denaturation step of 95°C for 3 min followed by 40 cycles of 
95°C for 10 seconds, 55°C for 30 seconds. Fold expression change for each gene of 
interest was calculated using the ΔΔCt comparative method (Pfaffl, 2001, 
Vandesompele et al., 2002) normalised against three reference genes: β-actin, 
GAPDH and heat shock protein. The data were transformed onto a log scale and 
analysed by univariate analysis of variance using PASW statistics version 18 (SPSS 
Inc.) (IBM, 2009) fitting individual snake, time point and venom protein as fixed 
effects. Differences in venom production attributable to time points were investigated 
allowing a Bonferroni correction for multiple comparisons. Following statistical 
analysis, raw data for each individual specimen was standardised by converting fold 
expression to a percentage of the maximum expression value for each specimen. At 
each time point, the expression of each toxin target was averaged for all specimens in 
the study. 
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          5.3.4. Venom protein composition profiling 1D SDS-PAGE:  
The protein composition of all venom samples available for each individual was 
analysed. Venom samples for each individual specimen were reconstituted at 
10mg/ml in PBS and diluted to 1mg/ml in reducing SDS-PAGE sample buffer. 
Samples were separated on 1mm 15% SDS-PAGE gels and stained with Coomassie 
Blue R-250 as described in Section 2.2.2 of Chapter 2. 
 
          5.3.5. Identification of venom proteins by LC-MS/MS  
Proteins of interest from SDS-PAGE profiles of individual juvenile and adult B. 
arietans specimens were excised, trypsin-digested and identified by LC-MS/MS as 
described in Section 2.5 of Chapter 2. 
 
          5.3.6. Venom enzyme activity profiling by substrate zymography:  
Zymography was carried out using gelatin substrate to visualise the degradative 
activity of the enzymes present in all individual venom samples as described in 
Section 2.4 of Chapter 2. 
 
5.4. Results: 
          5.4.1. Juvenile Bitis arietans survival, growth and venom yield rate 
Within the initial group of juvenile specimens (22 individuals), we experienced a 
rapid rate of attrition within the first 12 months of the study and a survival rate of 
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13.6% at completion of the study in year 4. However, the % of specimens yielding 
venom per venom extraction was consistently high throughout the course of the 
study with most specimens producing venom at each extraction, even during the first 
year of the study. Figure 5.2 shows specimen weight and wet venom weight data 
collated for all individuals.  
We observed correlation between the specimen weight and wet venom weight. 
Figure 5.2 A indicates that, on average for all specimens, the juvenile snake 
bodyweight and wet venom yield showed a gradual increase across time from birth 
throughout the course of the study. The increase in specimen weight (Figure 5.2 B) 
and wet venom weight (Figure 5.2 C) is also shown on an individual level. Snake 
bodyweight increased from 19.7g ±2.7 at birth to 393.3g ±25.2 in year 4. The wet 
venom yield increased from 28.0mg ±13.7 at birth to 185.1mg ±134.4 in year 4 per 
specimen, demonstrating a positive correlation between snake bodyweight and 
venom yield across time from birth to year 4. 
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Figure 5.2 Juvenile Bitis arietans growth rate and venom production: 
Relationship between snake weight (g) and weight of extracted venom (mg) in 
juvenile B. arietans specimens on average (panel A) and on an individual level; 
individual growth rate (panel B) and individual wet venom weight (panel C). Data 
shows a positive correlation between snake weight and quantity of venom produced. 
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          5.4.2. Quantitative PCR (qPCR) toxin expression profiles of juvenile B. 
arietans siblings from birth 
Toxin expression profiles were generated by relative qPCR for five juvenile snakes 
(BaN58-1, 3, 9, 12 and 19) to monitor changes in expression of mRNA from birth 
until years 3-4. The data showed variation in fold changes in expression levels 
between individual specimens (Table 5.1 and Figure 5.4 A). Specimens BaN58-1, 
BaN58-3, BaN58-12 and BaN58-19 showed broadly similar expression profiles 
whereas BaN58-9 showed a different expression profile with unusually high levels of 
expression of SVMP, SP and PDI genes in year one compared to other specimens. 
On average, analysis of juvenile toxin expression profiles showed a peak in 
expression of all transcripts analysed in this study observed in year 2 (Figure 5.3 B). 
This peak in expression in venom extracted in year two was shown to be statistically 
significant, confirmed by ANOVA and Bonferroni post-hoc testing. Statistically 
significant p-values (<0.005) were generated showing differences in expression 
between year 2 and years 1, 3 and 4 (Table 5.2). 
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Table 5.1 Relative qPCR gene expression levels during venom production in 
juvenile Bitis arietans specimens: Raw qPCR data generated from relative 
expression analysis to show fold changes in expression of venom genes of interest, 
including snake venom metalloproteinase (SVMP), serine protease (SP), C-type 
lectin (CTL), Kunitz inhibitors (KTI), protein disulphide isomerase (PDI) and QKW 
inhibitory peptides (QKW) in juvenile B. arietans venom from birth until year 3-4. 
Dashes indicate samples in year 4 which were not available in individuals BaN58-12 
and 19. Blue shaded areas indicate peak values in expression levels for each 
specimen and each gene of interest.  
 
 
 
  Snake ID 
Toxin Time point BaN58-1 BaN58-3 BaN58-9 BaN58-12 BaN58-19 
SVMP Year 1 1.00 1.00 5.78 0.50 0.83 
 Year 2 2.22 1.79 0.70 0.64 1.07 
 Year 3 2.14 1.77 0.83 1.29 1.24 
 Year 4 0.98 1.83 0.75 - - 
SP Year 1 1.00 0.96 5.00 1.11 1.16 
 Year 2 3.79 2.34 1.00 1.35 0.28 
 Year 3 4.32 2.12 1.70 1.11 1.02 
 Year 4 2.01 1.59 1.47 - - 
CTL Year 1 1.00 0.30 0.13 0.86 1.02 
 Year 2 6.14 2.34 1.00 1.25 1.49 
 Year 3 0.71 0.19 0.11 1.29 0.27 
 Year 4 0.36 0.10 0.05 - - 
KTI Year 1 0.76 0.38 0.27 1.11 1.16 
 Year 2 7.19 2.34 1.00 1.73 1.15 
 Year 3 0.75 0.27 0.30 1.28 0.84 
 Year 4 0.40 0.12 0.13 - - 
PDI Year 1 1.00 1.00 2.68 0.47 0.69 
 Year 2 0.76 1.65 1.00 1.61 1.34 
 Year 3 0.58 1.11 0.30 0.88 0.58 
 Year 4 0.75 1.99 1.61 - - 
QKW Year 1 0.44 0.18 0.13 0.69 0.64 
 Year 2 7.19 2.34 1.00 2.01 1.49 
 Year 3 0.27 0.09 0.10 1.02 1.01 
 Year 4 0.50 0.20 0.14 - - 
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Table 5.2 Statistical analysis of gene expression data from juvenile Bitis arietans 
venom samples: Fold changes in relative expression levels of venom genes of 
interest in juvenile B. arietans specimens analysed by ANOVA and Bonferroni post-
hoc testing showed a statistically significant difference in gene expression levels in 
year 2. * indicated significant p-value. 
 
 
  
 
 
Figure 5.3 B indicates that the expression of SVMPs and SPs, major enzymatic and 
highly pathogenic components of B. arietans venom, appeared to be maintained at a 
more consistent level with a less-pronounced peak in expression in year 3. In 
contrast, the non-enzymatic venom components which were surveyed in this study 
(CTL, KTI, PDI and QKW) appeared to show more highly variable levels of gene 
expression which appeared to peak in venom extracted in year 2. 
 
 
 
 
 
Time point (I) Time point (J) Mean difference (I-J) P-value 
Year 1 Year 2 -0.3203 0.003* 
 Year 3 0.0571 1.000 
 Year 4 0.1034 0.342 
Year 2 Year 3 0.3774 0.003* 
 Year 4 0.5193 0.000* 
Year 3 Year 4 0.1418 1.000 
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Figure 5.3 Juvenile Bitis arietans toxin gene expression profiles during venom production: qPCR profiles for five individual B. arietans specimens 
showing fold changes in expression levels of a range of venom genes of interest relative to three references genes for 5 individual juvenile B. arietans 
specimens (A) and % expression levels averaged for three specimens (BaN58-1, 3 and 9) indicating a peak in the expression of some genes in year 2 (B). 
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          5.4.3. Venom protein profiles of juvenile B. arietans siblings from birth 
The venom protein profile was analysed by SDS-PAGE for every available venom 
sample for each individual juvenile B. arietans specimen. Venom protein profiles are 
shown in Figure 5.4 indicating that, qualitatively, there were no pronounced changes 
in the overall protein composition of venom from birth to 4 years. The juvenile B. 
arietans venom protein profile consisted of numerous low molecular weight proteins, 
few mid-molecular weight proteins and several proteins present in the high molecular 
weight region and showed very little variation between individual siblings. In 
comparison to the maternal venom (BaN58), juvenile venom samples shared the 
majority of proteins present in adult venom, although all juvenile venoms appeared 
lack a distinct protein present in the maternal venom of around 33kDa in weight 
(Figure 5.4 BaN58, band circled in red). 
Although for many specimens, few venom samples were available for protein 
analysis due to poor survival rate, we found that interestingly, there was little change 
in venom protein composition during the 4 year maturation of specimens which 
survived the course of the study. Also, the protein composition of venom did not 
change in snakes which did not survive the course of the study, indicating that death 
of snakes was not reflected in venom composition. 
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Figure 5.4 Juvenile Bitis arietans venom protein profile: SDS-PAGE profiles for individual juvenile B. arietans specimens of venom (10mg/ml) 
extracted at regular intervals from birth until 4 years. Molecular weight markers (kDa) are shown on the left of each image. Band (circled) on BaN58 
(mother) profile indicates protein present in maternal venom which was apparently absent in juvenile venoms. 
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Figure 5.5 Mass spectrometry identification of protein bands from juvenile Bitis 
arietans venom: Protein bands of interest were excised from SDS-PAGE protein 
profiles of three individual juvenile and adult B. arietans specimens, including a 
protein band present in adult maternal venom which appeared to be absent in 
juvenile venoms (band 1). 
          5.4.4. Mass spectrometry identification of proteins of interest from 
juvenile B. arietans samples 
For the three surviving specimens (BaN58-1, 3 and 9), several proteins from low, 
mid and high molecular weight regions were excised from SDS-PAGE protein 
profiles and trypsin-digested for identification by mass spectrometry. Proteins of 
interest were also excised and identified from the maternal venom (BaN58). These 
proteins from B. arietans venom were confidently identified by mass spectrometry 
(Figure 5.5). Figure 5.6 shows full and partial length peptide sequences assigned to 
protein bands by LC-MS/MS.  
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Figure 5.6 continued on following page: 
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Figure 5.6 Full and partial-length peptide sequences identified by LC-MS/MS 
from juvenile Bitis arietans specimens: Peptide searches against contigs assembled 
from our B. arietans venom gland EST database were performed to identify protein 
bands 1-7 (Figure 5.5A). Signal peptides predicted using Signal P (Bendtsen et al., 
2004) are underlined. Peptides identified by LC-MS/MS are indicated in red. For 
SVMP sequence BAR00015, the RGD disintegrin tripeptide is boxed. ‘B’ amino 
acids = asparagine or aspartic acid. 
Figure 5.6 continued:  
 
 
Firstly, we identified a 33kDa protein band – PII SVMP isoform, BAR00015 - which 
was present in the maternal venom (Figure 5.5, band 1) but was not detected in any 
of the juvenile venoms. This was the most notable difference in protein composition 
between adult and juvenile venoms. We also identified several proteins which 
appeared to be conserved between individual juvenile specimens and which also did 
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not appear to significantly change in abundance across time from birth. These 
included CTL [BAR00473] (band 3), SP [BAR00031/BAR00263] (band 5) and class 
PI and PII SVMPs [BAR00027] (band 4) and [BAR00076/BAR00462/BAR00346] 
(bands 6), all of which are components of B. arietans venom known to significantly 
contribute to the pathological effects of envenoming, and VEGF [BAR00040] (band 
2) which is thought to play a less toxic role in venom. One protein band (band 7) 
could not be confidently identified following searches against our B. arietans 
database which could potentially indicate the presence of novel, uncharacterised 
protein groups. Table 5.3 shows a list of peptide sequences identified by mass 
spectrometry and Proteome Discoverer 1.1.0 (ThermoScientific) software for each 
protein of interest. For most proteins, a single cluster was confidently identified 
following searches of Uniprot databases and a B. arietans venom gland EST database 
using Proteome Discoverer. 
 
 
 
 
 
 
 
 155 
 
          Mascot Sequest 
Band Snake Molecular 
weight on 
gel (kDa) 
MS-
derived 
molecular 
weight 
(kDa) 
Cluster 
identified 
Protein 
family 
Accession 
no. 
Peptide 
ion m/z 
(Da) 
z MS/MS derived sequence  
Ion 
score 
 
Exp 
value 
 
Probability 
 
XCorr 
1 Adult 33 53 BAR00015 
PII-
SVMP 
ADW54354 403.535 +2 FNGGIIGK 47 2.27E-05 
  
  
  
 
  616.130 +2 HDNAQLFTGTK 47 7.64E-06 
  
       470.580 +2 IMVVADHR 39 1.69E-04   
       577.475 +2 AYIGTICDLK 34 2.27E-04   
       577.500 +2 AYIGTICDLK 18 9.42E-03   
       616.130 +2 HDNAQLFTGTK   76.57 3.72 
       577.475 +2 AYIGTICDLK   70.75 2.71 
       470.580 +2 IMVVADHR   63.49 2.41 
       577.500 +2 AYIGTICDLK   19.99 2.15 
       1153.400 +1 AYIGTICDLK   33.23 2.10 
       403.535 +2 FNGGIIGK   30.96 2.06 
       795.205 +1 SFAEWR   9.41 1.33 
       796.200 +1 SFAEWR   21.12 1.24 
       795.215 +1 SFAEWR   2.43 1.23 
2 Juvenile 12 14 BAR00040 VEGF C0K3N1.1 687.075 +2 TVELQVMQVTPK 84 2.93E-09   
       686.590 +2 TVELQVMQVTPK 69 9.71E-08   
       695.105 +2 TVELQVMQVTPK 66 2.46E-07   
       686.610 +2 TVELQVMQVTPK 64 3.92E-07   
       695.070 +2 TVELQVMQVTPK 62 5.17E-07   
       686.640 +2 TVELQVMQVTPK 57 1.91E-06   
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       687.055 +2 TVELQVMQVTPK 52 5.04E-06   
       687.045 +2 TVELQVMQVTPK 38 1.24E-04   
       695.095 +2 TVELQVMQVTPK 34 3.27E-04   
       686.910 +2 TVELQVMQVTPK 28 1.41E-03   
       660.265 +2 IFRPSCVAVLR 28 1.60E-03   
       439.935 +3 IFRPSCVAVLR 26 2.85E-03   
       1372.545 +1 TVELQVMQVTPK 25 2.88E-03   
       659.245 +2 IFRPSCVAVLR 21 8.59E-03   
       1373.570 +1 TVELQVMQVTPK 20 1.02E-02   
       687.075 +2 TVELQVMQVTPK   70.72 4.61 
       695.070 +2 TVELQVMQVTPK   59.24 4.26 
       1017.775 +2 CGGCCSDESLTCTSVGER   86.76 4.24 
       695.105 +2 TVELQVMQVTPK   75.68 4.02 
       686.640 +2 TVELQVMQVTPK   63.89 3.93 
       695.095 +2 TVELQVMQVTPK   40.25 3.67 
       686.610 +2 TVELQVMQVTPK   42.51 3.56 
       686.910 +2 TVELQVMQVTPK   57.90 3.51 
       687.055 +2 TVELQVMQVTPK   49.31 3.49 
       686.590 +2 TVELQVMQVTPK   60.39 3.46 
       1018.630 +2 CGGCCSDESLTCTSVGER   58.59 3.46 
       439.935 +3 IFRPSCVAVLR   40.77 3.42 
       687.045 +2 TVELQVMQVTPK   46.63 3.13 
       1372.545 +1 TVELQVMQVTPK   3.80 2.57 
       1373.570 +1 TVELQVMQVTPK   20.34 2.49 
       659.245 +2 IFRPSCVAVLR   18.47 2.39 
3 Juvenile 18 16 BAR00473 CTL Q6T7B6 731.145 +2 NCFGLEKESGYR 51 3.89E-06   
       730.185 +2 NCFGLEKESGYR 41 5.86E-05   
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       802.315 +1 TWLNLR 23 4.41E-03   
       434.470 +2 NCFGLEK 22 5.27E-03   
       401.970 +2 TWLNLR 22 8.35E-03   
       401.500 +2 TWLNLR 19 9.87E-03   
       631.010 +2 CGDDYPFVCK 19 8.91E-03   
       631.010 +2 CGDDYPFVCK   37.03 3.54 
       630.985 +2 CGDDYPFVCK   41.82 3.25 
       730.185 +2 NCFGLEKESGYR   73.75 2.99 
       867.225 +1 NCFGLEK   6.48 1.90 
       802.315 +1 TWLNLR   30.49 1.48 
       803.275 +1 TWLNLR   10.65 1.30 
  
  
BAR00015 
PII 
SVMP 
ADW54354 577.065 +2 AYIGTICDLK 26 2.08E-03   
       577.065 +2 AYIGTICDLK   49.75 2.79 
    BAR00076 SVMP ADI47583.1 679.550 +2 ACQLAATSEFMK 34 3.74E-04   
       679.550 +2 ACQLAATSEFMK   40.49 3.88 
4 Juvenile 24 21 BAR00027 SVMP ABN72547.1 713.545 +2 EISEYGMVDPGTK 53 5.70E-06   
       1033.685 +2 GTCPTLTNQCIALFGPDAK 50 6.15E-06   
       721.525 +2 EISEYGMVDPGTK 49 8.24E-06   
       908.495 +2 VSKDDCDLPEHCTGQSAECPMNR   107.58 4.82 
       1032.325 +2 GTCPTLTNQCIALFGPDAK   68.37 3.89 
       713.545 +2 EISEYGMVDPGTK   79.22 3.45 
       721.525 +2 EISEYGMVDPGTK   51.53 3.25 
       1032.715 +2 GTCPTLTNQCIALFGPDAK   103.55 3.24 
       907.560 +3 VSKDDCDLPEHCTGQSAECPMNR   22.29 2.60 
       1050.305 +1 VAPDTCFLK   26.99 1.75 
5 Juvenile 50 29 BAR00031 SP E0Y418.1 626.090 +2 DAYGDLPEKSR 26 1.87E-03   
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       538.005 +2 LYDYSVCR 23 6.31E-03   
       538.005 +2 LYDYSVCR   28.57 2.98 
       626.090 +2 DAYGDLPEKSR   45.70 2.35 
    BAR00263 SP Q6T6S7.1 785.685 +2 NVQNEDEEIRVPK 51 7.77E-06   
       530.475 +2 LFDYSVCR 51 1.37E-03   
       785.685 +2 NVQNEDEEIRVPK   42.83 3.74 
       530.475 +2 LFDYSVCR   48.07 3.04 
6 Juvenile 75 39 BAR00076 SVMP ADI47583.1 823.170 +2 ENDVKIPCAQEDVK 34 1.74E-04   
       548.990 +3 ENDVKIPCAQEDVK 27 9.16E-04   
       530.055 +2 IPCAQEDVK 25 5.78E-03   
       717.080 +2 IPCAQEDVKCGR 19 8.23E-03   
       823.670 +2 ENDVKIPCAQEDVK 18 1.10E-02   
       823.170 +2 ENDVKIPCAQEDVK   51.71 3.45 
       717.080 +2 IPCAQEDVKCGR   66.76 2.78 
       548.990 +3 ENDVKIPCAQEDVK   28.10 2.67 
       530.055 +2 IPCAQEDVK   31.60 2.59 
    BAR00462 SVMP ADI47619.1 595.560 +2 VVNNVNVIYR 54 4.64E-06   
       596.050 +2 VVNNVNVIYR 39 1.67E-04   
       594.935 +2 VVNNVNVIYR 28 1.70E-03   
       712.190 +1 YFNIR 21 6.79E-03   
       595.560 +2 VVNNVNVIYR   65.52 3.61 
       596.050 +2 VVNNVNVIYR   46.86 2.50 
       594.925 +2 VVNNVNVIYR   32.80 2.34 
       713.200 +1 YFNIR   14.11 1.18 
       712.190 +1 YFNIR   10.62 1.18 
    BAR00346 SVMP Q98UF9.3 633.440 +3 FINIHNPQCISNKPSK 39 8.95E-05   
       900.125 +2 TDIVSPPVCGNELLER 38 1.04E-04   
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Table 5.3 LC-MS/MS identification of venom proteins from juvenile Bitis arietans venom samples: Identification of protein components excised and 
trypsin-digested from individual juvenile and adult B. arietans venom samples in Figure 5.8. The table includes a list of peptide sequences derived by mass 
spectrometry for each protein of interest, the protein family assigned to each protein and the accession number of the protein which corresponds to the closest 
protein match identified by BLAST search. Ion score and E values indicate protein identification by Mascot algorithm and Probability and XCorr correspond to 
protein identification by Sequest algorithm. 
       633.440 +3 FINIHNPQCISNKPSK   68.08 3.77 
       882.155 +3 GECDVSDLCTGQSAECPLDVFKR   57.09 3.53 
       900.125 +2 TDIVSPPVCGNELLER   77.06 2.98 
7 Juvenile 
 
9 
 
N/A 
No 
confident 
hits 
         
 160 
 
Figure 5.7 Juvenile B. arietans venom enzyme activity profiles: Gelatin zymography to visualise enzyme activity of venom samples from juvenile and 
adult B. arietans specimens from birth until present/death shows that venom is highly enzymatically active immediately from birth and that juvenile venom 
activity appears to be comparable to that of adult (maternal – BaN58) venom. 
 
 161 
 
5.4.5. Enzyme activity of venom samples from juvenile B. arietans specimens 
Figure 5.7 illustrates the proteolytic activity of enzymes, such as SVMPs, present in 
venom samples extracted from juvenile specimens from birth until present/death 
using gelatin zymography. All juvenile venoms showed very similar regions of 
substrate degradation with a major mid-molecular weight region and a less intense, 
distinct region of degradation at a high molecular weight. Importantly, venom was 
highly enzymatically active immediately from birth and appeared to be maintained at 
a constant level throughout the course of the study. Again, it is interesting to note 
that enzyme activity of venom did not change or was not compromised in specimens 
which did not survive for the course of the study. The region/intensity of substrate 
degradation by juvenile venoms seemed to be comparable to that of the maternal 
venom (BaN58) (Figure 5.7).  
 
5.5. Discussion 
Several studies have demonstrated that venom composition and function are, to some 
extent, plastic and can be influenced by environmental conditions such as diet. It has 
been suggested that changes in diet, i.e. shifts from smaller (ectothermic) to larger 
(endothermic) prey, which are often observed as snakes mature from juveniles to 
adults, may be responsible for resulting in changes in the protein composition and 
toxicity of venoms (Andrade and Abe, 1999, Gibbs et al., 2011). Currently, limited 
information is available to understand the mechanisms underlying variation in venom 
composition and toxicity. Our previous findings in Chapter 3 indicated significant 
levels of intra-species variation in protein composition and enzyme activity of venom 
from a group of unrelated, wild-caught adult B. arietans specimens originating from 
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the same and different geographical origins (Currier et al., 2010), demonstrating that 
the adaptability of this species to occupy a wide range of habitats may be reflected in 
the composition of its venom. In contrast, here we have investigated the levels of 
variation in venom between a group of sibling, captive-bred B. arietans specimens 
and demonstrated that very little variability in venom composition and activity exists 
between familiarly related specimens. We also showed that the protein composition 
and activity of venom did not appear to significantly change from birth until 4 years, 
within the resolutions of SDS-PAGE and substrate zymography techniques used in 
the study. We observed that both the composition and enzymatic activity of juvenile 
venoms was highly developed and appeared to be comparable to that of the maternal 
adult venom immediately after birth. This indicated that the ability of specimens to 
produce biologically functional venom may be genetically ‘hard wired’, which most 
likely reflects the vital role of venom in both defensive and predatory mechanisms. 
This was also emphasised following observations that the high rate of attrition of 
specimens in the study did not appear to affect the production of venom.  
Our results generated by qPCR indicated a change in the gene expression profiles of 
venom proteins during maturation of snakes. We observed a peak in gene expression 
levels of all transcripts surveyed in this study in year 2. This was not reflected in our 
analyses of the venom protein composition and enzyme activity which remained 
relatively constant across time, although it was difficult to directly compare changes 
in gene expression with protein composition due to the high sensitivity of qPCR 
technology compared with gel electrophoresis. The peak in toxin expression in year 2 
did not appear to relate to any defined environmental or biological factors as the diet 
and environmental conditions were maintained constant throughout the study. 
However, due to circumstances beyond our control (herpetarium refurbishment), 
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specimens were moved to a temporary accommodation for a three month period from 
November 2009 to February 2010 during which a change in temperature and 
humidity may have occurred. During the three month period of temporary 
accommodation, venom was not extracted from specimens for safety reasons. This 
resulted in an interruption in the frequency of venom extractions which may have 
affected venom production in juvenile snakes as it has been documented that the total 
volume of venom present in venom glands of snakes may dictate venom synthesis, 
i.e. venom depletion of venom stores initiates re-synthesis of proteins (Mackessy, 
1991). For qPCR gene expression profiling, we selected a single venom sample for 
each year of the study which was available for all three specimens surviving the 
course of the study (BaN58-1, 3 and 9), in sufficient amounts required for qPCR 
(2mg). The venom samples we selected for qPCR profiling were extracted three 
months prior to and several months after the change in environmental conditions 
during temporary accommodation. Therefore, we cannot conclude whether the peak 
in gene expression observed in year two was related to the 3-month interruption in 
venom extractions. To conclude whether an interruption in the frequency of venom 
extraction resulted in a change in gene expression levels, we aim to increase the 
number of venom samples in qPCR profiling experiments to include venom samples 
extracted immediately prior to and after the change in environment. 
Although the results of this study demonstrated that venom from juvenile B. arietans 
specimens appeared to be similar to adult venom in terms of enzyme activity, we 
observed a difference in the protein composition of venom in the presence/absence of 
a class PII SVMP isoform BAR00015. We could not detect BAR00015 in the 
proteome of juvenile venom, potentially due to a complete absence of this transcript 
from the venom gland transcriptome or due to proteolytic processing of the protein. 
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This PII isoform is thought to be an important component of B. arietans venom as it 
contains an RGD-containing disintegrin domain, corresponding to bitistatin, a long-
chain disintegrin isolated from the venom of B. arietans (Juárez et al., 2006). 
Bitistatin, following release from the PII metalloproteinase domain through 
proteolysis, has been shown to act as a potent inhibitor of platelet aggregation and 
function through selectively blocking the binding of fibrinogen to the integrin αIIbβ3 
receptor (Shebuski et al., 1989, Huang et al., 1987). As SVMPs are highly 
pathogenic and important for B. arietans envenoming, we could suggest that the 
composition of these enzymes in venom could have implications on the overall 
toxicity and clinical effect of venom. Although our findings here showed that the 
overall proteolytic activity of juvenile and adult venoms were comparable, our tests 
were not sensitive enough to reveal differences in specific toxin activity.  
Further experiments including in vivo assays, are currently on going to explore 
differences in the clinical effects of envenoming. Differences in the toxic effects 
induced by juvenile and adult B. arietans venom may affect the manifestation of 
clinical symptoms in snakebite victims. This could have implications on the 
treatment of envenoming, if differences in activity of juvenile venoms are not 
accommodated for in the manufacture of antivenom. Previous in vivo studies have 
shown some differences in the clinical effects of B. arietans envenoming between 
adult and juvenile specimens (Theakston and Reid, 1983). The LD50 of juvenile B. 
arietans venom following injection into mice was slightly lower than adult venom at 
20.3µg/mouse compared to 25.0µg/mouse of adult venom indicating that juvenile 
venom may be more toxic. Differences in other venom-induced pathology were 
observed including haemorrhage, defibrinogenation and necrosis. The MHD 
(minimum haemorrhagic dose) indicated that juvenile venom (from Saudi Arabia) 
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was twice as haemorrhagic as adult venom (from Nigeria), although here it is 
important to note that snakes originated from different geographical locations. The 
MDD (minimum defibrinogenating dose) also indicated that the juvenile venom had 
a higher defibrinogenating activity than adults, although adult venom was more 
necrotizing than juvenile venom (Theakston and Reid, 1983). We are currently 
conducting MHD experiments to compare levels of venom-induced haemorrhage 
following injection of mice with either juvenile or adult B. arietans venom and also 
to assess whether the toxicity of venom changes as juvenile specimens mature. 
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6. UNUSUAL STABILITY OF MESSENGER RNA IN SNAKE VENOM 
REVEALS GENE EXPRESSION DYNAMICS OF VENOM 
REPLENISHMENT. 
 
The results of most of the work performed in this chapter have been published in 
Public Library of Science One (Currier et al., 2012).  
 
6.1. Abstract 
Venom is a critical evolutionary innovation enabling venomous snakes to become 
successful limbless predators; it is therefore vital that venomous snakes possess a 
highly efficient venom production and delivery system to maintain their predatory 
arsenal. 
Here, we exploit the unusual stability of messenger RNA in venom to conduct, for 
the first time, quantitative PCR to characterise the dynamics of gene expression of 
newly synthesised venom proteins following venom depletion. Quantitative PCR 
directly from venom enables real-time dynamic studies of gene expression in the 
same animals because it circumvents the conventional requirement to sacrifice 
snakes to extract mRNA from dissected venom glands. Using qPCR and proteomic 
analysis, we show that gene expression and protein re-synthesis triggered by venom 
expulsion peaks between days 3-7 of the cycle of venom replenishment, with 
different protein families expressed in parallel. We demonstrate that venom re-
synthesis occurs very rapidly following depletion of venom stores, presumably to 
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ensure venomous snakes retain their ability to efficiently predate and remain 
defended from predators. 
The stability of mRNA in venom is biologically fascinating, and could significantly 
empower venom research by expanding opportunities to produce transcriptomes 
from historical venom stocks and rare or endangered venomous species, for new 
therapeutic, diagnostic and evolutionary studies. 
 
6.2. Introduction 
Snake venom is an evolutionary innovation contributing to the success of venomous 
snakes as proficient limbless predators. Venom consists of a complex mixture of 
proteins and peptides that have evolved from normal physiological proteins (Fry, 
2005) into multi-isoform, multi-domain protein families with distinct biochemical 
targets. The collective spectrum of pharmacological specificities and biological 
potency of venom ensures rapid and efficient immobilisation, killing and digestion of 
a diverse range of prey species, irrespective of physiological differences (Kordiš et 
al., 2002). The pathological consequences of snakebite may also constitute an 
effective defence against predators and aggressors. Thus, an efficient venom 
production system is vital for venomous snakes to overcome their vulnerability 
following depletion of venom glands after a predatory or defensive snakebite. 
Venom glands are modified parotid glands comprising a densely folded secretory 
epithelium consisting of several distinct cell types, including glandular secretory, 
mitochondria-rich, horizontal and ‘dark’ cells (Oron and Bdolah, 1978, Mackessy, 
1991, Mackessy and Baxter, 2006). This abundance of secretory cells is required for 
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rapid re-synthesis of venom proteins and other components to replenish venom stores 
after a bite. The systems for storage of venom following  exocrine secretion depends 
upon the snake species, and include in (i) the central venom gland lumen, (ii) smaller 
tubular ductules, (iii) intracellular granules (Oron and Bdolah, 1978) and (iv) 
microvesicles within the lumen (Carneiro et al., 2007). The dynamics of venom 
accumulation and expression of individual venom components during synthesis is of 
great interest but little understood. Early studies observed temporal changes in the 
transcriptional activity of total venom gland RNA and total protein levels which 
peaked at day 3 and days 4 to 8 days post venom expulsion respectively (Paine et al., 
1992). However, as messenger RNA (mRNA) only constitutes 1-2% of total RNA, 
here it was not possible to elucidate variations in the expression profile of venom-
coding mRNA. Although it is thought that each secretory cell within the glandular 
epithelium produces all venom components (Taylor et al., 1986), early 
immunohistochemical studies suggested that the regeneration of depleted venom 
following expulsion may be asynchronous and that unique protein groups may be 
independently expressed, possibly relating to their toxic or physiological role in 
venom (Oron and Bdolah, 1973, Sobol Brown et al., 1975, Oron and Bdolah, 1978). 
Due to a lack of tools and the unpalatable need to sacrifice specimens (often rare, 
difficult to capture and CITES listed) for dissection of venom glandular tissue in 
conventional methods, the real-time study of gene expression of snake venom glands 
has been historically problematic and dynamic studies to track the expression of 
individual venom protein-encoding genes during venom synthesis have not been 
possible to date. 
Exploiting the unusual observations of Chen et al (Chen et al., 2002), which 
demonstrated that intact mRNA can be recovered, and toxins can be PCR-amplified 
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and cloned from snake venoms and other venomous animals, we aimed to 
characterise the expression profiles of venom genes during the course of venom 
protein replenishment following depletion of venom and correlate the resultant gene 
expression profiles with venom protein composition and enzyme activity, using the 
African Puff Adder (Bitis arietans) as a model viper species. We previously 
demonstrated in Chapter 5 that the venom delivery system of juvenile Bitis arietans 
snakes appears to be functional and capable of producing biologically active venom 
immediately from birth emphasising venom as an important predatory tool. 
Subsequently, in this chapter we aimed to monitor the expression of venom protein-
encoding genes during the course of venom replenishment following depletion and 
investigate how venom synthesis is coordinated. Here, we also demonstrate that 
mRNA is a remarkably stable component of venom during long-term storage of 
lyophilised venom samples and discuss how this unusual phenomenon has potential 
to significantly empower venom research. 
 
6.3. Methods 
          6.3.1. Venom samples and standards: 
Eight adult B. arietans specimens originating from Ghana (BaG) or Nigeria (BaN) 
were maintained in the herpetarium at the Liverpool School of Tropical Medicine 
under identical dietary and environmental conditions. Snakes were identified as 
BaG2, BaG4, BaG-LZS2, BaN11, BaN60, BaN68, BaN80 and BaN81. No venom 
was extracted from the animals for at least 25 days prior to the start of the study. The 
first venom extraction was referred to as mature venom. Thereafter, venom was 
extracted from the same individuals at four time points, referred to as day 0-1, day 0-
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3 and day 0-7, and immediately frozen at -20°C, lyophilised and stored at 4°C. Wet 
and dry masses of venom samples were recorded. Lyophilised venom samples were 
reconstituted in phosphate buffered saline (PBS) at their natural concentrations by re-
suspension in volumes of PBS identical to that lost during lyophilisation. 
 
          6.3.2. Extraction of Poly(A) mRNA from venom using Dynabeads®: 
Poly(A) mRNA was purified from 2mg of each individual lyophilised venom 
samples from all specimens using the Dynabeads® mRNA extraction protocol 
(Section 2.6 of Chapter 2). Concentration and purity of mRNA (measured by the 
ND-1000 Spectrophotometer) were recorded. 
 
          6.3.3. cDNA synthesis: 
cDNA was synthesised from 8µl of eluted mRNA per reaction using Superscript® III 
first strand synthesis system (Invitrogen) (described in further detail in Section 2.7 of 
Chapter 2) and stored at -20°C until required. 
 
          6.3.4. Quantitative PCR (qPCR): 
QPCR experiments were performed in accordance with the MIQE guidelines 
(Appendix VII) as described by Bustin et al (Bustin et al., 2009). Relative qPCR 
experiments to amplify a  range of venom protein-encoding genes including a class 
PII SVMP [BAR00042], SP [BAR00034], CTL [BAR00012], KTI [BAR00023], 
PDI [BAR00008] and QKWs [BAR00003] (Wagstaff et al., 2008) were performed 
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using optimised protocols as described in Section 5.2.3 of Chapter 5 using the 
BioRad CFX 384 real-time PCR system and analysed using the BioRad CFX 
manager software (version 1.5) Fold expression changes for each gene of interest 
normalised against three reference genes were transformed onto a log scale and 
analysed by univariate analysis of variance using PASW statistics version 18 (SPSS 
Inc.) (IBM, 2009) fitting individual snake, time point and venom protein as fixed 
effects. Differences in venom production attributable to time points were investigated 
allowing a Bonferroni correction for multiple comparisons. Following statistical 
analysis, raw data for each individual specimen was standardised by converting fold 
expression to a percentage of the maximum expression value for each specimen. At 
each time point, the expression of each toxin target was averaged for all 8 specimens 
in the study. 
 
          6.3.5. One-dimensional SDS-PAGE and gelatin zymography:   
Venom samples reconstituted to their natural concentrations were prepared in 
reducing SDS-PAGE sample buffer, separated on 1mm 15% SDS-PAGE gels 
according to the manufacturer’s recommendations (BioRad) and silver stained using 
a rapid staining protocol (Nesterenko et al., 1994) as described in Section 2.2 of 
Chapter 2. For zymography, venoms prepared in non-reducing SDS-PAGE buffer 
were separated on 0.75mm polyacrylamide gels co-polymerised with molten gelatin 
as described in Section 2.4 of Chapter 2. 
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          6.3.6. HPLC separation of venom and mass spectrometry protein 
identification 
Venom samples were fractionated and proteins identified as described in Currier et al 
(Currier et al., 2012). 
 
6.4. Results: 
          6.4.1. Quantity and quality of mRNA recovered from venom: 
 An average yield of 46.2ng (±13ng std. dev) mRNA was purified from the 2mg 
venom samples (approximately 7% of the typical venom yield). These venom mRNA 
recovery figures varied little from days 0-1 to mature venom. The average 260/280 
absorbance ratios of the venom mRNA samples was 2.43 ±0.57. These results 
demonstrate that potentially large quantities of mRNA, of high quality and purity, 
can be reproducibly recovered from B. arietans venom. More than adequate amounts 
of mRNA were recovered from each venom sample for downstream qPCR analysis: 
a representative cDNA synthesis reaction yielded 22.74µg (±3.03 µg std. dev) of 
cDNA (20µl) per reaction from 18.5ng of mRNA (8 µl) - amounts easily sufficient 
for 20 qPCR reactions. 
 
          6.4.2. Venom protein expression profiles during venom re-synthesis: 
We collected venom samples from eight puff adders (of varying size/age, sex and 
geographic origin) at intervals after venom the initial extraction of mature venom 
(day 0-1, 0-3 and 0-7) to investigate the time scale of venom re-synthesis. Relative 
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expression profiles of six venom transcripts (SVMP, SP, CTL, KTI, PDI and QKW) 
across the time course of venom re-synthesis were determined by relative 
quantitative PCR (qPCR). Table 6.1 and figure 6.1 show raw data generated by 
qPCR for all individual specimens. Figure 6.1 shows that there was variability in the 
levels of venom protein expression between individual specimens. Figure 6.2 
confirms reproducibility of venom gene expression profiles for three individuals 
using venom samples collected on a separate occasion. On average for all specimens, 
we identified a peak between day 0-3 and 0-7 in the mRNA expression of all 
transcripts surveyed in this study (Figure 6.3).  
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Table 6.1 Relative qPCR gene expression levels during venom replenishment for individual adult Bitis arietans specimens: Fold changes in relative 
expression levels of six venom transcripts including SVMP, SP, CTL, KTI, PDI and QKWs across the time course of venom re-synthesis were determined 
by relative quantitative PCR (qPCR) for each individual specimen. Shaded areas indicate peak levels of gene expression for each specimen. 
 
    
 
 
  Snake ID/Relative expression value 
Toxin Time point BaG2 BaG4 BaGLZS2 BaN11 BaN60 BaN68 BaN80 BaN81 
SVMP Day 0-1 33.60 0.01 4.36 5.36 0.24 0.38 1.00 0.93 
 Day 0-3 6.30 0.21 6.04 8.15 1.04 1.00 3.71 0.30 
 Day 0-7 69.92 1.02 3.42 1.00 0.10 0.95 10.25 6.62 
 Mature 0.15 0.00 1.00 2.65 1.66 0.89 6.63 2.45 
SP Day 0-1 10.49 0.62 10.68 9.12 0.35 11.84 1.00 4.01 
 Day 0-3 1.89 0.83 10.69 17.74 2.08 1.00 6.58 0.75 
 Day 0-7 8.28 1.02 7.57 1.00 0.46 1.44 30.01 6.62 
 Mature 2.48 0.34 0.93 7.58 1.04 5.37 11.00 10.38 
CTL Day 0-1 58.40 0.00 6.02 0.74 0.40 0.04 1.00 0.24 
 Day 0-3 4.40 0.07 8.17 0.49 0.80 1.00 7.14 0.06 
 Day 0-7 69.91 1.02 8.03 1.00 0.24 1.07 13.94 6.62 
 Mature 0.06 0.00 0.59 0.45 0.45 1.54 3.49 0.32 
KTI Day 0-1 15.24 0.040 4.22 3.18 0.13 0.22 1.00 1.01 
 Day 0-3 0.43 0.22 7.74 2.71 0.34 1.00 8.02 0.15 
 Day 0-7 4.30 1.02 8.03 1.00 0.47 0.87 26.43 6.62 
 Mature 2.48 0.01 0.28 1.61 0.60 2.57 6.18 0.79 
PDI Day 0-1 0.04 0.29 0.79 10.10 0.07 0.19 1.00 1.21 
 Day 0-3 0.19 0.32 1.15 15.04 0.17 1.00 0.15 1.00 
 Day 0-7 0.03 1.02 0.54 1.00 0.35 0.95 0.23 1.44 
 Mature 2.48 0.13 1.00 3.52 0.22 0.17 0.34 3.97 
QKW Day 0-1 7.94 0.01 3.77 14.55 0.14 0.02 1.00 1.13 
 Day 0-3 0.78 0.14 9.36 4.67 0.98 1.00 1.43 0.10 
 Day 0-7 6.01 1.02 8.03 1.00 0.09 1.30 3.22 6.62 
 Mature 2.48 0.00 0.26 12.00 0.50 2.49 1.66 0.88 
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Figure 6.1 Venom gene expression profiles during venom replenishment: Relative expression profiles of six venom transcripts (SVMP, SP, CTL, 
KTI, PDI and QKWs) across the time course of venom re-synthesis were determined by relative quantitative PCR (qPCR). (Red = day 0-1, orange = 
day 0-3, blue = day 0-7, green = mature venom). 
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Figure 6.2 Repeated venom gene expression profiles: The venom extraction time 
course was repeated for three available specimens to ensure reproducibility of 
results. Relative expression profiles of six venom transcripts (SVMP, SP, CTL, KTI, 
PDI and QKW) across the time course of venom re-synthesis determined by relative 
qPCR showed similar gene expression profiles in repeated venom extractions with a 
peak in expression levels in venom extracted on day 0-3 to 0-7. (Red = day 0-1, 
orange = day 0-3, blue = day 0-7, green = mature venom). 
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Table 6.2 Statistical significance of relative changes in gene expression during 
venom replenishment: Analysis by ANOVA and Bonferroni post-hoc testing shows 
a statistically significant difference in gene expression between day 0-1 and 0-7, and 
day 0-7 and mature venom. *indicates significant p-value (<0.05) (shaded areas). 
 
    
On average for all specimens, we identified a peak between day 0-3 and 0-7 in the 
mRNA expression of all transcripts surveyed in this study (Figure 6.3). Statistical 
analysis of relative gene expression data revealed highly significant differences in 
expression between individual snakes (p=0.001). These observations are in 
agreement with our previous studies in Chapter 3 which illustrated that venom from 
B. arietans showed considerable levels of intra-species variation in venom protein 
composition, enzyme activity and immunoreactivity between specimens of the same 
and different geographical origins, possibly in response to environmental pressures 
(Currier et al., 2010). Our findings here suggest that venoms from individual 
specimens also vary in terms of (i) toxin expression levels and (ii) expression of 
toxins at different time points after venom expulsion (p=0.006). Individual changes 
in toxin expression profiles over time are shown in Table 6.2 with p values 
Bonferroni-corrected for multiple comparisons, demonstrating that the relatively 
lower mRNA expression levels observed in day 0-1 and mature venom samples were 
statistically significant. The standard error in statistical analysis was 0.131 for all 
samples. 
Time point (I) Time point (J) Mean difference (I-
J) 
P-value 
Day 0-1 Day 0-3 -0.149 1.000 
 Day 0-7 -0.375 0.028* 
 Mature 0.054 1.000 
Day 0-3 Day 0-7 -0.226 0.515 
 Mature 0.202 0.747 
Day 0-7 Mature 0.429 0.008* 
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Figure 6.3 Average gene expression profiles of all Bitis arietans specimens: 
Relative expression profiles of six venom transcripts (SVMP, SP, CTL, KTI, PDI 
and QKW) across the time course of venom re-synthesis were determined by relative 
quantitative PCR (qPCR). The average fold changes in % venom protein gene 
expression for A) 3 Ghanaian B. arietans specimens and B) 5 Nigerian B. arietans 
specimens was normalised against three references genes (β actin, glyceraldehyde-3-
phosphate dehydrogenase and heat shock protein) and indicate that the expression of 
venom protein genes peaks on day 0-3 to 0-7 (Red = day 0-1, orange = day 0-3, blue 
= day 0-7, green = mature venom). 
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          6.4.3. Protein profiles and venom activity during venom re-synthesis: 
The same B. arietans venoms samples used in relative gene expression analyses were 
fractionated by HPLC to examine the protein composition of venom during the 
course of venom re-synthesis (Figure. 6.4). HPLC protein profiles of pooled venoms 
extracted at different time points from Ghanaian specimens (Figure 6.4 A-D) and 
Nigerian specimens (Figure 6.4 E-H) revealed very little quantitative differences in 
venom composition and relative proportions of venom proteins within the time-
course of venom replenishment examined (day 0-1 to maturity). We further observed 
very little quantitative changes in venom protein composition between individuals 
(Figure 6.5). Proteomic data suggested that the majority of venom proteins appear to 
be synthesised rapidly following extraction.  
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Figure 6.4 HPLC-MS/MS protein profiling of Ghanaian and Nigerian Bitis 
arietans venoms: Identification of proteins from pooled venom samples from Ghana 
and Nigeria showed very little quantitative changes in the protein composition of 
venom during protein re-synthesis. A range of proteins were identified by mass 
spectrometry including disintegrins (DISI, peaks 3, 4), Kunitz inhibitors (KI, peak 
8), PLA2 (peak 13), cysteine-rich secretory proteins (Cyst, peak 14), serine proteases 
(SerProt, peaks 15-18), CTLs (peaks 22, 25) and PI (peak 26, 27) and PIII SVMPs 
(peak 29) which were present in all venom samples from day 0-1 to mature venom. 
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Figure 6.5 Protein profiling of individual venom samples by HPLC and 1D 
SDS-PAGE: Analysis of venom samples extracted on day 0-1, day 0-3, day 0-7 and 
mature venom for each individual specimen across the time course of venom re-
synthesis by HPLC showed very little quantitative differences in protein profile. 1D-
SDS-PAGE panels are shown to the right of HPLC profiles which confirm 
observations by HPLC. Molecular weight markers (M) are shown to the far right. 
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This result also correlates with gelatin zymography assays, used to assess venom 
proteolytic activity during the time course of venom re-synthesis. Our results showed 
that the enzyme activity of venom did not appear to change over the time course of 
venom re-synthesis and, most notably, venom extracted on day 0-1 was equally 
efficient at degrading gelatin substrate as mature venom (Figure. 6.6 A). There was 
also little variation in the substrate-degrading ability of venoms from different 
specimens, irrespective of geographical origin (Ghana or Nigeria) (Figure 6.6 A). We 
also demonstrate that this assay was not saturated by the levels of enzyme 
degradation by venom used in these experiments (Figure 6.6 B). 
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Figure 6.6 Venom enzyme activity profiles during venom replenishment: Gelatin 
zymography of venom samples extracted at day 0-1, 0-3, 0-7 and mature venom and 
reconstituted at natural protein concentration was used to assess enzyme activity of 
venom (A). The enzymatic degradation of substrate by venom extracted on day 0-1 
was equal to mature venom. Panel B shows a range-finding zymogram which shows 
that the dynamic range of this assay (arrow above indicate the range of venom 
quantity used in panel A). Molecular weight markers (M) are shown to the left. 
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6.5. Discussion 
Here we describe a novel technique which utilises mRNA in venom to monitor gene 
expression and transcriptional activity of venom glands throughout the course of 
venom synthesis in a dynamic real-time study. This would be unachievable using 
conventional methods which require sacrificing specimens for dissection of venom 
glandular tissue. Results following PCR amplification of proteins from venom 
indicate that a similar spectrum of intact mRNA is present in venom as venom gland, 
suggesting that the venom transcriptome may be an accurate representative of the 
venom gland transcriptome, demonstrating the potential viability of utilising venom 
as an alternative source of mRNA. Our study shows that the ability to extract toxin-
encoding mRNA from venom, thus obviating the need to sacrifice animals, has the 
potential to substantially improve the volume and diversity of venom research, 
including therapeutic, diagnosis and toxin evolutionary studies and in the study of 
rare or endangered venomous snakes. 
As proof of concept, we have utilised this technique to monitor transcription of 
venom protein genes in response to their requirement for venom re-synthesis, for the 
first time, and demonstrate using qPCR and proteomics, that venom proteins appear 
to be rapidly replenished following depletion of venom stores by manual extraction. 
We observed that a range of venom proteins including proteases, C-type lectins, 
Kunitz inhibitors, protein disulphide isomerases and QKW inhibitory peptides, we 
synthesised within 7 days following initial depletion of venom. 
The prolonged presence/stability of mRNA in snake venom is very unusual and 
interesting from both a biological and research standpoint. In most organisms, 
mRNAs are characteristically highly labile with rapid turnover rates (Sachs, 1993, 
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Meyer et al., 2004). In E. coli, the half-life of typical mRNAs is 1-2 min, and 15 min 
for the most stable mRNAs (Coburn and Mackie, 1999). In yeasts, half-lives range 
from 2-3 min to over 90 min in stable mRNAs (Herrick et al., 1990, Wang et al., 
2002) and in mammals, from 15 min to 24 hours for the most stable mRNA, β globin 
(Shyu et al., 1989). This instability of mRNA in biological systems is important as it 
permits the cell to adapt and respond to changing environmental or developmental 
cues requiring rapid up or down-regulation of gene expression (Ross, 1995). Our 
demonstration that mRNA can be detected in venom at each time point during the 
complete time course of venom synthesis is remarkable because we would expect 
snake venom glands to present a highly unfavourable environment for mRNA 
preservation due to the diverse array of destructive nucleases and phosphodiesterases 
(Dhananjaya and D'Souza, 2010), and naturally acidic conditions (Mackessy and 
Baxter, 2006). In an extreme extension of this investigation, we also demonstrated 
that mRNAs encoding SVMP, SP, CTL, KTI, PDI and QKWs could be PCR 
amplified from B. arietans venom which was extracted and lyophilised in 1984 
(Figure. 6.7 Ai and Bi), emphasising the potential of this approach to exploit 
historical venom stocks for gene expression and transcriptomic investigations. Here 
we also show that a similar quantity and purity of mRNA (indicated by the 
absorbance 280/260 ratio measured by the ND-1000 spectrophotometer) could be 
yielded from venom stocks extracted from specimens nearly 30 years ago in 
comparison to venom extracted more recently (2009), indicating that mRNA may not 
be susceptible to degradation in venom (Figure 6.7 Bi and Bii). 
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Figure 6.7 Stability of venom mRNA during long-term storage of lyophilised 
venom: PCR amplification of a range of venom protein transcripts including SVMP, 
PLA2, SP, CTLs, VEGF, LAO, KTI, PDI and QKW (Ai) and ND-1000 
Spectrophotometer absorbance profile of mRNA (Aii) isolated from venom extracted 
from Bitis arietans specimens in 2009 and PCR amplification (Bi) and Bii) ND-1000 
Spectrometer absorbance profile of mRNA isolated from venom extracted from B. 
arietans specimens in 1984 showed amplification of similar range of PCR products. 
 
 
 
 
Understanding the stability and potential role of mRNA in venoms is the focus of 
future work. We expect that multiple factors are involved in maintaining mRNA 
stability. Firstly, lyophilisation and preservation of venom may initially prevent 
degradation of venom components, although mRNAs found specifically in venom 
could have unique properties leading to an unusual long-term stability. 
Physiochemical properties of venom, including the presence of high concentrations 
of citrate (Francis et al., 1992, Frietas et al., 1992, Odell et al., 1998) and a weakly 
acidic pH (Mackessy and Baxter, 2006, Sousa et al., 2001, Viljoen and Botes, 1979), 
may provide universal stability to many venom components. Finally, there is 
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evidence for toxin-specific inhibitors in venom such as the QKW tri-peptide 
inhibitors of SVMPs (Wagstaff et al., 2008), and such specific or non-specific 
inhibitors may play a role in stabilising other components of venom, including 
mRNAs. Overall, the venom gland microenvironment appears to impart unusual 
stability upon mRNA. Our studies demonstrate that venom as a source of mRNA can 
be exploited to significantly expand opportunities to research venoms and venom 
biology, particularly in the study of CITES listed venomous species and in 
conducting real-time investigations of the venom gland transcriptional activity. 
In the first study of its kind, we applied this technique to investigate the time scale of 
venom synthesis and established that expression of several venom transcripts peaks 
between days 3 to 7 of the cycle of protein replenishment. Analysis of venom 
transcript and protein expression profiles suggests that there is a close temporal 
correlation between transcription and incorporation of proteins into venom during 
venom synthesis. Our results also demonstrate that biologically active venom 
proteins, such as the tissue-destructive SVMPs, are present in venom within one day 
of venom depletion. The speed at which venom was replenished reflects the critical 
requirement for snakes, as limbless predators, to rapidly re-synthesise functional 
venom for both predatory and defensive purposes. 
The qPCR transcription profiling indicates that re-synthesis of all of the venom 
transcripts examined in this study occurs in parallel rather than by a coordinated 
serial expression of different venom protein families. This appears to be contrary to 
early immunohistochemical reporting the asynchronous regeneration of distinct 
venom protein families (Oron and Bdolah, 1973, Sobol Brown et al., 1975, Oron et 
al., 1978), that utilised very different methods from those used here. Since the venom 
proteins we surveyed exhibit a wide range of pharmacological/physiological 
 188 
 
functions, our observations suggest that the dynamics of venom replenishment may 
not be dependent on the biological roles of venom proteins. Using these new tools, 
further work will aim to characterise the complete transcription profile of all venom 
components during the entire venom production cycle, thus confirming our 
observations of a parallel expression of venom transcripts. 
Although the evolution of venom protein-coding sequences has been extensively 
studied, we currently have very little understanding of the machinery involved in 
coordinating venom expression and gene regulation. This is important for our 
understanding of both the biology of venomous animals and the evolution of toxicity. 
Snake venom has evolved into a highly complex mixture of proteins and peptides by 
mechanisms of gene duplication and selection from ‘normal’ ancestral non-toxin 
homologues, and is continually subjected to adaptive evolutionary pressures 
involving gene recruitment and domain loss events (Casewell et al., 2011b, Casewell 
et al., 2011a). Understanding how newly recruited toxin prototypes are placed under 
the control of the venom production apparatus is the focus of future work aimed at 
characterising and comparing the specific regulatory machinery responsible for 
robust, yet selective expression of different toxins in venom. 
 
3.1. Author contributions 
All experimental work in this chapter was conducted by myself apart from the HPLC 
separation and mass spectrometry identification of protein components of B. arietans 
venom samples which was conducted by Professor Juan Calvete from the 
Laboratorio de Proteinomica Estructual at the Instituto de Biomedicina de Valencia 
in Spain. 
 189 
 
7. INVESTIGATION OF THE GENETIC ORGANISATION AND 
MECHANISMS RESPONSIBLE FOR REGULATING THE EXPRESSION 
OF VENOM PROTEIN-ENCODING GENES 
 
7.1. Abstract  
Snake venom is a highly complex mixture of multi-isoform, multi-domain protein 
families as a result of repeated gene recruitments, duplication and selection processes 
from proteins with normal physiological functions expressed in non-salivary tissues. 
The mechanisms responsible for controlling and regulating the recruitment and 
expression of proteins by the venom production apparatus are currently little 
understood. Previously in chapter 6, we observed a peak in gene expression levels of 
several different venom protein-encoding genes during the cycle of venom 
replenishment. As it appeared that different venom proteins may share similar 
expression levels, the overarching aims of this work were to investigate whether 
venom genes also show similarities in their genomic location, organisation and 
structure, and regulatory elements responsible for controlling expression levels.  
Here, we have taken the first steps to begin to investigate the genomic structure and 
organisation of genes encoding key venom protein families. Sequence analysis of 
genes encoding venom protein families expressed in Bitis arietans venom including 
serine protease and vascular endothelial growth factors, suggested that the genomic 
structure and organisation of genes may be highly complex. 
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7.2. Introduction 
Snake venom has evolved into a highly complex and diverse mixture of proteins and 
peptides with distinct pharmacological effects (Kordiš et al., 2002, Kordiš and 
Gubenšek, 2000). Venom toxins have been recruited into the venom arsenal by 
accelerated evolutionary mechanisms including gene duplication and selection from 
‘normal’ ancestral non-toxin homologues (Fry, 2005). Selective expression of 
proteins in the venom gland and subsequent structural and functional divergence of 
proteins has resulted in the formation of multi-isoform, multi-domain protein 
families in snake venom (Fry, 2005). Venom protein families are continually 
subjected to adaptive evolutionary pressures involving frequent gene duplication and 
alterations in the protein domain structure, and as a result show complex 
evolutionary histories (Casewell et al., 2011b, Casewell et al., 2011a). Following 
recruitment of venom proteins from ancestral homologues, we assume that newly 
recruited proteins, or ‘toxin prototypes’, require testing before selection into the 
venom arsenal. However, we currently have little understanding of how newly 
recruited ‘toxin prototypes’ are placed under the control of the venom production 
apparatus and the mechanisms involved in controlling venom gene expression. 
The genomic structure and organization of snake venom protein-encoding genes has 
not been fully investigated. The majority of studies have focussed on elucidating the 
structure of neurotoxins and three finger toxins (3FTXs) genes. Studies observed a 
high level of homology in the structure of neurotoxin genes of elapids, including 
cardiotoxins from Naja naja atra (Taiwan cobra) and Naja naja sputatrix (spitting 
cobra) (Chang et al., 1997, Lachumanan et al., 1998), α neurotoxins from N. n. 
sputatrix (Afifiyan et al., 1999), γ-bungarotoxin from Bungarus multicinctus (Taiwan 
banded krait) (Chang et al., 2002), short/long chain neurotoxins from Laticauda 
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semifasciata (black-banded sea krait) (Fujimi et al., 2003) and demonstrated that the 
genomic structure of genes encoding neurotoxins in elapids comprise of three exon 
regions interrupted by two introns. The organisation of toxin genes from vipers and 
colubrids is less well studied. Doley et al characterised the genomic structure of 
3FTXs from the viperid species, Sistrurus catenatus edwardsii (Doley et al., 2008), 
demonstrating a structural similarly to those from elapid and hydrophiid 3FTX genes 
comprising 3 exons and 2 introns (Doley et al., 2008), whereas a low similarity of 
colubrid 3FTXs with the elapid 3FTXs has been observed (Pawlak and Kini, 2008). 
Regarding the gene structure of other toxin families, a recent study by Sanz et al 
provided the first report of the genomic structure of a PIII SVMP transcript from 
Echis ocellatus (Sanz et al., 2012). This study employed an iterative strategy to PCR-
amplify each domain of the enzyme (including the signal peptide, pro-domain, N-
terminal of the metalloproteinase domain and disintegrin domain) to produce 
overlapping sequences. Sequences were assembled to produce a 15 kb sequence 
containing 12 exons interrupted by 11 introns (Sanz et al., 2012). 
In chapter 6, we showed that several different venom components, including 
enzymatic and non-enzymatic proteins, appeared to be co-expressed at the same time 
point during venom replenishment (between days 3-7 following the initial depletion 
of venom). This suggests that the expression of different venom protein-encoding 
genes may be controlled by conserved regulatory mechanisms. The underlying 
mechanisms controlling gene expression in eukaryotes are complex and multifaceted. 
Each stage in the process of gene expression can be subject to dynamic regulation, 
from structural changes in chromatin, transcription of DNA into RNA, 
splicing/editing of RNA, translation of mRNA into protein and finally post-
translational modifications of the protein (Maniatis and Reed, 2002). Initiation of 
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transcription occurs as a result of interplay between multiple factors including those 
in the vicinity of the transcription start site (promoters), enhancers lying upstream of 
transcription start sites and other DNA-binding regulatory proteins (transcription 
factors and non-coding RNAs) (Heintzman and Ren, 2007, Venters and Pugh, 2009). 
The core promoter element in eukaryotic protein-encoding genes, containing the 
transcription start site, RNA polymerase binding site and TATA box, is sufficient to 
initiate basal transcription (Lee and Young, 2000). However, many other upstream 
transcription factors and regulatory sequences acting in several different 
combinations are involved in regulating transcription initiation (Pedersen et al., 
1999). This diversity and complexity of eukaryotic promoters leads to difficulties in 
promoter prediction and characterisation. Although the regulatory regions of venom 
protein-encoding genes have not been well defined, it is thought that snake venom 
gene promoters contain common promoter elements, such as TATA motifs and 
multiple transcription initiation factors (Afifiyan et al., 1999, Lachumanan et al., 
1998) and studies have shown similarities between the putative promoter regions of 
human, murine and snake venom genes (Ohbayashi et al., 1996, Reza et al., 2007). It 
is also thought that the genomic organisation and regulation of venom protein-
encoding genes may be further complicated by the role of accelerated segment 
switch in exons to alter targeting (ASSET) which involves radical changes in 
sequences within exons of venom genes (Doley et al., 2009, Doley et al., 2008) and 
intragenic transposable elements (Sanz et al., 2012). 
The overarching aims of this work were to investigate the genomic organisation of 
viper venom protein-encoding genes and to identify and characterise the mechanisms 
responsible for regulating gene expression. As many eukaryotic gene promoters have 
several conserved elements, we decided to look for promoter regions upstream of the 
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transcription start site as an initial step to identify regulators controlling venom gene 
expression through the use of a genome walking approach. 
 
7.3. Materials and methods 
          7.3.1. Isolation, quality control and PCR amplification of venom 
transcripts from Bitis arietans genomic DNA 
Extraction of genomic DNA from B. arietans liver tissue is described in greater 
detail in Section 2.10.1 in Chapter 2. Genomic DNA at a concentration of 
approximately 0.1µg/µl was eluted and stored at -20°C until further use. To assess 
whether the genomic DNA was clean and of high quality/molecular weight, DraI 
digestion of B. arietans genomic DNA and control human genomic DNA was 
performed (Section 2.10.2 in Chapter 2) and long range PCR was performed using 
primer pairs designed to amplify full length sequences of venom toxin groups 
including SVMP, SP, PLA2, CTL and VEGF from genomic DNA using the 
Advantage 2 PCR kit (ClonTech). 
 
‘GENOME WALKING’ 
‘Genome walking’ is a PCR-based method which enables regions of DNA outside of 
known boundaries to be characterised. By designing specific primers complimentary 
to the extremities of a known sequence (e.g. the signal peptide of a cDNA sequence), 
we can amplify flanking regions of unknown DNA which may contain upstream 
regulatory elements. Figure 7.1 shows the overall experimental strategy of genome 
walking. Figure 7.2 illustrates the primer-directed approach to amplify the region of 
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Figure 7.1 Genome walking protocol: Flowchart of the GenomeWalker
TM
 
(ClonTech) Protocol (N = amine group at 3’ end of DNA, AP = adaptor primer, GSP 
= gene specific primer). 
DNA upstream of the signal peptide in greater detail. Methods are described in 
further detail in Section 2.10.4 of Chapter 2. 
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Figure 7.2 Identification of DNA upstream of transcription start site by genome 
walking: Region of non-coding DNA amplified by Genome Walking protocol (ORF 
= open reading frame, AP = adaptor primer, GSP = gene specific primer). 
 
          7.3.2. Construction of ‘Genome Walker libraries’ 
Pools of uncloned, adaptor-ligated genomic DNA fragments (referred to as genome 
walker libraries) were constructed using the Genome Walker Universal Kit 
(ClonTech, UK) as shown in Figure 7.1 using four different restriction enzymes 
(DraI, EcoRV, PvuII and StuI). 
 
          7.3.3. Genome walking by long-range PCR 
Long range PCR amplification of targets from genome walker libraries was carried 
out using the Advantage 2 PCR kit (ClonTech) as described in Section 2.10.5 of 
Chapter 2. PCR amplicons were excised and purified as described in Section 2.10.5 
of Chapter 2. 
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Table 7.1 PCR primer sequences for genome walking protocol: Genome walking 
gene-specific primer (GSP) sequences for venom toxin families including SVMP, 
SP, CTL, LAO, VEGF, KTI, QKWs and PDIs. GSP1 indicates primary primer and 
GSP2 secondary (nested) primer. AP1 and AP2 indicate primary and secondary 
adaptor primer sequences. 
          7.3.4. Primer design 
PCR primers were designed complementary to the conserved signal peptide 
sequences of 8 venom protein families; SVMPs, SPs, CTLs, VEGF, LAOs, KTIs, 
QKWs and PDIs. Primers were 28 nucleotides in length, had a GC% content of 
approximately 40-60% and similar melt temperatures of 65-70°C. The primary gene-
specific primer (GSP ) was designed to bind close to the 5’ end of the known 
sequence. The secondary gene-specific primer (GSP2) was designed to avoid 
overlapping the GSP1. Primer sequences of gene-specific and adaptor primers are 
shown in Table 7.1. 
 
Toxin group 
Primer 
length 
(bp) 
Melt 
temperature 
°C 
GC% Primer sequence 
SVMP GSP1 28 70.5 64.3 CTCAGGCTGCTTAGCTGCTCCCTTGGGC 
SVMP GSP2 28 53.5 32.1 TGGACTACTTCATAATCATTAATGTTCC 
SP GSP1 28 54.2 32.1 GATGTTCATTTATGTTACATTCATCACC 
SP GSP2 28 62.8 46.4 CAATGACCAGTTCAGAAGACGTTTGTGC 
CTL GSP1 28 71.0 60.7 GGACATGAGATCCCCACCGTTCACCAGC 
CTL GSP2 28 69.7 53.6 TCCTTGCAGAATTTCTCTGCATCGGCCC 
LAO GSP1 28 64.7 53.6 CCCTGCAAGAACATAGGCTGCACTAAGC 
LAO GSP2 28 63.4 50.0 CTGCTCCTACAATCACAACGTGTTGTGG 
VEGF GSP1 28 74.2 64.3 GCATCGCAACACAGCCACACAGGACGGC 
VEGF GSP2 28 58.4 46.4 CTGCTCCTACAATCACAACGTGTTGTGG 
KTI GSP1 28 66.7 50.0 GCATATTTTCCATGTCGCAGTGTGCAGC 
KTI GSP2 28 71.3 60.7 AGCGGTGACCACCCATTCCTGGTTGAGC 
QKW GSP1 28 79.0 71.4 AAGCTCGTGCGGCTCCATCGGCGACGGC 
QKW GSP2 28 64.4 53.6 GAGCTTTACAGTGACCACACCATGGTGC 
PDI GSP1 28 68.1 50.0 TTGCAGCTGCTTTCGCATATTCAGGTGC 
PDI GSP2 28 77.4 71.4 GGGTTGCAGCGGCTTCCGCCAGTCCTGC 
AP1 22 59.0 45.5 GTAATACGACTCACTATAGGGC 
AP2 19 71.0 57.9 ACTATAGGGCACGCGTGGT 
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          7.3.5. Sub-cloning and sequencing 
Sub-cloning of PCR amplicons from genomic DNA using full length toxin-specific 
primers (Section 7.3. ) and amplicons generated from ‘genome walking’ (Section 
7.3.2) was performed using the TOPO® XL PCR cloning kit (Invitrogen, UK), 
designed to efficiently clone long (3-10kb) PCR products, as described in Section 
2.10.6 of Chapter 2. Purified PCR amplicons were sub-cloned into the linearized 
plasmid vector, pCR-XL-TOPO®. The construct was transformed into chemically 
competent E. coli cells and cultured on IPTG/Xgal/Kanamycin impregnated agar 
plate. Recombinant plasmids were identified by restriction digestion purified using 
the mini-spin kit (Qiagen) and submitted to Beckman Coulter Genomics UK for 
DNA sequencing with M13 forward and reverse primers.  
 
          7.3.6. Bioinformatics interrogation of sequences for promoter and 
transcription factors 
The bioinformatics pipeline used to analyse genomic sequence data is described in 
Section 2.10.10 of Chapter 2. Briefly, the ORF for each contig was identified using 
the ORF finder tool from NCBI (NCBI, 2012b) and a protein family was assigned to 
each sequence by performing a BLAST similarity search (NCBI, 2012a). To map 
intron-exon boundaries in gene sequences, Wise2 algorithm (NCBI, 2012c) was used 
to compare translated protein sequences and genomic DNA sequences, allowing for 
frameshifting errors. Gene structure schematics were constructed using Gene 
Structure Display Server (GSDS) (Guo et al., 2007). 
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7.4. Results: 
          7.4.1. Isolation and quality control of genomic DNA from B. arietans liver 
tissue 
Following isolation of genomic DNA from B. arietans liver tissue using the DNeasy 
Kit (Qiagen® UK), DNA was run on an agarose-EtBr gel alongside DNA ladder and 
control human genomic DNA (Figure 7.3). In comparison to the control human 
genomic DNA, which had a high molecular weight of >10kb, (Figure 7.3A, lane 2), 
the B. arietans genomic DNA (Figure 7.3A, lanes 1 and 3) appeared to be smeared 
across the gel and a lower molecular weight than the human genomic control DNA. 
The human control DNA was efficiently digested by DraI (Figure 7.3B, lane 3) 
indicated by smearing and a reduction in molecular weight of DNA following 
restriction digestion. This was also the case for the B. arietans genomic DNA 
although more difficult to observe due to some initial smearing of DNA prior to 
digestion (Figure 7.3B, lanes 1 and 2). Due to the smearing of B. arietans genomic 
DNA observed, it was possible that the DNA was sheared/damaged during the DNA 
isolation procedure. However, due to time constraints and insufficient sample 
material, isolation of genomic DNA from liver tissue could not be repeated as 
obtaining fresh liver tissue would require sacrificing snakes. To assess whether the 
quality of genomic DNA was sufficient for downstream applications (e.g. PCR), we 
decided to PCR-amplify gene targets from genomic DNA. The amplification of 
amplicons with the expected molecular weight would suggest that genomic DNA had 
not been degraded. 
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Figure 7.3 Analysis of genomic DNA extracted from Bitis arietans liver tissue: 
Agarose gel electrophoresis of genomic DNA isolated from B. arietans liver tissue. 
Gel A) shows B. arietans genomic DNA separation on a 0.6% agarose gel (lane 1: 
1µg B. arietans genomic DNA, lane 2: 1µg human genomic DNA and lane 3: 100µg 
B. arietans genomic DNA). Gel B) shows electrophoresis of genomic DNA 
following DraI digestion (lane 1: 1 µg B. arietans DNA + DraI, lane 2: 1µg B. 
arietans DNA – DraI, lane 3: 1µg B. arietans DNA – DraI and lane 4: 1µg human 
genomic DNA – DraI. DNA ladder is shown to the left of each gel. 
 
 
 
 
          7.4.2. Amplification of venom protein targets from B. arietans genomic 
DNA using long-range PCR 
Long-range PCR amplification of a range of venom targets including SVMP, SP, 
PLA2, CTL and VEGF from genomic DNA was performed to assess the quality of 
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Figure 7.4 PCR amplification of venom targets from Bitis arietans genomic 
DNA: Agarose gel electrophoresis of PCR products amplified from A) B. arietans 
venom gland cDNA library and B) genomic DNA isolated from B. arietans liver 
tissue. PCR products include SVMP, SP, PLA2, CTL and VEGF. Panel C indicates 
purified PCR products (SP and VEGF) from B. arietans genomic DNA. DNA ladder 
is shown to the left of the gels. 
DNA isolated from B. arietans liver tissue and to obtain genomic sequences 
encoding venom proteins. Firstly, targets were amplified from B. arietans venom 
gland cDNA as a positive control. Figure 7.4A shows that all targets could be 
amplified from venom gland cDNA with the exception of SVMP, possibly due to 
problems with primer efficiency. Analysis of PCR amplicons from genomic DNA 
showed that only SP and VEGF targets could be efficiently amplified (Figure 7.4B). 
SP and VEGF amplicons amplified from genomic DNA were of a higher molecular 
weight (approx. 6 and 3kb respectively) (Figure 7.4B) than the same targets 
amplified from B. arietans venom gland cDNA (approx. 600bp-1.75kb and 600bp 
respectively) (Figure 7.4A). It was possible that other components (e.g. PLA2 and 
CTL) were not efficiently amplified from genomic DNA due to their large size. 
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Figure 7.5 Analysis of venom target inserts following sub-cloning: Agarose gel 
electrophoresis of EcoRI-digested clones containing A) serine protease (SP) PCR 
construct and B) vascular endothelial growth factor (VEGF) PCR construct excised 
from Figure 7.2. Numbers circled in red indicate constructs which were submitted 
for sequencing. DNA ladder is shown to the left of each gel. 
          7.4.3. Sub-cloning and sequencing of PCR products amplified from B. 
arietans genomic DNA 
Purified SP and VEGF PCR amplicons from Figure 7.4C were excised and sub-
cloned into the plasmid vector (pCR-XL-TOPO®). A sample of each clone was 
restriction-digested with EcoRI and analysed on an agarose-EtBr gel to check that (i) 
the insert was present and (ii) the insert was of the correct size (Figure 7.5A). 
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For each venom protein family, two clones were submitted for sequencing (circled in 
red, figure 7.5). Two sequences (forward and reverse) were obtained for each clone 
and assembled using SeqMan (DNASTAR) and for each protein family, sequences 
clustered into two contigs named SP contig 1 and 2 and VEGF contig 1 and 2. Full 
sequences are shown in Figure 7.6.  
 
          7.4.4. Sequence analysis of PCR products amplified from B. arietans 
genomic DNA 
Each genomic contig was firstly assigned a protein family by performing a BLAST 
search against the NCBI nucleotide sequence database. SP contig 1 and contig 2 
sequences showed highest sequence homology to Bothrops atrox batroxobin, a 
thrombin-like SP (BLAST accession number X12747.1). Both VEGF contig 1 and 
contig 2 sequences showed highest sequence homology to Trimeresurus flavoviridis 
VEGF precursor sequence (BLAST accession number FJ554640.1). To investigate 
the structure and organisation of genomic sequences, intron-exon boundaries were 
predicted using Wise2 algorithm (NCBI, 2012c). In SP contig 1 sequence, one intron 
was predicted from base pairs 662-1003 and no intron regions were predicted in the 
sequence of contig 2. For VEGF contig 2, three intron regions were predicted from 
316-447, 525-997 and 1036-1206 and no intron regions were predicted in the 
sequence of contig 1. The genomic structure schematic of SP and VEGF genomic 
sequences were generated using Gene Structure Display Server (GSDS) and are 
shown in Figure 7.7. 
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>SP contig 1 
TTCCTCCCCCAAGGGATCTTTTAGCCAAGATTCCTGCCTTTTTGTTTTGGGCCCCA
ATCCAAAATTTATGGGTTTTTCTTCATTTTTCAGATATGGAAGTTTCAATACACTG
GCTTGAGGAATTTTGGGAGTGGAAGTTCAAAAGTCTTGAAGTTGCCAAGTTTGG
AGACCCCCATTCTTAGGTCACCTCCAGGGGATGCGAGATCAGTTCTATGACTTTT
GAACTAGCAAAAGCCCCACTTTTCCAACAAGGCAATCTTTGCGTAGAGTGCCAC
GAGAAATTTGAGAAGCCTTCAAATGCCCATCAGCTGATTTAATACTTATTAATAT
CTTGACAAAAAAACATTTAACTAAGTCCATTTTTCCCAGGAGTCCCTTTGAACAG
CTTTGAAAGACAATACTTTCTATTCCCAGGCAATGAGATCAGCTCCATTGGTTGG
AGACTATGGAAATTATAGCTCTAGGCATCTAGGTGATAAATTATGAAAGGTAAA
ATTTTGCCTATTTTTTATTTTTtCCAGAGTTTTATCCTGATGTCCCTCATTGTGCTA
ACATTAAGTTATTTGATTATTCGGTGTGTCGAGCAGCTCACCAAAAGTTGCCAGA
GAAAAGTAGAACATTGTGTGCAGGTATCCTGGAAGGAGGCATAGATTCATGTAA
GGTAAGAGGATCCATTTTAAGACAGATTCCTAAAGAAATGATGCCAATTTTCAA
AGCTATGACAGAGATCTAGCCTTAAAGGCATCTTGTAGAAACATACAAAGTTAT
GGCTTTTTCTAACTCAAGTAGTTACTAGGTATCTAGATTTCCAGACTTCCCAATA
CTGGTGATTCTGGTGGGGGAAACTCAAGAATTTAAATTCTTCTACAAGGATCCTG
AATTGGGGAACACTGAAGTGAAACATTTGGGGCTGTATGTGAATGGACGATGGG
AGGGAATTGTTTGCTTCACTTCCCATTTATAGATACGGTAGTAATGTTTCATGTTT
GATTTTTCTCAAAAGGTTGACAATGGGGGACCCCTCATCTGTAATGGACAAATC
CATGGCATTGTATCTTGGGGGGGGCATCCTTGTGCCCAACCGCTTAAGCCTGCCC
TATACACCAATGTCTTTGATTATACTGACTGGATCGAGGGCATTATTGCAGGAAA
TACAGCTGCGACTTGCCCCCGGTGACTCGAGAAGGGCGAATTCTGCAGATATCC
ATCACACTGGCGGCCGTTACTAGCATGGATCCGAGCTCGGTACCAAGCTTGATG
CATAGCTGATATC 
>SP contig 2 
TAGATACTCAAGCTATGCATCAAGCTTGGTACCGAGCTCGGATCCATGCTAGTA
ACGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTGGATCCATGGTGCT
GATCAGAGTGCTAGCAAACCTTCTGGTACTACAGCTTTCTTACGGTAAGAGCCTG
GACAATGGAGCAAAGGATGGACGGAGCTTTAGGGGTCTTTTTTGGTTTAAACCT
CAAGTTACAGGAATAAACTTGGACGTAACTATTAGCTCTAGATGTACAAGCGAG
TCACGAGTAGAGAGTGGGTGAAGAAGTCCCAGTTGGTGCAATGGGGAAGACCA
TTGCTGTGTTTCTAATGATAGTATGAATTGATACATTTATTCATATCAGAAAAAC
TAGTCAGTTAAAAATATATAGTCCAATTATGGTCAGCTTCCTTTCGTGTTTCTATT
TATTTGGCAACTGACTTCAATAGAAGACGATAATTTATTAATTAATATAAGATGC
ATTGAGAAAAAAGTTGGGGAGTGGTTTGCAGTGTTAAGGTTGCCTTTATAAAAT
GCCACTGATTTTTATTCAAACTGGTAAAATAAATGTGTTGGATTTTAGCTAGCTG
CCACTCTGTTAGATTTGCTGCATTATATAGCGTGCAATATCTGGGTCATTGCTTCT
GAAACAAATATGAAAACCGGTATGTAGGGATTTTACTACCATCAATGTTGGCTC
AAACTGCTTTTAGTTAACTAAATCCTAATGGTATCAACTTCCCATCCAAACTCAT
AGATTAAATTCCATTTTCTTTGATCTCTTCCCAATTTCACTTCTTCTGCCCCCTATT
CTCCCCATCACAAGAGCATACTGTATATTTTGCTTTGCAATGCGGTACAGCAAGA
TCACACTCTGGGCCAAATGCTTCTAAATGTCCATCCTTTTTAGAAGCTCATCTGA
GCCGTTCTTCTTACTTCAACTGATTAGCGTAAACTGGCTGGCCGTGATACATTAA
GTTACTGGG 
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>VEGF contig 1 
TCATAGGCGATTGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGA
TATCTGCAGAATTCGCCCTTGGATCCATGGCTGCGTACCTGCTGGCAGTTGCCAT
CCTCTTCTGCATCCAGGTGAGAAACTGTGGGGATCTGGCCTGGAATCCTCACAG
GCAATTTTCAGCCAAACAAGGGGGGAAAACAGATTAAATCTGTTATTTAGCCAG
GGTAACCAATAAAAGTAACTTCTAAGGTTGGAGAATTCATGTCCCTCTGTTGCA
GTTTAGAATTAAATTACCTCTGTAGGATCCTGCAGTTTTATGCATCTCTGGGAGA
CAAAGGAGTGGGTTGGGGATGGGGATGGGAGAAGCTGTGGCAGGAGGCAGAAA
TTACTTCTGTCCTTCACAGCTGGGTCAAGCATGGTGCTCTGAGTTGCTTTGCTTCA
TGGAAGGACAGGGGGCTGTGCTGGATTCAAGCAGGAGCTTTCTTCCAAAGTCAC
CTTGGGTTCTGCGCCAGCTTTCCAGAGGCCAGAGCAGGGTTGGGGGGGGGGGGT
GTCTGCTGTACATGTAGATGATGGCAGATTTAATTTGGGGGGGCTGAAAGTGGG
GGAGCTCAATGTGCTGCTGCTGCTGCTGCCTGTGAAGGGAGAGGCAGAGAATCG
GGCCCTTCCCTCAAGACCAGGCGGGGCCCCCTGGTGCTGGAAACAGAAGATGGT
CCAGGAGAACAGGGGCACCACAGCAGGGCATAATAACCAAGCGCTCCTGGCAT
AGGTCAATCTGCCACGGGCACGGAAAAGGCTCGGGTGCCTGGGAGATATTGCTC
AGGTGTCTTGCCCTGCAGGGTGCAAAGCGACAGCAGTCCTGACTTTGGAGCTGG
GGTCTTCTGAGGGCTGACCCACAGCCAGTGGAGCTTTCCCCAAGGAATGGATGC
CCGGGTCCATTAAAGGGTCCAGGACCCCCGAAGCTCCTCCTTCCGGATGAACGT
GGGTGCCCTTGCGAAACGTCCAAGGTTTTGCTTGGGGGAAAGAAACAaGGTTGG
GCAGGTGGTTGGCAAGCCCTCCTCCAACTAACAATGGCATTGGGCACCCTGGGC
TTTGATTTCCCCATGACAATCCACAGAGCAGCTTGGATGCTTCTAGGGAGAAAA
AACCGACCTGGTTCTCTCTTGCCCCCTGGAAGGAAACCCAGAACAGGTGCCCCG
GCTGGCATCTCCCTTCTGGGGGTCATCCAAGGGGCCTAAAAAGCTTCTTGGATTT
CAAAAGTTAAGCCATTGGACTGGCCAAGGAACCCCTGAAGGACAAGGCAACTG
GGGCAAGGGGTTAAAACTTTCCATGGCCAGCTTTTGAGATTGTGGGGAATTCCA
CTCC 
>VEGF contig 2 
TCATAGGCGATTGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGA
TATCTGCAGAATTCGCCCTTGGATCCATGGCTGCGTACCTGCTGGCAGTCCCCTT
CTTCAGGGAGGCCCTTTATGGAAAGTTCCCAGGGCAGGGTTTTGCCAAGCCCAG
GGAGCCAATCGTGTCCCATACTTGAAGAGTACCCTGATAAAATTTTTAAGATCTT
CAGGCCGTCCTGTGTGGCTGTGTTGCGATGCGGTGGCTGCTGCTCTGACGAAAG
CTTGACGTGCACCTCTGTGGGAGAGCGCACTGTCGAACTGCAGGTCAGGGGCGG
TTTGTGCTGAGGCGACTGGAGTGTGTCTCAGGACAGCTCTTGGGAGCCGGGAAG
AGCAGCACCCAGCCTTGGACTGCTGCTGGGGTGCAGCTGAACGGTGCCTTTCTCT
CCCCTCGGGTAGGTCATGCAGGTGACTCCCAAAACACTGTCTTCCAAAATCAAG
GTGATGAAATTCAGGGAGCACACAGCCTGTGAATGCAGGTGAGGAAGGGGGCC
GAAGAGTGGCCGTCCTGGGCGGCTGGTCAGAGGGGTGGGGAAAACGGGGAGAA
TTGCTGGAGGTGGAAGATGACAAGTAGTTCTTAGTTCACACAACCCTTCCCCTCC
CTCCATTTTTCTTGCTTGCTTGCTTTCTCCCACCTTTATTATTTTTACAAATAACTC
AAGGTGGCAAAGATACCCTCCTCCTATTTTCCCTGCCACAACAGCCCTGTGAGGC
AGGTTTGGCTGAGAGAGATGGAACAGGCCAAAGTCACCCGGCTCATTTTCTACA
CTGGGGCTCTGCAGGGGTCTCTGAGCAGGAGGAGAGAAGTGGGGGCTCCAGAC
CTGTGCAGGCGCCTCCTCAGAGGCCATGCTTCTTTGCCTCTTTCCTCTTCCTGGAG
CCCCCAGCTGTGGGTCAAGCCCTGCGCCCACTGGTTATGCAGACTGTATCTGGGT
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Figure 7.6 Genomic DNA sequences encoding Bitis arietans venom proteins: 
Sequences of SP and VEGF contigs amplified from B. arietans genomic DNA. Open 
reading frames (ORF) were predicted using ORF finder (NCBI, 2012b) and are 
highlighted in red. Intron regions were predicted using est2genome (Mott, 1997) and 
are highlighted in grey. 
TATTTCCTCTTTCCAGGCCTCGATCAGGAAGCAGGGTGAACATCGGGAAGCACA
AGAGGTACGTGGGGTGGGGCTGGGGGTTAACAGAATAAGAAAGTTGTAAGGGA
CCTTGGAGGTCTTCTAGCCCAACCCCTGGCTCAGGTTGGCTGGGGGCAGGCTGG
GAGGGTGGGGCAGGAGGGCAAGATGGCCCACTTGAGCCGAACTCTTTTTTTTCC
CCCTTTGCAGAAGCCCAGAGGAAGGGGAGCGAGAGCCAAGTTCCCCTTTGACTC
CAGGATCCCTTTGACTCGAGAAGGGCGAATTCCAGCACACTGGCGGCCGTTACT
AGTGGATCCGAGCTCGGTACCAAGCTTGATGCATAGCTGATATCTACG 
 
Alignment of B. arietans genomic sequence SP contig 1 and 2 with the closest 
homologue identified by BLAST, batroxobin (B. atrox) demonstrated that SP contig 
  showed homology only to the 3’ region of the batroxobin sequence whereas the SP 
contig 2 showed homology only to the 5’ region of the batroxobin sequence. This 
indicated that the contigs were not overlapping and therefore did not form the 
complete genomic sequence encoding the B. arietans SP. The structure of the gene 
encoding batroxobin has been defined. The gene spans 8kb and contains 5 exons (the 
mature batroxobin enzyme encoded for by exons 2-5) and shows exon/intron 
organization very similar to those of the trypsin and kallikrein genes (Itoh et al., 
1988). Alignment of B. arietans VEGF contig 1 and 2 with the closest homologue 
identified by BLAST search, VEGF precursor from T. flavoviridis venom again 
demonstrated that VEGF contig   showed homology to the 3’ region of the T. 
flavoviridis VEGF sequence whereas the VEGF contig 2 showed homology to the 5’ 
region of the T. flavoviridis VEGF sequence. Alignments of genomic DNA 
sequences with batroxobin and T. flavoviridis VEGF gene sequences are shown in 
Appendix VIII. 
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Figure 7.7 Gene structures of venom protein-encoding genes: Schematic diagram to illustrate gene structure of venom genes encoding serine protease 
and vascular endothelial growth factor generated using GSDS (Gene structure display server) (Guo et al., 2007). Green box indicates exon, red box 
indicates signal peptide, blue box indicates untranslated region (UTR) and black line indicates intron. 
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          7.4.5. Amplification of gene targets from ‘Genome walker’ libraries 
Genome walking protocols were used with the aim of amplifying regions of DNA 
upstream of the transcription start site. DNA was amplified from genome walker 
libraries by PCR using gene specific primers and primers specific to bind the 
adaptors ligated onto DNA fragments. Following primary PCR cycles, products were 
amplified with low specificity, observed by smearing of PCR products (Figure 7.8).  
This could be because PCR primers were designed to amplify a region of DNA in the 
signal peptide, which is conserved across many different isoforms within a large, 
multi-gene protein family. It appeared that all targets were amplified from each 
genome walker library, except in the case of QKWs which were not efficiently 
amplified.  
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Figure 7.8 Primary PCR amplification of targets from Genome Walker 
libraries: Analysis of PCR products amplified from restriction digested genome 
walker libraries following primary PCR including SVMP, SP, CTL, LAO, VEGF, 
KTI, PDI and QKW. B. arietans genomic DNA was digested with four different 
restriction enzymes to generate DL (digestion library): DL1 = DraI, DL2 = EcoRV, 
DL3 = PvuII and DL4 = Stu I. Controls (C) : -ve 1; negative water control for each 
primer pair (absence of genomic library), +ve 1; amplification of tPA  from human 
PvuII genomic library, -ve 2; negative water control for human genomic library and 
+ve 2; amplification of tPA from pre-constructed human PvuII genomic library 
provided in Genome Walker kit). 
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Following secondary PCR, which aimed to increase the specificity of PCR 
amplification, we observed several clear DNA bands and an absence of smeared 
DNA for most venom protein families (Figure 7.9). All target genes could be 
amplified following secondary PCR with the exception of CTLs. This could be due 
to inefficiency of the secondary PCR primers to amplify specific targets, or that the 
incorrect gene had been amplified following primary PCR cycles. For other venom 
protein families, numerous products were amplified from each genome walker 
library of a range of molecular weights (250bp-3kb), indicating the multiple isoforms 
present in venom protein families. For cloning, products amplified from each venom 
protein family (one product per family) were excised from an agarose gel and 
purified (circled in red in Figure 7.9). PCR products with the largest molecular 
weight were selected for sub-cloning and sequencing as we considered these more 
likely to contain sequences of interest upstream of the signal peptide to which the 
primers were designed to specifically bind.  
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Figure 7.9 Secondary PCR amplification of targets from Genome walker 
libraries: Analysis of PCR products amplified from restriction digested genome 
walker libraries following secondary PCR including SVMP, SP, CTL, LAO, VEGF, 
KTI, PDI and QKW. B. arietans genomic DNA was digested with four different 
restriction enzymes to generate DL (digestion library): DL1 = DraI, DL2 = EcoRV, 
DL3 = PvuII and DL4 = Stu I. Controls (C) : -ve 1; negative water control for each 
primer pair (absence of genomic library), +ve 1; amplification of tPA  from human 
PvuII genomic library, -ve 2; negative water control for human genomic library and 
+ve 2; amplification of tPA from pre-constructed human PvuII genomic library 
provided in Genome Walker kit). Bands circled in red in panel B were excised and 
sub-cloned for sequencing. 
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Although sequences of PCR products amplified from genome walker libraries were 
obtained, these were shorter in length (700bp-2kb) than expected (2-3kb) which 
possibly suggests that the quality of DNA was not optimal for this work. Sequences 
of PCR products amplified by genome walking protocols are shown in Appendix IX, 
annotated with the open reading frame (ORF) predicted by ORF Finder (NCBI, 
2012b), regions of the sequence showing highest sequence homology to BLAST hits 
and exons boundaries predicted by Wise2 (NCBI, 2012c). 
Sequences amplified from genome walker libraries were screened against the B. 
arietans EST library using est2genome (Mott, 1997), assigning a specific EST to 
each genomic sequence. Protein families were assigned to each genomic sequence 
amplified from genome walker libraries by BLAST searching the NCBI nucleotide 
database (Table 7.2). Proteins were correctly assigned to most sequences amplified 
from genomic DNA, however, several genomic sequences (e.g. SP, VEGF and PDI) 
showed homology to the PLA2, ammodytin from Vipera ammodytes venom, by 
BLAST search although est2genome assigned the correct EST sequence to the each 
genomic sequence. 
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Table 7.2 Identification of PCR products amplified from genome walker libraries: For each PCR product, the amplicon size (kb) and 
sequence length (bp) are recorded. The EST sequence was assigned to each genomic DNA sequence using est2genome (Mott, 1997). A BLAST 
search against the NCBI nucleotide database was used to assign a protein family to each genomic sequence. The protein family, accession 
number and sequence coverage of the protein with the highest sequence homology are provided in the table. 
Protein group 
PCR 
amplicon 
size (kb) 
Sequence 
length 
(bp) 
EST 
sequence 
Highest scoring BLAST hit 
Accession 
number 
BLAST 
sequence 
coverage 
(%) 
EST sequence 
coverage with 
BLAST hit 
(%) 
SVMP contig 1 2.25 1143 BAR00015 Crotalus adamanteus metalloproteinase HQ414109.1 23 98 
SVMP contig 2 2.25 967 BAR00015 Agkistrodon contortrix microsatellite GQ192660.1 8 11 
SP contig 1 2 1094 BAR00596 Vipera ammodytes ammodytin PLA2 AJ580214.1 5 18 
SP contig 2 2 1078 BAR00377 V. berus berus ammodytin PLA2 AJ580250.1 4 7 
SP contig 3 2 1124 BAR00034 Vipera aspis aspis ammodytin PLA2 AJ580156.1 5 11 
LAO contig 1 1 1432 BAR00017 E. ocellatus LAO FM177950.1 11 100 
VEGF contig 1 2 2098 BAR00040 A. contortrix microsatellite GQ184956.1 9 14 
KTI contig 1 2.5 1085 BAR00596 Bothrops atrox batroxobin X12747.1 64 40 
KTI contig 2 2.5 700 No sig. hits B. atrox batroxobin X12747.1 39 N/A 
PDI contig 1 2.5 1309 BAR00008 V. ammodytes ammodytin PLA2 AJ580214.1 4 11 
PDI contig 2 2.5 1077 No sig. hits V. aspis aspis ammodytin PLA2 AJ580156.1 6 N/A 
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7.5. Discussion 
The genomic organization of venom protein-encoding genes and the mechanisms 
involved in regulating gene expression are currently little understood, but thought to 
be complex due to the continual adaptive evolutionary pressures exerted on venoms 
(Fry, 2005). Here, we have begun to characterise the structure of genes encoding SP 
and VEGF in B. arietans venom and initial analyses indicated a complexity in the 
organisation of these genes. Analysis of sequences amplified from B. arietans 
genomic DNA illustrate different architectures in the genomic structure between the 
two venom protein families (SP and VEGF) in the number of introns in the genomic 
DNA sequences with the sequence encoding SP containing one intron and the 
sequence encoding VEGF containing three intron regions. Here, the genomic 
structure of SP and VEGF genes were not fully determined and further investigation 
may reveal additional complexity in genomic organisation. 
Genome walking is a method regularly used to characterise unknown regions of 
DNA flanking the coding regions of a gene and has been employed to effectively 
identify and characterise regulatory regions controlling the expression of eukaryotic 
genes (Leoni et al., 2008, Rishi et al., 2004, Siebert et al., 1995), including snake 
venom genes. Previous studies suggested that multiple transcription initiation sites 
may be commonly present in snake venom genes (Afifiyan et al., 1999, Lachumanan 
et al., 1998), which has also been frequently observed in other highly regulated 
eukaryotic genes (Kozak, 1986). In our study, the region of genomic DNA upstream 
of the transcription start site which was amplified using PCR walking was unusually 
short (700bp-2kb). Although it is thought that some regulatory elements are 
relatively close to the transcription start site, including promoters of venom protein 
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genes (Pawlak and Kini, 2008), others may be present in locations more distant from 
the transcription start site or span intron-exon boundaries. Due to a lack of data, we 
could not find the promoters or transcription factors of venom protein-encoding 
genes. This could potentially be due to poor quality of genomic DNA used in these 
experiments, or because the distance of the promoter from the transcription start site 
was longer than expected. In this study, we were not able to obtain DNA of a higher 
quality by repeating genomic DNA extraction from B. arietans tissues due to time 
and sample constraints, as repeating genomic DNA isolation from fresh tissue would 
require sacrificing specimens. 
As we have begun to observe, the genomic structure and organisation of venom 
genes are complex. In snake venom toxins, an accelerated segment switching in 
exons to alter targeting (known as ASSET) has been shown (Doley et al., 2009, 
Doley et al., 2008). ASSET, and other such alternative splicing variations has 
resulted in the formation of ordered, conserved exon structure within members of a 
gene family and could play a significant role in the genomic organisation of venom 
protein genes. Currently, elapid and viperid 3FTXs genes have been shown to 
undergo changes in genomic structure due to ASSET (Doley et al., 2009, Doley et 
al., 2008). The role of ASSET in other protein families such as Kunitz inhibitors, 
phospholipase A2, serine proteases and metalloproteinases has also been investigated 
but not yet clearly defined. Although the molecular mechanisms of ASSET are 
currently unknown, it is thought that this phenomenon plays an important role in the 
functional evolution of venom proteins. A study by Sanz et al also identified that 
retrotransposable elements contained in intron regions of the gene structure may play 
an important role in recruitment and neofunctionalization of multi-gene protein 
families in venom (Sanz et al., 2012). Transposable elements can represent a large 
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proportion of eukaryotic genomes and are a rich source of genomic variation as they 
are inserted into genes or gene regulatory regions, disrupting the gene structure and 
potentially altering gene function (Biemont and Vieira, 2006). The importance of 
intragenic regions and mobile elements could be explored by investigating the 
distribution of transposable elements in the structure of venom genes in comparison 
to physiological non-toxin homologues. 
Substantial work is required to fully investigate and define the genomic organisation 
of genes encoding other families of venom proteins in viper venom. To date, very 
little is known about the genomic structure of venom genes and, until very recently, 
only the organisation and regulation of some neurotoxins and PLA2s genes has been 
elucidated. A study by Sanz et al provided the first report of the genomic structure of 
a PIII SVMP transcript from Echis ocellatus venom (Sanz et al., 2012) employed an 
exhaustive strategy to PCR-amplify and assemble sequences for each domain of the 
enzyme, producing overlapping sequences to form the complete gene sequence. 
Although genome walking has been shown to be an efficient method to obtain large 
amounts of sequence data for several multi-gene venom protein families in a single 
experiment, the approach described by Sanz et al may provide a more direct and 
comprehensive method to determine the organisation of venom protein-encoding 
genes. 
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8. GENERAL DISCUSSION 
Venom is a highly complex predatory tool with the primary function of 
immobilising, killing and digesting prey (Kordiš et al., 2002). Therefore, the 
production of venom is vital to the success of venomous snakes as proficient 
predators. Venom is a complex mixture of multi-isoform, multi-gene protein families 
which evolved following accelerated adaptive evolutionary processes including 
repeated gene recruitment, duplication and selection events. Venom is synthesised by 
specialised secretory glands but the dynamics of venom production are yet to be fully 
understood. The overarching aims of the work described in this thesis were to 
investigate the protein composition of venom, the dynamics of venom protein 
replenishment, the production of venom in juvenile snakes, the genomic organisation 
of venom protein-encoding genes and the mechanisms by which venom protein 
synthesis is controlled and regulated. This work has provided a detailed investigation 
into the protein composition, gene expression and production of venom in the 
African Puff Adder, Bitis arietans. 
Inter and intra-species variation in venom composition and function has been 
reported on several taxonomic levels, reflecting the complexity of the protein 
composition of snake venoms. Variation in venom composition is most evident in 
species with wide-ranging geographical distributions, emphasising that 
environmental factors (most importantly diet) play a role in influencing the 
composition and activity of venom (Calvete et al., 2007b, Casewell et al., 2009, 
Daltry et al., 1996a, Daltry et al., 1996b). Variation in venom composition has been 
previously documented for other members of the Bitis genus (e.g. B gabonica 
gabonica, B. g. rhinoceros, B. nasicornis and B. caudalis) (Calvete et al., 2007a, 
Calvete et al., 2007b), but had not yet been investigated in the most medically 
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important species of the genus, B. arietans. We have observed high levels of intra-
species variation in the protein composition, immunoreactivity and proteolytic 
activity of venom between B. arietans variants of different and the same 
geographical origin. Variation was most notable in the expression and activity of the 
SVMP enzyme group which are responsible for the characteristic symptoms of viper 
envenoming such as tissue necrosis and haemorrhage (Gutiérrez and Rucavado, 
2000, Gutiérrez et al., 2005b). These observations could have significant clinical 
implications if variations in the protein composition and activity of venom translate 
into variations in the clinical manifestation of B. arietans envenoming. From an 
evolutionary perspective, B. arietans is one of the most geographically diverse 
viperid species in sub-Saharan Africa and we have demonstrated that this is reflected 
in its venom phenotype (Currier et al., 2010). There are currently two recognised 
sub-species of B. arietans; B. arietans arietans and the Somali Puff Adder, B. 
arietans somalica. However, phylogenetic and phylogeographic studies using 
multiple independent loci are currently aiming to define the speciation of African and 
Arabian specimens (Barlow et al 2012, in preparation), suggesting that B. arietans 
may be a collection of sub-species based on geographical distribution. Our 
observations of intra-species variation in venom composition and activity between 
different B. arietans geographical variants across sub-Saharan Africa and Saudi 
Arabia could be used to support the speculation that a number of B. arietans sub-
species exist, particularly between the African and Saudi Arabian variants, the latter 
of which showed a distinctive venom profile with lower SVMP expression and 
activity in comparison to African venoms.  
Several studies have also demonstrated intra-species variation in venom composition 
and biological function between juvenile and adult specimens with the overall 
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consensus conclusions that venom from juvenile specimens may be more toxic than 
adult venoms (Furtado et al., 1991, Reid and Theakston, 1978, Saldarriaga et al., 
2003, Zelanis et al., 2007). We investigated changes in the protein composition and 
proteolytic activity of venom from juvenile B. arietans specimens from birth until 
maturity. Although the proteolytic activity of juvenile venoms appeared to be 
qualitatively comparable to the maternal adult venom, we observed differences in the 
composition of SVMPs between juvenile and maternal B. arietans venoms. The 
current literature emphasises that diet is a major factor influencing the protein 
composition and prey-specific toxicity of venoms (Barlow et al., 2009, Casewell et 
al., 2009, Daltry et al., 1996a, Daltry et al., 1996b). Our findings indicate that some 
aspects of venom are genetically hard-wired and not plastic, as functional venom 
appeared to be produced by juvenile snakes immediately from birth. The protein 
composition and enzyme activity of juvenile venoms did not appear to change from 
birth to maturity, which most likely reflects the vital role of venom in both defensive 
and predatory mechanisms.  
We have demonstrated that venom shows great complexity and diversity, even 
within a single viperid species. Our observations lead us to question how such a 
complicated, yet fundamental predatory tool is controlled, synthesised and regulated 
by snake venom glands? The dynamics and mechanisms underlying the regulation 
and synthesis of venom are thought to be equally complex and multifaceted but little 
understood. To investigate this we aimed to explore how our observations of the B. 
arietans venom proteome may be reflected in the transcriptome. However, current 
conventional methods used to analyse the transcriptional activity of the venom gland 
require sacrificing snakes to dissect venom gland tissue, making the real-time study 
of venom gene expression ethically undesirable or unachievable. To address this, we 
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developed and optimised novel techniques which exploited the unusual stability of 
messenger RNA in lyophilised snake venoms. The major outcomes of this work were 
to determine the amplification of venom transcripts from venom vs. venom gland 
cDNA and to exploit new protocols to elucidate the real-time dynamics of venom 
production. Messenger RNA was identified as an unusually stable component of 
venoms ten years ago when several key studies demonstrated that mRNAs could be 
isolated, amplified and sequenced from venoms of snakes (Chen et al., 2002), 
scorpions (Chen et al., 2003b), lizards (Chen et al., 2006) and amphibians (Chen et 
al., 2003a, Chen and Shaw, 2003, Chen et al., 2005), although little attempt has been 
made to explore the mechanisms of mRNA stability, nor to demonstrate how mRNA 
in venom can be exploited to empower venom research. Our studies have 
demonstrated, for the first time, that venom mRNA can be applied in research to 
address important biological questions, such as investigating the time course of 
venom production using quantitative PCR gene expression analyses (Currier et al., 
2012). Venom, as an untapped alternative source of transcriptionally active mRNA, 
could have numerous applications in venom biology ranging from the generation of 
transcriptomes for the venoms of CITES-protected venomous species, the 
comparison of relative gene expression levels of specific venom proteins in venoms 
from different geographical variants and in the identification of species by DNA 
barcoding from mitochondrial DNA isolated from lyophilised snake venoms (Pook 
and McEwing, 2005).  
The stability of mRNA in venom is a highly unusual and exciting phenomenon. The 
mechanisms responsible for regulating mRNA stability in eukaryotes has been 
reviewed, suggesting that stability of mRNA is achieved through a balance of 
intracellular transcriptional activity and degradative processes (Saini et al., 1990). In 
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eukaryotes, the importance of the poly(A) tail, the 5’ and 3’ untranslated regions 
(UTR) and regulatory sequences at the 5’ end of mRNA have all been implicated in 
protecting mRNA from degradation (Dreyfus and Régnier, 2002, Sheiness et al., 
1975), illustrating that the complexity of the mechanisms regulating mRNA 
stability/decay are clearly still not well defined. It is thought that components 
including the 5′-cap structure, 5′-UTR, the protein coding region, 3′-UTR and the 3′-
poly(A) tail act synergistically to regulate mRNA stability (Gallie, 1991, Guhaniyogi 
and Brewer, 2001). 
The stability of mRNA in venom is surprising as venom contains many destructive 
enzymes including nucleases and phosphodiesterases (Dhananjaya and D'Souza, 
2010). In other systems, the nearest biological comparison to venom would be saliva, 
which has also been shown to contain full length and partially degraded mRNAs in 
humans (Park et al., 2006). Studies suggest that salivary mRNAs could be used as 
biomarkers for disease (e.g. oral cancer) (Li et al., 2004b). However, the stability of 
mRNA in saliva is little understood as saliva also contains an abundance of 
ribonucleases and digestive enzymes (Eichel et al., 1964, Morita et al., 1986). It has 
recently been suggested that microvesicular bodies, derived from endosomal 
membrane compartments after fusion with the plasma membrane, present in human 
saliva (Kapsogeorgou et al., 2005) may provide an environment to contain and 
protect mRNA from extracellular RNases, ensuring the stability of mRNA 
(Palanisamy et al., 2010). As microvesicles have also be identified in snake venom 
(Carneiro et al., 2007), we could suggest that they could also play a role in regulating 
mRNA stability in venom. 
We exploited the stability of mRNA in venoms using our novel optimised 
approaches to (i) establish the real-time gene expression dynamics of venom 
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replenishment and (ii) investigate venom production in juvenile B. arietans 
specimens during maturation from birth. In the literature, the dynamics of venom 
protein production are currently unclear (i.e. whether venom proteins are synthesised 
in parallel or independently). We could predict that perhaps physiological/structural 
proteins or components involved in inhibiting and stabilising venom enzymes during 
storage (e.g. QKW peptides) may be synthesised prior to components with primary 
toxic functions (e.g. SVMPs). On the other hand, venom proteins which play a vital 
role in subduing or killing prey may be synthesised as a priority as in the absence of 
their toxic arsenal, venomous snakes may be vulnerable. Early studies using 
immunohistochemical techniques suggested that although all venom gland epithelial 
cells are capable of synthesising and secreting all venom proteins, some proteins may 
be synthesised at a different rate than others, possibly relating to their biological role 
in venom (Oron and Bdolah, 1973, Sobol Brown et al., 1975, Oron and Bdolah, 
1978). By quantitatively surveying the transcription levels of venom protein-specific 
mRNAs during the cycle of venom replenishment, we demonstrated that the 
expression of genes encoding different venom proteins, which included enzymatic 
toxins and inhibitory components or physiological proteins, peaks between days 3-7 
following venom extraction. Although we did not survey the complete range of 
venom proteins in this study, we targeted transcripts which we considered to be the 
most important and abundant in B. arietans venom such as SVMPs, SPs, CTLs and 
QKWs. The transcripts surveyed in the study also encompassed venom proteins with 
a range of biological activities such as proteolytic enzymes (SVMPs), enzyme 
inhibitors (QKWs) and structural proteins (PDI). Our data conflicts the previous 
literature by demonstrating that several different venom components, whether 
enzymatic or non-enzymatic, appear to be expressed at the same time during venom 
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synthesis. Replenishment of depleted venom proteins occurs relatively quickly 
emphasising the critical requirement for snakes, as limbless predators, to rapidly re-
synthesise functional venom for both predatory and defensive purposes.  
Here, we have demonstrated levels of variation in the proteome and transcriptome of 
B. arietans venom. Our findings suggest that tightly-controlled mechanisms may be 
in position to ensure the rapid synthesis of venom, both in terms of the production of 
venom in juvenile snakes at birth and in the expression of proteins during 
replenishment of venom stores following snakebite. However, the mechanisms 
responsible for operating and controlling venom synthesis and secretion remain to be 
fully elucidated, implicating the overall complexity of the venom production system. 
Our questions may be addressed by exploring the genomic structure and organisation 
of venom protein-encoding genes. In this work, we have taken initial steps to 
investigate the genomic structure of venom genes and, following initial 
investigations aiming to define the organisation of vascular endothelial growth factor 
and serine protease genes expressed in B. arietans venom, we suggest that the 
structure of venom genes is highly complex. Studies have shown that accelerated 
segment switching in exons to alter targeting (ASSET) observed in the structure of 
venom genes may play an important role in the functional evolution of venom 
proteins (Doley et al., 2009, Doley et al., 2008). Studies have also shown that 
intragenic regions containing retrotransposable elements (Sanz et al., 2012) and 
domain alteration/loss events (Casewell et al., 2011a, Fry et al., 2008, Wagstaff et al., 
2006) are important in the recruitment and neofunctionalization of multi-gene venom 
protein families. These observations suggest that the structure of genes encoding 
these venom protein families may be complex and diverse. 
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Most of the current literature has focussed on defining the genomic organisation of 
genes encoding neurotoxins in elapid venoms (Afifiyan et al., 1999, Chang et al., 
2002, Chang et al., 1997, Fujimi et al., 2003, Lachumanan et al., 1998), and to a 
lesser extent in viper and colubrid venoms (Doley et al., 2009, Doley et al., 2008, 
Pawlak and Kini, 2008) and the first genomic structure of an SVMP has only very 
recently been reported (Sanz et al., 2012). Thus, the lack of genomic data for snake 
venom genes may be concealing details on the mechanisms of gene recruitment and 
the molecular events which have resulted in the formation of multigene toxin 
families. A recent advance and drive in snake genomics has seen sequencing of the 
first model snake genomes from the Burmese Python (Python molurus bivittatus) 
(Castoe et al., 2011) and King Cobra (Ophiophagus hannah) which aim to provide 
insight into the diversity, structure and organisation of snake genomes. 
 
9. FUTURE WORK 
Our observations of variation in protein composition and biological activity of 
venom from B. arietans specimens from different and the same geographical origins 
may be of therapeutic importance if they directly translate to variations in the clinical 
manifestation of envenoming following snakebite, and subsequent patient response 
to antivenom treatment. To address this, investigations to determine further levels of 
variation in activity between venoms from multiple B. arietans geographic variants 
could be performed. Firstly, we could perform a range of in vitro spectrophotometric 
assays to assess and identify variation in the specific activity of venom enzymes such 
as LAO, PLA2 and hyaluronidase. Following this, the lethality of venom determined 
by LD50 experiments (the dose of venom required to induce death in 50% of a group 
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of mice) and haemorrhagic activity of venom by determining the minimum 
haemorrhagic dose (MHD) could be investigated. The effect of intra-specific 
variation in venom composition and enzyme activity on the efficacy and 
effectiveness of antivenom treatment could be tested by ED50 experiments (the 
minimum dose of antivenom that is required to neutralise venom-induced pathology 
in 50% of a group of mice). Potential differences in the toxic effects induced by 
juvenile and maternal B. arietans venoms, which may translate to differences in the 
symptoms of snakebite victims, could be investigated by performing MHD 
experiments. Although the current antivenom used to treat B. arietans envenoming 
(EchiTAb-Plus_ICP) has been shown to be effective by preclinical testing (Segura et 
al., 2010), there is no data on the clinical efficacy of antivenom treatment in victims 
of B. arietans snakebite. Our observations of high levels of variation in venom 
composition and activity of B. arietans emphasise that great care should be taken 
when selecting B. arietans specimens for antivenom production to ensure that the 
complete diversity of venom is considered.  
The unusual stability of mRNA in lyophilised snake venom provided an alternative 
non-invasive approach to conventional methods which enabled the interrogation of 
the venom gland transcriptome without sacrificing specimens. However, to validate 
and support the use of venom as an alternative source of mRNA to venom gland 
tissue, future experiments would firstly aim to determine whether preservation of 
toxin-encoding mRNA in venom is a universal property of all venoms including 
viper and elapids representing a spectrum of species, geographic origin, size and 
habitat of venomous snake taxa. To determine whether the B. arietans venom 
transcriptome is an accurate representation of the venom gland transcriptome we 
would aim to sequence and compare each transcriptome. This would be one of the 
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most important assessments in our future work as by confirming the venom 
transcriptome as a true representative of the venom gland transcriptome, we will 
prove that venom is a reliable and accurate source of transcriptionally active mRNA. 
To define the mechanisms potentially involved in preserving mRNA in venom, 
including inhibitors of mRNA degradation (e.g. other RNAs or protein/peptide 
components) and physiochemical properties of venom, the degradation rates of 
venom mRNAs from different species in the presence of total RNA, micro RNAs 
and small interfering RNAs could be examined. Other potential protective 
components (e.g. proteins and peptides) could be identified by chromatography and 
mass spectrometry. 
In this work, we have begun to investigate the genomic structure and organisation of 
venom protein-encoding genes, demonstrating that the structure of venom genes may 
be highly complex. Further work would aim to characterise the gene structure of 
different viper venom-encoding genes and expand genome walking protocols to find 
elements such as promoters and transcription factors responsible for regulating gene 
expression of proteins by snake venom glands. By focussing primarily on the SVMP 
enzyme group, we could utilise our knowledge of the domain organisation of this 
medically important toxin family to elucidate the structure and organisation of genes 
encoding different classes of SVMPs in a directed approach as described by Sanz et 
al (Sanz et al., 2012) to produce the complete genomic sequences encoding one of 
the most important and diverse toxin groups in viper venoms.  
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APPENDICES 
APPENDIX I: Recipes for buffers and stock solutions 
1D SDS-PAGE and staining: 
 10X Phosphate-buffered saline (PBS): 
80g NaCl 
2g KCl 
14.4g Na2HPO4 
2g KH2PO4 
Up to 1L dH2O 
 
 Non-reduced 2X protein loading buffer (2X PLOB):  
10ml 0.5M Tris-base pH 8.5  
6ml 20% SDS 
30ml glycerol 
1.8mg bromophenol blue 
Up to 100ml dH2O 
 
 1.5M Tris solution, pH 8.8:  
181.71g Tris-base  
Up to 1L dH2O 
 
 0.5M Tris solution, pH 6.8:  
60.57g Tris-base 
Up to 1L dH2O 
 
 5X Tris-glycine-SDS (TGS) running buffer:  
151g Tris-base 
720g glycine 
50g SDS 
Up to 10L dH2O 
 
 Coomassie blue stain:  
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2.5g Coomassie Blue R-250 
500ml methanol 
400ml dH2O 
100ml glacial acetic acid 
 
 Coomassie Blue de-stain:  
4.5L methanol 
1L acetic acid 
Up to 10L dH2O 
 
Immunoblotting: 
 Immunotransfer buffer:   
6g Tris-base 
28.8g glycine 
400ml methanol 
Up to 2L ice cold dH2O 
 
 1X Tris-buffered saline-Tween (TBST):  
10ml Tween-20 
50ml 2M Tris-base (pH 8.5) 
300ml 5M NaCl 
Up to 10L dH2O 
 
 1 X Ponceau S dye 
2g Ponceau S 
30g trichloroacetic acid 
30g sulphosalicylic acid 
Up to 100ml dH2O 
 
 Blocking buffer:  
5% skimmed milk (Marvel) in 1 x PBS.  
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 DAB peroxidase developing solution:  
100mg DAB 
50µl hydrogen peroxide 
200ml 1 x PBS 
 
Substrate zymography: 
 Re-naturing buffer (per gel):  
2.5ml Triton X-100 
97.5ml distilled H2O 
 
 Developing buffer (per gel):  
2.5ml 1M Tris pH 8 
250µl 1M CaCl2 
Up to 50ml dH2O 
 
In-gel trypsin digestion of protein gel bands: 
 Destaining solution:  
50ml 100mM Ammonium bicarbonate 
50ml 100% Acetonitrile  
 
 DTT reducing solution:  
15.4mg dithiotheitol 
10ml 100mM Ammonium bicarbonate  
 
 IAN alkylating buffer:  
102mg iodoacetamide 
10ml 100mM Ammonium bicarbonate  
 
 Trypsin digestion solution: 
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25µg trypsin in 250µl of 50mM acetic acid, diluted 1:10 in 50mM 
Ammonium bicarbonate/50%Acetonitrile. 
 
Agarose gel electrophoresis: 
 50X Tris-Acetate-EDTA (TAE) buffer:  
242g Tris-base 
100ml 0.5M Na2EDTA pH 8 
57.1ml glacial acetic acid 
Up to 1L dH2O 
 
 6 x DNA loading buffer: 
1X TAE 
20% (w/v) glycerol 
1mg/ml Bromophenol Blue 
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APPENDIX II: The ‘Minimum information for Publication of Quantitative 
Real-time PCR Experiments’ (MIQE) guidelines. 
MIQE checklist for authors, reviewers and editors
a 
Item to check Importance Item to check Importance 
Experimental design:  qPCR oligonucleotides:  
   Definition of 
experimental and control 
groups 
Essential    Primer sequences Essential 
   Number within each 
group 
Essential 
   RTPrimerDB 
identification number 
Desirable
 
   Assay carried out by the 
core or investigator’s 
laboratory? 
Desirable    Probe sequences Desirable 
   Acknowledgement of 
authors’ contributions 
Desirable 
   Location and identity of 
any modifications 
Essential 
Sample:  
   Manufacturer of 
oligonucleotides 
Desirable 
   Description Essential    Purification method Desirable 
   Volume/mass of sample 
processed 
Desirable qPCR protocol:  
   Macrodissection or 
microdissection 
Essential 
   Complete reaction 
conditions 
Essential 
   Processing procedure Essential 
   Reaction volume and 
amount of cDNA/DNA 
Essential 
   If frozen, how and how 
quickly? 
Essential 
   Primer, (probe), Mg
2+
, 
and dNTP concentrations 
Essential 
   If fixed, with what and 
how quickly? 
Essential 
   Polymerase identity and 
concentration 
Essential 
   Sample storage 
conditions and duration 
Essential 
   Buffer/kit identity and 
manufacturer 
Essential 
Nucleic acid extraction:  
   Exact chemical 
composition of the buffer 
Desirable 
   Procedure and/or 
instrumentation 
Essential 
   Additives (SYBR Green 
I, DMSO etc.) 
Essential 
   Name of kit and details 
of any modifications 
Essential 
   Manufacturer of 
plates/tubes and catalog 
number 
Desirable 
   Source of additional 
reagents used 
Desirable 
   Complete thermocycling 
parameters 
Essential 
   Details of DNase or 
RNase treatment 
Essential 
   Reaction setup 
(manual/robotic) 
Desirable 
   Contamination 
assessment (DNA or RNA) 
Essential 
   Manufacturer of qPCR 
instrument 
Essential 
   Nucleic acid 
quantification 
Essential qPCR validation:  
   Instrument and method Essential    Evidence of optimization Desirable 
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(from gradients)  
   Purity (A260/A280) Desirable 
   Specificity (gel, 
sequence, melt or digest) 
Essential 
   Yield Desirable 
   For SYBR Green I, Ct of 
the NTC 
Essential 
   RNA integrity: 
method/instrument 
Essential 
   Calibration curves with 
slope and y intercept 
Essential 
   RIN/RQI or Ct of 3’ and 
5’ transcripts 
Essential 
   PCR efficiency 
calculated from slope 
Essential 
   Electrophoresis traces Desirable 
   CIs for PCR efficiency 
or SE 
Desirable 
   Inhibition testing (Ct 
dilutions, spike or other) 
Essential    r
2
 of calibration curve Essential 
Reverse transcription:     Linear dynamic range Essential 
   Complete reaction 
conditions 
Essential    Ct variation at LOD Essential 
   Amount of RNA and 
reaction volume 
Essential    CIs throughput range Desirable 
   Priming oligonucleotide 
(if using GSP) and 
concentration 
Essential    Evidence for LOD Essential 
   Reverse transcriptase 
and concentration 
Essential 
   If multiplex, efficiency 
and OD of each assay 
Essential 
   Temperature and time Essential Data analysis:  
   Manufacturer of 
reagents and catalogue 
numbers 
Desirable
    qPCR analysis program 
(source, version) 
Essential 
   Cts with and without 
reverse transcription 
Desirable
 B
 
   Method of Ct 
determination 
Essential 
   Storage conditions of 
cDNA 
Desirable 
   Outlier identification 
and disposition 
Essential 
qPCR target 
information: 
    Results for NTCs Essential 
   Gene symbol Essential 
   Justification of 
number/choice of 
reference gene 
Essential 
   Sequence accession 
number 
Essential 
   Description of 
normalization method 
Essential 
   Location of amplicon Desirable 
   Number and 
concordance of biological 
replicates 
Desirable 
   Amplicon length Essential 
   Number and stage of 
technical replicates  
Essential 
   In silico specificity 
screen (BLAST etc.) 
Essential 
   Repeatability (intra-
assay variation) 
Essential 
   Pseudogenes, 
retropseudogenes or 
homologs  
Desirable 
   Reproducibility (inter-
assay variation, CV) 
Desirable 
   Sequence alignment Desirable    Power analysis Desirable 
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Appendix II: The Minimum Information for Publication of Quantitative Real-
time PCR experiments (MIQE) guidelines (Bustin et al., 2009). 
   Secondary structure 
analysis of amplicon 
Desirable 
   Statistical methods for 
results significance 
Essential 
   Location of each primer 
by exon or intron 
Essential 
   Software (source, 
version) 
Essential 
   What splice variants are 
targeted? 
Essential 
   Ct or raw data 
submission with RDML 
Desirable 
a
All essential information must be submitted with the manuscript. RIN, RNA 
integrity number; RQI, RNA quality indicator; GSP, gene-specific priming; dNTP, 
deoxynucleoside triphosphate. 
B
Assessing the absence of DNA with a no-reverse 
transcription assay is essential when first extracting RNA. Once the sample has been 
validated as DNA free, inclusion of a no-reverse transcription control is desirable but 
not essential. 
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APPENDIX III: Optimisation of annealing temperature for amplification by quantitative PCR. 
Predicted optimal Temp.°C (PrimerSelect): 
 SVMP 52.3 SP 55.8 CTL 57.7 PLA2 54.5 LAO 54.8 VEGF 58.7 
Temp. °C Ct Tm °C Ct Tm °C Ct Tm °C Ct Tm °C Ct Tm °C Ct Tm °C 
65.0 28.98 78.50 28.20 75.00 32.61 81.00 30.38 76.50 32.58 79.00 28.79 83.00 
64.7 29.39 78.50 28.29 74.50 32.50 81.00 30.51 76.50 32.70 79.00 28.55 82.50 
64.2 29.06 78.50 28.98 75.00 32.28 81.00 30.81 76.50 32.16 79.50 28.42 83.00 
63.6 30.00 78.50 28.22 75.00 32.70 81.00 30.98 77.00 32.58 79.00 28.58 83.00 
62.5 28.92 78.50 27.77 75.00 32.48 81.00 31.36 N/A 32.14 79.50 29.73 N/A 
61.5 30.21 78.50 28.61 N/A 33.26 81.00 31.08 75.50 32.90 78.00 28.98 83.00 
60.0 29.42 79.00 31.24 75.00 31.94 81.00 31.46 76.50 32.55 79.00 28.90 82.00 
58.5 30.09 78.50 28.24 N/A 33.01 81.00 31.14 76.00 32.74 N/A 29.12 82.00 
56.6 29.48 78.50 27.64 72.50 32.59 80.00 30.32 77.00 31.81 78.50 28.88 81.50 
55.1 29.78 78.00 29.38 74.00 33.39 79.50 30.20 76.50 30.73 81.00 28.83 83.00 
53.8 29.35 79.00 27.46 73.00 32.99 80.00 29.68 76.50 32.50 75.00 28.87 81.50 
52.6 29.37 78.50 27.19 75.00 33.25 N/A 31.17 N/A 32.18 79.00 28.83 82.00 
51.6 29.15 79.00 27.31 74.00 32.74 81.00 29.52 76.00 32.98 N/A 28.42 83.00 
50.8 29.85 76.50 27.19 74.50 33.00 81.00 29.77 76.50 31.88 78.50 28.54 82.50 
50.3 29.39 77.00 26.48 75.00 32.47 81.00 29.49 75.50 32.07 78.50 28.19 83.00 
50.0 28.90 78.50 27.44 N/A 32.57 81.00 29.58 76.00 32.15 79.00 28.53 82.50 
Mean 29.46 78.34 28.04 74.42 32.74 80.77 30.47 76.32 32.29 78.75 28.76 82.50 
Std. Dev. 0.42 0.68 1.12 0.84 0.40 0.50 0.70 0.46 0.54 1.28 0.36 0.57 
 KTI 58.2 PDI 51.6 QKW 53.0 ACTIN 58.6 GAPDH 54.8 HSP 56.8 
Temp. °C Ct Tm °C Ct Tm °C Ct Tm °C Ct Tm °C Ct Tm °C Ct Tm °C 
65.0 30.88 74.50 30.14 79.50 27.89 79.50 32.58 82.00 33.38 74.00 28.77 77.00 
64.7 30.10 74.50 29.87 79.50 28.17 79.50 32.73 81.50 33.79 74.00 28.92 76.50 
64.2 30.01 74.50 30.01 79.00 27.80 79.50 32.65 81.50 33.95 73.50 29.66 76.00 
63.6 30.00 74.50 29.66 79.50 29.20 78.00 33.04 81.50 33.91 73.50 35.24 N/A 
62.5 29.64 74.00 30.11 79.50 28.86 77.50 32.90 81.50 34.31 N/A 37.01 77.50 
61.5 29.45 74.00 32.04 N/A 28.75 79.50 33.17 82.00 34.56 73.50 28.41 76.50 
60.0 29.46 74.00 28.90 78.00 28.66 79.00 32.42 82.00 35.33 74.00 28.74 76.00 
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58.5 31.41 71.00 29.69 N/A 29.20 N/A 30.78 N/A 34.91 N/A 29.29 77.00 
56.6 30.55 71.50 28.86 N/A 29.02 79.00 32.38 N/A 35.34 80.50 28.75 76.50 
55.1 30.28 72.50 28.90 N/A 29.01 78.00 31.84 81.50 34.37 80.50 29.46 77.00 
53.8 30.22 74.50 28.67 79.00 28.92 78.50 30.88 82.00 33.92 80.50 28.89 76.50 
52.6 30.13 74.00 28.67 N/A 28.92 79.50 31.03 81.50 32.87 80.00 29.19 75.00 
51.6 30.29 73.50 28.62 N/A 29.06 78.00 30.14 N/A 33.60 79.00 28.72 77.00 
50.8 30.02 73.50 27.75 74.00 29.18 79.50 31.00 N/A 34.51 78.00 29.10 76.50 
50.3 30.25 73.00 27.83 N/A 29.20 79.00 31.11 80.00 33.29 77.50 28.61 77.00 
50.0 29.71 74.00 28.24 N/A 29.21 77.50 30.65 N/A 33.15 80.00 29.03 76.50 
Mean 30.15 73.59 29.25 78.50 28.12 78.77 31.83 81.55 34.07 77.04 29.86 76.57 
Std. Dev. 0.50 1.08 1.07 1.89 0.46 0.78 1.01 0.57 0.74 3.09 2.49 0.59 
 
 
 
 
 
 
 
 
Appendix III: Optimisation of annealing temperature for amplification by quantitative PCR: The cycle time (Ct) value of amplification 
across an annealing temperature gradient from 50 to 65°C was recorded for each gene of interest. Very little variation in the cycle time across 
the annealing temperature gradient was observed (Standard deviation: 0.36-3.09 cycles). 
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APPENDIX IV: Optimisation of starting cDNA quantity for amplification by quantitative PCR. 
Venom protein target/Ct: SVMP SP 
 
CTL 
 
PLA2 
 
LAO 
 
VEGF 
 
cDNA 
ng/reaction 
Rep 
1 
2 Average Rep 
1 
2 Average Rep 
1 
2 Average Rep 
1 
2 Average Rep 
1 
2 Average Rep 
1 
2 Average 
5 28.18 28.67 28.43 30.00 29.15 29.58 31.36 31.63 31.50 26.98 26.80 26.89 27.40 27.22 27.31 26.10 26.30 26.20 
10 28.70 28.29 28.50 29.76 29.40 29.58 31.95 32.10 32.03 27.14 27.29 27.22 27.70 27.32 27.51 25.62 25.86 25.74 
20 28.70 28.89 28.80 29.82 29.30 29.56 31.73 31.85 31.79 27.20 27.05 27.13 27.03 27.72 27.38 26.15 26.18 26.17 
50 27.10 27.15 27.13 28.20 28.36 28.28 31.57 31.70 31.64 27.30 27.48 27.39 27.42 27.71 27.57 26.70 26.73 26.72 
Standard deviation: 0.74 
 
0.65 
 
0.21 
 
0.21 
 
0.12 
 
0.40 
 KTI PDI QKW ACTIN GAPDH HSP 
5 26.39 26.54 26.47 27.23 28.14 27.69 26.47 26.42 26.45 28.39 28.35 28.37 31.64 30.72 31.18 29.50 29.26 29.38 
10 27.01 26.60 26.81 27.40 27.79 27.60 26.59 26.79 26.69 27.98 27.94 27.96 31.32 31.56 31.44 29.89 30.02 29.96 
20 25.37 25.35 25.36 27.27 27.40 27.34 26.94 26.49 26.52 28.17 28.35 28.26 31.53 33.32 32.43 29.64 30.28 29.96 
50 26.85 27.01 26.93 27.56 27.44 27.50 26.29 26.69 26.49 28.61 28.42 28.52 31.28 31.55 31.42 30.76 31.55 31.16 
Standard deviation: 0.72  0.15  0.11  0.24  0.55  0.75 
 
 
 
 
Appendix IV: Optimisation of initial cDNA quantity per reaction for amplification by quantitative PCR: The cycle time (Ct) value of 
amplification by qPCR was recorded for each gene of interest using different initial quantities of cDNA per reaction ranging from 5 to 50ng. 
Results showed very little difference between amplification (Ct score) between reactions with less than 1 cycle difference between different 
initial starting quantity of cDNA. 
 
 236 
 
APPENDIX V: Optimisation of quantitative PCR by standard and melt curve analysis. 
Gene 
target 
cDNA 
conc. 
Ct 
Average 
Ct 
Melt temp. 
°C 
Peak height 
Gene 
target 
cDNA 
conc. 
Ct 
Average 
Ct 
Melt temp. 
°C 
Peak height 
 ng/µl 
Rep 
1 
2  
Rep 
1 
2 Rep 1 2  ng/µl 
Rep 
1 
2  
Rep 
1 
2 Rep 1 2 
SVMP 2000 27.08 27.19 27.14 79.00 79.00 2422.40 2436.42 KTI 1000 26.43 26.69 26.56 74.50 74.00 1095.46 709.77 
 1500 27.64 27.70 27.67 79.00 79.00 2351.72 2529.77  500 27.61 27.69 27.65 74.50 74.50 1047.71 863.84 
 1125 27.71 28.00 27.86 79.00 79.00 2393.54 2376.25  250 28.85 29.10 28.98 74.50 74.50 1166.09 961.26 
 843.75 28.49 28.37 28.43 79.00 79.00 2794.84 2492.94  125 30.21 30.29 30.25 74.50 74.50 986.05 903.48 
 632.81 29.36 28.92 29.14 79.00 79.00 2460.80 2565.13  62.50 30.55 30.92 30.74 74.50 73.50 1026.16 579.97 
 474.61 29.45 29.48 29.47 79.00 79.00 2446.97 2399.96  31.25 31.24 31.59 31.42 74.50 74.00 1004.70 661.98 
 355.96 29.66 30.21 29.94 79.50 79.00 2247.97 2349.04  15.63 N/A N/A N/A N/A N/A N/A N/A 
 266.97 29.79 30.07 29.93 79.00 79.00 2622.35 2275.28  7.81 N/A N/A N/A N/A N/A N/A N/A 
SP 2000 25.83 26.28 26.06 81.50 81.00 1346.70 1228.55  3.91 N/A N/A N/A N/A N/A N/A N/A 
 1500 27.09 26.36 26.73 81.00 81.50 1504.01 1175.27  1.95 N/A N/A N/A N/A N/A N/A N/A 
 1125 28.30 27.25 27.78 81.50 81.50 1478.69 1434.77 PDI 1000 27.77 27.61 27.69 78.50 79.00 656.06 655.42 
 843.75 29.47 29.86 29.52 81.50 81.50 1596.04 1353.44  500 28.24 28.09 28.17 79.00 79.00 681.51 709.49 
 632.81 31.13 31.40 31.27 81.50 81.50 1522.45 1231.22  250 28.81 29.05 28.93 79.00 76.50 624.74 370.16 
 474.61 31.76 31.90 31.83 81.50 81.50 1542.89 1367.49  125 29.12 29.91 29.52 79.00 75.00 489.20 333.80 
 355.96 34.23 32.61 33.42 81.50 81.50 1268.86 1321.62  62.50 29.46 29.69 29.58 79.00 78.00 491.34 356.76 
 266.97 33.09 33.80 33.45 81.50 81.50 1654.04 1335.10  31.25 30.01 30.17 30.09 79.00 79.00 455.34 389.82 
CTL 1000 29.23 29.30 29.27 80.00 81.00 705.14 741.31  15.63 N/A N/A N/A N/A N/A N/A N/A 
 500 30.44 30.14 30.29 81.00 80.50 719.04 724.26  7.81 N/A N/A N/A N/A N/A N/A N/A 
 250 31.12 31.54 31.33 81.00 80.50 865.19 649.73  3.91 N/A N/A N/A N/A N/A N/A N/A 
 125 32.12 33.15 32.64 80.50 80.00 739.54 567.06  1.95 N/A N/A N/A N/A N/A N/A N/A 
 62.50 33.38 33.42 33.40 81.00 80.00 750.16 588.38 QKW 1000 25.76 25.62 25.69 79.50 79.00 666.09 605.49 
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 31.25 34.39 34.17 34.28 81.00 80.50 757.75 600.74  500 26.45 26.17 26.31 79.50 79.50 607.17 737.15 
 15.63 35.59 35.34 35.47 79.00 81.00 469.65 744.29  250 27.25 27.07 27.16 79.50 77.50 616.40 522.39 
 7.81 36.44 36.50 36.47 79.50 80.50 464.06 435.52  125 28.65 28.62 28.64 78.50 78.00 602.49 482.76 
 3.91 N/A N/A N/A N/A N/A N/A N/A  62.50 29.69 30.00 29.85 77.50 79.50 469.44 355.43 
 1.95 N/A N/A N/A N/A N/A N/A N/A  31.25 31.11 30.82 30.97 79.50 79.50 546.23 568.19 
PLA2 1000 26.66 29.56 28.11 76.50 75.50 294.91 313.98  15.63 31.74 31.80 31.77 77.00 77.50 436.88 435.86 
 500 29.03 N/A 29.03 77.00 N/A 451.08 N/A  7.81 32.95 32.69 32.82 79.50 79.50 430.40 490.35 
 250 29.28 29.67 29.48 77.00 77.00 529.33 407.98  3.91 N/A N/A N/A N/A N/A N/A N/A 
 125 29.30 29.68 29.49 77.00 77.50 496.49 434.08  1.95 N/A N/A N/A N/A N/A N/A N/A 
 62.50 29.62 30.45 30.04 76.00 77.00 378.54 307.69 ACTIN 2000 27.46 27.28 27.37 82.00 82.00 1401.66 1352.96 
 31.25 29.40 N/A 29.40 77.00 N/A 466.12 N/A  1500 27.27 27.73 27.50 82.50 82.00 1502.60 N/A 
 15.63 30.02 29.64 29.83 74.50 77.00 341.71 430.93  1125 28.57 29.10 28.84 82.00 82.00 1762.19 1545.41 
 7.81 29.79 30.07 29.93 77.50 77.00 450.24 376.65  843.75 29.18 29.39 29.29 82.00 82.00 1776.96 1427.34 
 3.91 29.43 29.33 29.38 76.50 76.50 426.20 366.14  632.81 29.79 29.85 29.82 82.00 82.00 1586.77 1503.81 
 1.95 28.87 29.82 29.35 77.00 74.00 648.70 296.03  474.61 30.25 30.59 30.42 82.00 82.00 1768.03 1456.04 
LAO 1000 31.29 30.74 31.02 75.50 79.00 486.33 750.30  355.96 30.88 31.16 31.02 82.00 82.00 1666.15 1301.34 
 500 30.17 31.01 30.59 79.00 76.00 983.96 500.63  266.97 31.15 31.31 31.23 82.00 82.00 1832.43 1499.32 
 250 31.42 31.18 31.30 77.50 78.50 602.13 587.33 GAPDH 2000 28.54 24.49 26.52 81.00 81.00 2093.75 1214.42 
 125 31.15 30.89 31.02 79.50 79.00 839.26 698.82  1500 30.25 35.31 32.78 80.50 78.50 2090.13 957.54 
 62.50 31.39 31.43 31.41 79.00 78.50 631.02 579.32  1125 30.66 31.38 31.02 80.50 80.50 1932.03 1700.08 
 31.25 31.06 31.17 31.12 79.50 79.50 924.76 699.99  843.75 31.08 33.76 32.42 80.50 80.00 2070.54 1374.73 
 15.63 30.77 30.71 30.74 77.00 79.50 611.16 873.48  632.81 31.55 32.54 32.05 80.50 80.50 1997.44 1616.25 
 7.81 30.72 31.13 30.93 79.50 77.00 1030.99 525.10  474.61 32.21 34.66 33.44 80.50 80.00 2010.73 1257.04 
 3.91 30.88 31.51 31.20 79.50 79.00 1029.12 700.95  355.96 33.87 33.91 33.89 80.50 80.50 1632.25 1554.41 
 1.95 31.03 31.35 31.19 79.50 79.00 1149.00 833.82  266.97 33.51 36.35 34.93 80.50 80.00 1996.45 1030.75 
VEGF 1000 27.35 26.69 27.02 79.50 83.00 395.77 549.78 HSP 1000 27.99 28.24 28.12 76.50 76.50 975.42 873.97 
 500 27.38 27.43 27.41 81.50 80.50 533.81 445.63  500 28.85 29.64 29.25 77.00 76.50 951.01 906.75 
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 250 27.53 27.72 27.63 83.00 81.00 620.55 403.92  250 30.24 30.15 30.20 77.00 77.00 1208.82 1165.18 
 125 27.35 27.38 27.57 82.50 83.00 673.92 670.00  125 31.69 31.14 31.42 77.00 77.00 760.41 752.93 
 62.50 27.14 27.54 27.34 83.00 82.00 640.71 473.06  62.50 30.84 30.48 30.66 76.50 74.00 1012.19 640.77 
 31.25 27.61 27.60 27.61 79.00 81.00 412.33 421.69  31.25 31.51 31.81 31.66 77.00 76.50 937.25 944.70 
 15.63 27.47 28.25 27.86 83.00 80.00 639.78 383.03  15.63 N/A N/A N/A N/A N/A N/A N/A 
 7.81 27.33 27.35 27.34 82.00 82.50 622.45 623.42  7.81 N/A N/A N/A N/A N/A N/A N/A 
 3.91 27.58 27.69 27.64 83.00 82.00 684.44 474.66  3.91 N/A N/A N/A N/A N/A N/A N/A 
 1.95 27.03 27.32 27.18 82.50 82.50 854.63 703.63  1.95 N/A N/A N/A N/A N/A N/A N/A 
 
 
 
 
 
 
 
 
Appendix V: Optimisation of quantitative PCR by standard and melt curve analysis: The cycle time (Ct) value of amplification, melt 
temperature and height of melt peak following standard curve and melt curve were recorded for each gene of interest across a series of diluted 
cDNA concentrations. 
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APPENDIX VI: Juvenile Bitis arietans specimens 
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Appendix VI: Juvenile Bitis arietans specimens: Variation in the coloration and 
scale patterns of related juvenile B. arietans siblings. 
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APPENDIX VII: Optimisation of relative real-time gene expression analysis 
with reference to the MIQE guidelines. 
Experimental design: 
Number within each 
group 
8 individual Bitis arietans specimens (originating from Ghana or Nigeria) 
were used in the study. 
Location where 
assay carried out 
Laboratories of the Alistair Reid Venom Unit of the Molecular and 
Biochemical Parasitology Research Group, Liverpool School of Tropical 
Medicine. 
Acknowledgement 
of authors’ 
contributions 
All experiments were carried out by RB Currier. 
Sample: 
Description 
Lyophilised venom extracted from 8 individual adult Bitis arietans 
specimens originating from Ghana or Nigeria (historical snake ID numbers: 
BaG2, BaG4, BaLZS1, BaN11, BaN60, BaN68, BaN80 and BaN81). 
Volume/mass 
sample of processed 
2-10mg lyophilised venom. 
Processing 
procedure 
Once extracted, venom was frozen at -20°C before being lyophilised for 3-
4 hours. 
If frozen, how and 
how quickly? 
Fresh venom samples were frozen immediately after extraction. 
Sample storage 
conditions and 
duration 
Freeze-dried venom samples were stored at 4°C. 
Nucleic acid extraction: 
Procedure and/or 
instrumentation 
mRNA extraction 
Name of kit Dynabeads® mRNA DIRECT™ kit (Dynal, Invitrogen, UK). 
Details of DNase or 
RNase treatment 
DNase treatment was performed on a standard sample (pooled mature 
venom). Conventional PCR was carried out and products were run on a 1% 
agarose gel. There were no differences in PCR products between DNase 
and non DNase treated mRNA samples. 
Contamination 
assessment 
Reverse transcriptase negative controls for all toxin, non-toxin and 
reference genes were carried out using a standard mRNA sample (isolated 
from pooled mature venom). Amplicons from conventional PCR were run 
on a 1% agarose gel. No products were visible indicating that there was no 
contamination. 
Nucleic acid 
quantification 
The concentration of mRNA extracted from venom was measured using the 
Nanodrop spectrophotometer. 
Instrument and 
method 
Nanodrop spectrophotometer, Thermo Scientific. 
Purity(A260/A280) 
OD260/280 of a control sample (pooled mature venom mRNA) measured 
using a Nanodrop. The OD260/280 reading of mRNA extracted from 10mg 
lyophilised B. arietans venom was 4.67. 
Inhibition testing 
Standard curves of cDNA dilutions (including cDNA concentrations of up 
to 2µg/µl) were sufficient to detect the presence of PCR inhibitors 
introduced in nucleic acid preparation. 
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Reverse transcription: 
Complete reaction 
conditions 
1µl Primer (50µM oligo dT) and 1µl 10mM dNTP mix were added to each 
mRNA sample. The cDNA synthesis master mix contained (per reaction): 
2µl 10x RT buffer, 4µl 25mM MgCl2, 2µl 0.1M DTT, 1µl RNaseOUT 
(40U/µl), 1µl Superscript III RT (200U/µl). 1µl RNase H was added to 
each reaction following termination of cDNA synthesis to degrade any 
RNA template. 
Amount of RNA and 
reaction volume 
8µl 2-5ng/µl mRNA was added to each 20µl reaction volume. 
Reverse 
transcriptase and 
concentration 
Superscript® III reverse transcriptase (Invitrogen) at a concentration of 
200U/µl. 
Temperature and 
time 
First, samples were incubated for 5 minutes at 65°C and placed on ice for 1 
minute. Following addition of the mastermix, samples were incubated for 
50 minutes at 50°C. The reactions were terminated following incubation at 
85°C for 5 minutes. Following addition of RNaseH, samples were 
incubated at 37°C for 20 minutes. 
Manufacturer of 
reagents and cat. 
numbers 
Superscript® III first strand synthesis system manufactured by Invitrogen 
(cat. number 18080-051). 
Storage conditions 
of cDNA 
cDNA was stored at -20°C. 
qPCR target information: 
Amplicon length 
Amplicon lengths for toxin, non-toxin and reference gene primers: 
Snake venom metalloproteinase – 150 
Serine protease – 195 
C-type lectin – 131  
Kunitz inhibitor – 80  
Protein disulphide isomerase – 160  
QKW inhibitors – 181  
β-actin – 156  
GAPDH – 158  
Heat shock protein - 148 
Secondary structure 
analysis 
Secondary structures were avoided during primer design. 
qPCR oligonucleotides: 
Primer sequences Cluster 
number 
Protein 
group 
Forward primer sequence Reverse primer 
sequence 
 
BAR00042 SVMP ATACTGCGTGGTCTAGAAATG
TGG 
AGCGCCTGTGAATAA
CTGAGC 
BAR00034 SP AGGAGGCGAGGAGAAGAGAC
G 
TTCCGCCCCATCCCA
TAATAC 
BAR00012 CTL GCTCCGGCTTGCTGGTCGTGT
TC 
TCGATCGGCCCAGGT
CTTCTCTAC 
BAR00023 KTI GGGCCTATATCCGTTCCTTCTT ATTCCCATAGCATCC
ACCATAAAA 
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BAR00008 PDI CCCGAATATTCTGGTGGAGT AAATTGTTGGGCGAG
TTCTG 
BAR00003 QKW TGCGCCCCCAAATCCTCCTA TGGCATACGCAGCTG
GTTTACTCA 
- β-actin CTCAGAGTCGCCCCGGAAGA
ACAT 
AGAGGCGTACAGGGA
GAGCACAGC 
- GAPDH GAATATCATCCCAGCATCCAC
AGG 
CATCATACTTCGCCG
GTTTCTCTA 
- 
Heat 
shock 
protein 
CTGCCAGAAGATGAAGATGA
AAAG 
CAATACAACACGGGG
AAGAGACTA 
Manufacturer of 
oligonucleotides 
Sigma, UK. 
Purification method Desalting 
qPCR protocol: 
Complete reaction 
conditions 
1µl cDNA sample per reaction was added to 4µl ultrapure water. 6µl 
KAPA SYBR® FAST qPCR master mix was added to the diluted cDNA 
sample. 
Reaction volume 
and amount of 
cDNA 
11µl reaction volume containing 1µl cDNA. 
Primer, Mg
2+
 and 
dNTP 
concentrations 
Primers were added to the master mix from 10µM solutions to produce a 
final concentration of 200nM in the master mix. There was no deviation in 
Mg
2+
 and dNTP to those provided within the manufacturer’s mastermix. 
Polymerase identity 
and concentration 
There was no deviation in the concentration of KAPA SYBR® DNA 
polymerase to that provided within the manufacturer’s mastermix.  
Buffer/kit identity 
and manufacturer 
KAPA SYBR® FAST qPCR kit, KAPA Biosystems, AnaChem. 
Additives (SYBR 
green I, DMSO etc.) 
SYBR green I was contained within the manufacturer’s mastermix. 
Manufacturer of 
plates and cat. 
number 
BioRad, UK (Cat. HSP-3805) 
Complete 
thermocycling 
parameters 
The following thermocycling protocol was used: enzyme activation 95°C, 3 
minutes, [denaturation 95°C, 10 seconds, anneal/extend 55°C, 30 seconds] 
x 40 cycles. Melt curve were performed following amplification: 10 sec 
(95°C), ramping from 55°C to 95°C at 0.5°C increments. 
Reaction setup Manual. 
Manufacturer of 
qPCR instrument 
BioRad CFX 384 real time PCR detection system manufactured by BioRad. 
qPCR validation: 
Evidence of 
optimisation 
PCR with a temperature gradient from 50-65 ºC using all primer pairs was 
performed in order to determine optimal annealing temperature. An average 
optimal temperature for all primer pairs was calculated to be 55ºC. 
Specificity (gel, 
sequence, melt or 
digest) 
Melt curves for example primer pairs are provided in supplementary figure 
1. 
For SYBR green I, 
Ct of the NTC 
All Cts for NTCs were negative indicating no DNA contamination. 
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Calibration curves 
with slope and y 
intercept 
Standard curves example primer pairs are provided in supplementary figure 
1. 
PCR efficiency 
calculated from 
slope 
Amplification efficiency (%) -   
Snake venom metalloproteinase: 94.0 Serine protease: 28.0 
C-type lectin: 96.9 
Kunitz inhibitor: 100.7 
Protein disulphide isomerase: 122.6 
QKW inhibitory peptide: 91.2 
β-actin: 62.2 
GAPDH: 51.7 
Heat shock protein:89.5                  
Data analysis: 
qPCR analysis 
program (source, 
version) 
BioRad CFX manager version 1.5. 
Method of Ct 
determination 
Single threshold. 
Number/choice of 
reference genes 
3; β-actin, GAPDH and heat shock protein were used as reference genes. 
Description of 
normalised method 
The ΔΔC(t)) method for normalized relative gene expression was used. 
Number of 
biological 
replicates 
8 individual West African B. arietans specimens were used in this study. 
Repeatability (intra-
assay variation) 
To assess intra-assay repeatability, samples used for standard curve analysis 
were run in duplicate. All unknown samples were run in triplicate. 
Reproducibility 
(inter-assay 
variation, CV) 
The venom extraction time course was repeated for all available specimens 
used in the study. mRNA extraction, cDNA synthesis and qPCR were 
performed under identical conditions as in the first time course. Relative 
expression analysis from both runs was in agreement. 
Statistical methods 
for results 
significance 
Multiple regression analysis and Bonferroni post-hoc testing. 
Software (source, 
version) 
PASW Statistics, SPSS Inc. Version18. 
 
 
 
 
Appendix VII: Optimisation of relative real-time gene expression analysis with 
reference to the MIQE guidelines: Reference to the ‘Minimum information for 
Publication of Quantitative Real-time PCR Experiments’ (MIQE) guidelines in 
conducting real-time PCR experiments to monitor relative changes in gene 
expression levels of venom transcripts during venom replenishment. 
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APPENDIX VIII: Sequence alignments of Bitis arietans serine protease and 
vascular endothelial growth factor gene sequences with homologous genes. 
A) 
 
Appendix VIIIA continued on following page: 
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Appendix VIIIA continued: 
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B) 
 
Appendix VIIIB continued on following page: 
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Appendix VIII: Sequence alignments of Bitis arietans serine protease and 
vascular endothelial growth factor gene sequences with homologous genes: A) 
B. arietans genomic SP contigs 1 and 2 aligned with Bothrops atrox batroxobin gene 
sequence and B) B. arietans genomic VEGF contigs 1 and 2 with Trimeresurus 
flavoviridis VEGF precursor gene sequence. Alignments show that the B. arietans 
genomic sequences showed sequence homology to each of the 5’ and 3’ ends of the 
B. atrox batroxobin and T. flavoviridis VEGF gene sequences but regions did not 
overlap, thus do not form the complete sequence of B. arietans SP and VEGF-
encoding genes. 
Appendix VIIIB continued: 
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APPENDIX IX: Sequences and BLAST analysis of PCR products amplified and 
cloned from genome walker libraries. 
SVMP_contig 1 BLAST ID: Crotalus adamanteus metalloproteinase (Accession 
number HQ414109.1) 
ATCAGCTATGCATCAAGCTTGGTACCGAGCTCGAGATCCATGCTAGTAACGGCCGCCAGT
GTGATGGATATCTGCAGAATTCGCCCTTACTATAGGGCACGCGTGGTCGACGGCCCGGGC
TGGTCTGTCATTTTTGGAGTGACATGCGCTAAGCCACCTGGAAAACTGCCCTCCAGTAGT
ATTGTTACAACTCAGAATTTGTGCAAATCCTTCTCATATAAAGTCATGAATGAAGCTGAA
GGAGTCATTCCTTGCTTCTCATAGTCAAAGGGAGAAGAGCTCAGGTTGGCTTGAAA
GCAGAAAGAGGTTGCCTCTCTTCAAGCCAAATCCAGCCTCCAAAATGATCCAAGTTC
TCTTGGTAATTATATGCTTAGCGGTTTTTCCATATCAAGGTAAGATGTTCTCTTTGG
TTCCCTTGTTCAGAATCTTACTGCTAAAAGACTATTGTCCCCAACAGATTACTATGT
TGTTGGGTTTTGTTTTGGCTTTTATTTTTGACAATTAACCAAAATTTGTTCCACATTTG
TTCTAAAGTTACATTAATGGTTACTTGGTATTTGTTTAACTTTTGTCAAGCCACAAGCAGA
TCCTTATGAGAAAAGCATGTTCTAGTTGGAGAGAAAGTTTTCCAATGATGTGAGTTTTAA
AAAAAGGATTAGAAGACTGAAGAGGACAGAGAGACAGAGTTTGACAAGAAAATGTCAG
AAAGCAATATTTTAAAGAAAAATAAAGTGTTTTCAGTTTCAATTTTCTTTCAGTGGGTCA
GTTAGACATCTTATAATTAAGCTTGCATAATATTTAGCCAAATAATAGCCAGTTCTTTCAT
TGTTACAGAGAATCTTCAACCTGTACTCATGATAATATGACACTAACTTTTCTCCATGCAA
GATTTTGAATTATTTTAAATTATTTCTTCCCTCTTTTCCTTTTACTCTGCAGAGAACCAGGG
AGGTTCTCTTCTGAAATTCCTCCCAAGTTATCCTTCCTTCTGTGGGCTGAAATACTTTTTA
GATGTCAGTTAACCAGTCTATGGCTCTTCTCCCTATGTACCTAAGTCATTCCCACATATCA
TTACAAACGATGATACTGAATTGATACAGAAGTTGCCAAAATCTATTAACAGTCAGAGG
CTCACTGGAATAA 
SVMP_contig 2 BLAST ID: Agkistrodon contortrix microsatellite (Accession 
number GQ192660.1) 
AATACTCAAGCTATGCATCAAGCTTGGTACCGAGCTCGAGATGCATGCTCGTAGCGGCCG
CCAGTGTGATGGATATCTGCAGAATTCGCCCTTTGGACTACTTCATAATCATTAATGTTCC
CAGATTCCAGGATTATAGAGCTCCCTTTGTAAGGAAACAGAAAAGAAGGTTTTGTTTACT
TTGGGATATTATTTTACCATTTTCACATCCACAACACGATTTGTTATTCAGTTATCAGTGA
AGAAAGGAATCTTTTTCCAGTGGGACACAGCACAGAAGTTCAGATTTTCTCTGGAAATGC
AATTTGCTGAATGACGTTTGGGAGATGGAAGTCTAGGTGGAGACATTGCTTTGGCAGGTG
CAAAGGAAATATTTTGCAGCTTGAATAATCAGAAAAATATATAAACAAATCTGAACCAA
TGTGCAAGTTTGTGCACTGAGAGATAAGGCTAAGATGAGAAATCACAATAATCTGTTTCA
CATAGTTTAGTAAACCTACTGTATTATGGTTAGCATATCCATTAATCAAAAAGCTAGGCA
AACTTAGATTTTTATGCAAATGCAACTTATTAAGAATTCCCTTCAGTTGAACTGCTATTTC
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ACTGCCATCCTAATAGTTTGCTGACTTTCCTTTCTTTCATTTTTAAAAGAATCTATGGACA
GCCCACAGAATCTTAATTATCAAAGGGGCATCTAACAACATGTAAATAACTCAGTGGTTT
CAGAATTAGACTAATAGCAGAAAAAAATAGAGTTGGTCCCCATATGGATATTGTATGTTC
ACCTGGTATTTGCTCCTTGACTTATTTTGTAAATGTGGCAGTCTGACACCTGCAAGATCCT
TTTGGATGCACAATTACAACTGAGACCAAGATATGTTAGCAGATTAAAGGAAAGAAGGA
AAGAAGGAAAGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGA
AGGAAGGG 
SP_contig 1 BLAST ID: Vipera ammodytes ammodytin (Accession number 
AJ580214.1) 
TATCAAAAATTATATTTGTTTAATGCTGAAGGAGGAGAATACTATTGGGAGAAGGGAAG
CTCAAGGAAATATATTATCTATTGGTGTACTAATTATGGAAATTTTAAAAATAATTATTAT
TGACTGTTAATTAACTATTATTGATTGTATATCTTTTTTTTAAAAAAAATCATGAACCCAG
ACAACACGCTGCACACCAGGCACTAAGGTTGTTATTTAAAAAAAAAATTCAATAAAATT
CTTACCCCTCCTCCCCAAAAATAAAYAAATTTTGAGCTCAGTTGTGGTTGTAAAGTAGAG
GACTACCTGTAGATGGCTAAATCTGACTTTGCAAGTCTGCACAGCTATACTTTCCAGTGC
TTTTTTGCAYACSAGTTAGGGTCCTTGTACTGGAGCCAAAAACTGGGATCATYTTGGTCA
AATCACGACAAATGGCAAACATAAAGAGTAATTCCTGGTTTCAGGTTTAACATCCAAGA
AAATTAATTAGAAACAAAAAGGAATATTTGATTTTCCAGCTTCAGATCTAAAAATTAATA
TTCTTCACATCTCCAGTAATGCTGCAAATAGGTTAAAGAGCATGATTCTGAATAGCTTCA
GCCATTCCAATGGCTGAGATCTAAGGCATCTGGTCTTATGAGAAGCTTTGGCATATTTTG
CTTCACTTCTCCACTGCTCAGTAACTTAATGCCAGCCAGATTACACTAAGTAAGAAGTAA
GAAGAATAGCTCAGATGAGCTTCTAAAAAGGATGGACATTTAGAAGCACTTGGTCCAGA
GTGTCATCTTGCTATACTGCATTGCTAAGCAAAATCTATGGCCTCGTGATGGGGAGAATA
GGAGGCAGAAGGATTGAAAGTAGGAAAGAGATTGATGAAAATGGAATTTAATCTATGGG
AAGTTGATACCATTAGTATTTAGTTTGGATGGGAAGTTGATATTGTTATGTTGTGGGCTCT
GATGAGCAGGAATGAAGACACACAGACCAGCCCGGGCCGTCGACCACGCGTGCCCTATA
GTAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAA
GCTTGATGCATAGCTGAG 
SP_contig 2 BLAST ID: Vipera berus berus ammodytin (Accession number 
AJ580250.1) 
ATGCTGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTACTATAGGG
CACGCGTGGTCGACGGCCCCGGCTTCTTTACCGTCGCCTCGCGTAAACAGGGCGATGGGG
TGTGGGGACGCCGCCTGAGCGGATTCTTTACCGCTGCCGCCTGTATAAAGGGCGAAGGG
GCGTGGGGCGGTCACCGGAGCGGCTTCTTTCCCGCTGCCGCCCGTAAATAGGCCGAAGG
GGCGTCGGGCAATCGCCTGAGCAGCTCGTTTACCGCTGCTGCCCGTAAACAGGGCAAAG
TGGCGTGGGGCTGGAGCGGCTTCTTTACCGCTGCCGCCCGTAAATAGGGCGACGTGGCGT
GGGGAGGCCGCCGGAGCGGCTTCCTTACCGCTGCCGCCCGTAAACAGGGCGACGGGGCG
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TGGGGCCGGAGCGGCTTCTTTACCGCTGCTGCCCGTATAAAGGTCGAAGTGACGGGGGG
CGGCCGCCGGAGCGGCTTCTTTACCGTCGCGGCCCTATAGTGAGTCGTATTACTATGATA
TTCATTTATGTTACATTCATCACCTATGTTCATTTATATTACATTCATTACTGATGTTCA
TTTATGTTACATTCATCACCCTATAGGGCCCTATAGTGAGTCGTATTACACTGATGTTCAT
TTATGTTACATTCATCACCGATGTTCATTTATGTTACATTCATCACTGATGTTCATTTATGT
TACATTCATCACTCTATAGGGCCCTATAGTGAGTCGTATTACACTGATGTTCATTTATGTT
ACATTCATCACCGATGTTCATTTATGTTACATTCATCACTGATGTTCATTTATGTTACATTC
ATCACCCTATAGTGAGTCGTATTACAGTGATGTTCATTTATGTTACATTCATCACCTTATA
GGGCCCTATAGTGAGTCGTATTACATGATGTTCATTTATGTTACATTCATCACCCTATAGT
GAGTTGATGTTCATTTATGTTACATTCATCACTGATGTTCATTTATGTTACATTCATCACC
CTATAGTGAGGGATGTTCATTTATGTTACATTCATCACCCGATAAGGTCATTTA 
SP_contig 3 BLAST ID: Vipera aspis aspis ammodytin (Accession number 
AJ580156.1) 
GGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCC
TTCAATGACCAGTTCAGAAGACGTTTGTGCTGCAAAGAAATAAAAAAAGCTCAGTGTTTG
GCTGTGGAGTAGAACAGAATATCTTTTATTGGTAATGTTTCTATCAGTACACTAATATTG
AAGGGTAACAGATGACTGAGGGACACACAGCATCAAACCAGTTGAATAAAATGGAGATC
ACCAAAACTAAAAATGTATTTAAAATTTAGCTTTCCTCAGCGTCTGCTGAGATCGTCAGA
GTTTAAGCCAGGATTGAGGGCAGGAGCTCAATAGACCCGATGTTATGTACATAAGGGGT
GATCCTTGCAGCATGAGCCACTGACACCACCAGGTGGCATTGTACTATGTCTGGATTGGC
TGGGTGGCCACACAGTGGGAAATCYAGATAAGGGGATTGGTCCCAGGTATGCCTGGCCA
GGTATATATGAGGGACCAGTAGCCCCTTTGTTCCAGTTCAGTGCTAACATCAATAAAGAG
CTGTTATGCTGCACTCTGCTGTCCAGCGTTTGCCATGCAGTCCTTGCGGTCCAGAACTCAC
TACACAATTCCCGTAACATGCTCATTAGGTAAACTTTTGGCTTTGCAGAGACTATAAGAA
TGTGTCCCTTAATCCTGGCTTAAACTCTGACAATGTCAGCAGATGCTGACAAAAGCTAAG
TTTTAAATAAATTTTTAGTCTTGGTGATCTGCGTTTTTTGATGTTTTATAAGATTTCCAAAA
CAGGAGAGTTGATTTATTCAACAGGGAAGTGAAACAGACACTTTTATCACGCCCTGAATT
CACACTCCAGGATCGTAGTTATTTAAAGCAGGGTCTTTAGAGCACTTTATAAATTACAAT
ACCAATGAGCTGATTGTACTTTCAACCCATTAAACCAGTGTTTCTCAAGCTTGGCAACTT
AGAGATGTATGGATTTCAATTCCCAAAAGTCCCTGGCCAGCATGGCGAATTCTGGGAACT
GAGCTCCATATGCCTTCAAACTGCAAGAGAAAGGCCATAACCTGAAAGCTTGGACTGCA
AAGCTGGAGACAGATGTGTAGTACTTTCCACTCAGTCTCCCTGGC 
LAO_contig_1 BLAST ID: Echis ocellatus LAO (Accession number 
FM177950.1) 
GCTATGCATCAAGCTTGGTACCGAGCTCGGATGCATGCTCGAGCGGCCGCCAGTGTGATG
GATATCTGCAGAATTCGCCCTTACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGTAT
CAAATAAATGTACTATGTGTATTATGGATCATAGAAACCAACTGTTAATTATTTTTCTTTA
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CAAATGTAAACCCAGCAAACACACTGTTTACCAACTATTGAGTGATTTATGTTTTTAAAA
AAATCAATAAAATATATGGGGGGAAAATGTGTACAAAATCAATTAATGTCTGTGCATGG
GAAGTTTGAATGACAGTTTTGGAAGAGCGTCAGACTAACCAAATATCCACTTGGTGAGA
AATATTTGAGTAGAAGGATACTTTGAATGTTGTAATATTTGCAGAAATCTGGAAATCAGA
ATTGTCCCACCAACCAACATTCAAGTATTATACACTGGATGGCACAACACCCTGAGACCT
AGCCAATCAGAAAATCTCCAGATATAACAGAATAATAGAGTTGGAAGGGATCTTAAAGG
TCTTCTAATCCAATCCCCAGTTCAAGCAGGAAACGCTATAACAATTCTACACAAATGATG
TGTTGGGAGCACACACAACTTTTGGAAGCAAATTGTTCTGGAGGCAAGTTGTTAATTGTT
CTGTCAGGAAATTTCTCCTTAGTTCTAGGTTGGTTCTGTGAAGCACTTGAGTATAATTTTC
AGGCCAGATTAATTTCATTATAGGTATTATTACAGCTACTTGGGAGGATAATCTCAAAAA
ACTAAGCAAGTAAGAATTTGAATAAGAGTCCGCCAAGAAAATACTTGAGATTGGGAAGC
AAAACCCCTTCCAAGTAGCAACCCCTTTCATGCTGCTGCCAAGAAAAGAAGATGGACGTT
GAAATCGAAAAGAGTTAAGCTTGGGTTGAAGAGGACTTATTTGTGATGAGGTCCTTTGTG
TGACCAGAGAAGCAGAAGGAATGATTCTGTGTCCATTTTTCCTCATTTTATAGCAGTTTA
GATGTAGCGTAGGAGACCTCAGAAACTCTAGTTAGAAGGTGGTTCAATGACACATATAA
AAGAATGAAACAAATGAACAGAACCAGAGGCAAAAAATCCAGAATAAGAAAAAACAGG
AAAATGCCATCCTTGTACATATTCCATTTTTGTATGTGTTTTATCCAGTTATGTTCTCA
CTGCTGTTCTTGGCTACCTTGGGAAGCTGTGCAGATGACAAAAACCCCCTAGAGGA
ATGCTTCCGAGAAGCTGACTATGAAGAATTTCTAGAGATCGCCAGAAATGGTCTGA
AAAAGACATCAAACCCACAACACGTTGTGATTGTAGGAGCAGAAGGGCGAATTCTG
CAGATATCCATCACACTGGCGGCCGTTACTAGCATGGATCTCGAGCTCGGTACCAA
GCTTGATGCATAGC 
VEGF_contig_1 BLAST ID: Agkistrodon contortrix microsatellite (Accession 
number GQ184956.1) 
GGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCC
TTACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGTCCTGGAGGACCGTTGTCCGTAG
GGTCACAATGGGTCGGACACGACTGCGCAGCTAACAACAACAACATCATGCACTAAAGC
TCTTTCCACTTACCCTCCCTCTCCCCAAATAGTTGTTTAATGTTGCCCTTTAATTATTCAAA
ATAGCAAGAATAAGAGTTTACTTTTTAGGAGAAGACACCCTTCTGCCATTTTAATGGCAG
ATTGAGCTCTGCCATGGGGCCAGGCCCCCCTCACTTGAGATGCTTCCCACCCTGGCCTCG
GCCCTGGTAGGAAGCTGCCTCTGCCAGGCTGGGTTCCTTGGGGACCCTTGCTGGGGCAGC
CCTGGGCTGACAAAGGGGCCTGGACACGGGTATGGGGAGAACCTAGGGGAGCAGGCTG
AGCCCCAGGCATGCCCAGCCCTCTTTACCAGGAGCTGGGCAGGCTGCAAGGCACAGGGG
GCGGGGCATGTGGCTCTCTGATGCAATGCACTGGGGAGATGCCCCTCCTTCCAAGAGCAG
ACCCCCATGGGGACTCCTCCTTCCCCTTTTCCTCCTCCTCCTCCTCCTCCTTTCCTGGTTGC
AGAGCAACTGCTGCCCACCAGGAGCCCCCTGCACCAGAAGCCAAAGAACTGAGGAAGCT
TCTTTAATGAGAAGCAAAACATTTTCAAGGAAAAAATCCCAAGAAAGTCCAGTTGCCTTT
TGGAAAAAAGCACCTTTGGGACAACCACGATCTGGATGATGGAGAATCTCCAGAGACAT
CTAGAATAAATTGGCACCCGGTCCAGAAAGGAGGCAGCGCTGCCGATGGGCAATGGGGA
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GGGAGAAACGTAGAATCCCCTGGAGATCCGAGTGGGATCAACCCCCCCACCCCCCCAGT
GCAGAAGGAGGCGGAGGGGGCTCCACAGAGTCTTCCTTTGCAAGCAACAGAGGCTCCAA
GGAACCGGAAGGCAACTGTGCCCGCAGCATCGCCCGACTCGCCAGTTCAGACTCTTCCG
GGAGCCAGGAAGAGACGGAGAAAGACCCCTCAGTCAACCAGTGGACTGCAGAAGAGAT
AATTATTCCTATTTAAGAGTACGTTCTCCATTAAGCGAAGAGGCGGGATTGGCTTTGAGC
CAAACTTGTATGGCTGCTGCAAAGCCAGAATATGAAAGCCTGAGGCAGAAGACTTTTGC
CACCAGGCAAGAAAGAGATCTCAAGCAAGCAAGTCGGAGAAAAGGAGGAAAACTAGAT
AACCTTTGGGTCACCCTTTCAGAGATAGTGCCTTACCTACACAGATCCACAGGGTGGCCA
CAGGCAGTGGAAGCAGGAAGGACTTCTGACTTCCTGCTGGCTTCCCCATTGAGTTTCCTT
GTGGGAAGTTGGCAGAGAGAAAGTCAACGGGGAAACTGGCAGGGGAGGCCACAAGTTG
CTCTGGTAAGTTTCCCCCATCTGTGCACATTCCCTAGCCCATTCCTGAGTACTCTCAATCA
ATCAATCAATCAATCAATCAGAATAGAGCTGGAAAGGACCTTGGAGTCTTCTAGTCCAAC
GCCCCTGGCTCAAGGAGGACACCCTATACCATTTCTGACAAGCAACTGTCCAGTCTCTTC
TTGAAAGCCTCCAGTGTTGAAGCACCCATAATTTCTAGAGGCAGATTGTTCCACTGGTTA
ATTGTCCTCAATTATTCTTCTTAATTTCAGACTGCTTCTCCCCGCGATTAGTTTCCAACCGT
CGGCACTAACATAGGCACTAACATAGTCGAAGCCAAAAACTGAGTTCCCCTGCCTTGAG
CACCGAGTATCAAAGCACAATTTCTTCCCCCAGCTAACAGTCACAAATTACAATCCCCAC
TTAGTTTGAAATGCGAGCTTCCCCCCAGCTCTCCAGCCTGCCAATTCTTTATCATCTCTTA
TTTCAATTACCTTGGTTCTCACACTCGTGTCCATACTTGAAGAGTACCCTGATAAGGGC
GAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGATGC
ATAGCTTGA 
KTI_contig_1 BLAST ID: Bothrops atrox batroxobin serine protease (Accession 
number X12747.1) 
GGCGAATTGGGCCCTCTAGATGCATGGCTCGAGCGGCCGCCAGTGGTGATGGATATCTGC
AGAATTCGCCCTTACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGTCCTGGTTGGTG
CAAATGGGGAAGACCATTGCTGTATTTGTAATGATAGTATGAATTGATATATTTATTTATT
AGACCAAAGCTAGCCAATTAAAAATATATAATCTCAAATATGGTCAGCTTCCTTACGTGT
TTCTATTTATTTGGCATCTGACTTCAATAGAAGAAGATAACTTATTAATTAATATAAGATG
CATTGAGAAAAAAGTTGGGGAGTGGTTTGGAATGTTAAGGTTGTCTTGATAAAATGCCAT
TGATTTTTGTCCACACTGGTAAAATAATCTGTTGGATTTAAGCTAGCTCCCATTCTGTTAG
TTTTGCTGCATTATACAGCATGCAATATCTGGGCCAGTGCTTCAGAAACAAATATCAAAC
CTGGTATGTAGGGATTTCACTGCCATCAGTGTTGGCTCAAACTCTTTTTAGTGAATATTTA
TTTTTAGTGAACTAAATGTTATCAACTTCCCAGAGATTAAATTGCATTTTCATCAATCTCT
TCCCCATTTTCACTGCTTCTGTCCCTTATTCTCCCCATCACGAGGCCATATATTTTGCTTAG
CAATGCAGAACAGCAAGATCACAATCTGGGCCAAGTGCTTCTAAATGTCCATCCTTTTTA
GAAGCTCATCTGAACTATTCTTCTTACTTCAACTGTTTAGCGTAATCTGGCTGGCAGTGAT
ACCATTAAGTTACTGAGCAGCAGAGAAGTGAAGCAGAATATGCCAGTGTTTCTCATAAG
ACCAGATACCTTAGATCTTAGCCATCAGAATGGCTGATGCTATTCAGAATCATGCTGTTT
AACCTATTTGTACCATTACTGGAGATRTGAAGAATGATAATTTTTAGATCTGAAACTTG
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AAAATCAAATATTTCTTTTTGCTTCTACTTAATTTCTCTTGGGTTGTTTGCCATATGTCCTG
ATTTGATTAAGATGATCCCAGTTTTTGGCTCCAGTACAAGCACCCTAACTGGTGTGC 
KTI_contig_2 BLAST ID: Bothrops atrox batroxobin serine protease (Accession 
number X12747.1) 
ACATATACACACACAAACACACAATACACATACACACACAGAGAGAGAGAGACACACA
CACACAGACACATTTTTTATACATTAAAAAACGGAGATCACCAAGACTAAAAAAATTATT
TAAAATTTAGCTTTCTTCAGTGTTTAGCCAGGATTGAGGGACACATTCTTATATTCTCTGC
AAAGCCAATAGTTTAGCTAATGAGTGTGTTACGGGTTTCTTCGTCTCCTGCCCTCAATACT
GGCTTAAACTCTTACAATGTCAGCACACGGTGATGAAAGCTAAGTTTTAAATAATTTTTT
ACTCTTGGTGATCTCTGTTTTATTCAACTGGTTTGATACTATGTGTCCCACATTTAACTCTT
ACCCTCCAAAATTAGTGTACTGACAGAAACTCTACCAATGAAAGCGATTCGGTTCTACTC
TACAGCCAAACACTGAACTGTTTTGATTTCTTTGCAGCACAAAAGTCTTCTGAACTGGTC
ATTGGAGGTGATGAATGTGACATAAATGAACATCCTTTCCTTGCACTCATCTATAACTCT
ACATCTATGAGGTTTCACTGTTCTGGGACTTTGCTCAACCAGGAATGGGTGGTCACCGCT
AAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGC
TTGATGCATAGCTTGAGTATTCTAACGCGTCCCTAAAGC 
PDI_contig 1 BLAST ID: Vipera ammodytes ammodytin (Accession number 
AJ580214.1) 
TGTGATGGATATCTGCAGAATTCGCCCTTACTATAGGGCACGCGTGGTCGACGGCCCGGG
CTGGTCTGCAACAGGATTTGCGCTGATTCTGGCTTGTCACTGGCCCAGGCGCCGGCGGAG
TGTTTAGCCTGCAAATATCCCGGCAACCTTGGCTGTGGGCGACTAACGAAAGCTGTGCAG
GAAAGCGAGCATAAAACGATAAATGTTGCTTTCCGGACCCGAATAGCAAGCAGTAAGGC
CTGCGCGAAATATGAAGAAATTGCATCGCATCGCGAAAAAGAGGGGTGTGCGGCTTAAG
TGAAGGCGTTGGATAAAGTGTCAGGTGTGCAGGGGTAGTTGTGTGTTCCCCGCAGATCCT
CTATGCTATTCACGGATAGACATTTTTTTAAAAAAAAAATAATAGAGCGAAATATTGTAC
AACGGGGGAGTTGAGTACCTTTTATCAAGAGACTTGTAAATTCTGGCTTAAAGTAATCTA
GAAAGGTACCATACTTTTTCTAAAATACTGCCTTGGTTGTAAGAAAACTGCGCCCCCCCT
TTTTTTTTTTTGCTGCTCTACGTACACGTCTTAATTTTGTGAGACGTGACTCCCCACATGTG
GAAGGCATGAGGGATGGTGTAATTCCTACTATGTTCCTGCTAATTTCCTTAATAAAACAG
TTGCACTTTCTGCTGCTCAGCTTTGAAAGGAAAGTTAAAGTAGTCTACTTTTTTTCTCAGC
ATTAACTTTTAAATAGTGTTAAAAGCCTAGTAGTTTATCAAATGTTTATCACAGTCAAGG
ATTTCTGGAGTAATTTTGGCACACAATGCTTTGCACTAATGCGGCAATTGCTTATAAGGT
GAGAGCTATACCAAGCATTTTTTAAATTAAGGGTCTATTGTGGCATTCTAAAGCTGAATG
ATATACCTCAAACATTTTTAGGCACTTTTTAAAGTGAAATTTTCCTGTAGGAGAATAATG
CACTTTTACTGTGAAAATTCATGGGGCTAGATAAGTTTATAGACAGTATTATAAATTAAA
GTTGAAATGTTTTGAATAAAATTTTGGATATCATTCTATTGGAGGATAATTCTTGAGAAA
TTTTTGCAATGCTACTGGCATTTTTACGAATGGAAGGTATCCGTAGAAAATACACAAT
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Appendix IX: Sequences and BLAST analysis of PCR products amplified and 
cloned from genome walker libraries: Protein families with highest sequences 
homology were assigned to genomic sequences amplified from genome walker 
libraries for snake venom metalloproteinase (SVMP), serine protease (SP), L-amino 
acid oxidase (LAO), vascular endothelial growth factor (VEGF), Kunitz inhibitors 
(KTI) and protein disulphide isomerase (PDI). Underlined in black (bold) indicates 
the open reading frame (ORF) predicted by ORF Finder (NCBI, 2012b), grey shaded 
area indicates sequences matching BLAST hits and underlined in red (bold) indicates 
exons predicted by Wise2 (NCBI, 2012c). 
TCATTTGATGCTGTGTTTTCTAGATGTTCATTTTTTTTTTTCCACAGATGCACCATGG
TGTGGTCACTGTAAAGCTCAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGT
GGATCCGAGCTCGGTACCAAGCTTGATGCATAGCTTGAGTATTCTAACGCGTCACT 
PDI_contig 2 BLAST ID: Vipera aspis aspis ammodytin (Accession number 
AJ580156.1) 
GGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAG
AATTCGCCCTTACTATAGGGCACGCGTGGTCGACTGCCCGGGCTGGTCTGGAAAAGCTGG
CACCCAAAGCATCATGCAATGGGGCGAGTTTCTGTCCTCACCCCAGCTCCTGACAATCTA
TCAGTAAAATCCAGACTCCTTTTACCTTTTTCTTATATTATTCACATTTGTTAACATGTGCC
ACAAATGTAGCACCCCACTCTCATATATTTATTTTTATGCAAGATAGAAAAGGATTGTAC
TGATATGAAAAGTGCTCCAATTTTCATAAAAACAAGCCAAATGATACTGTTTCTTCTTAC
TTCTTTTATTATTTTTGTAATCATTTGGTTCTGTAGTTTTGTTGTGTGTGTGTTTTAAAAAT
ATATAAACGCATGAATAAACGGTTTGGAGAATATTTATTCTTTTTAAGCCACCCAGTAAT
GGTTAAACTGGAAGGCAAGACTTTTATCTCAGAAGCAGCGAAAGACCACTTCAGCCTAC
ATTCCTTGTCCCAGGCAAGTGCGTTACTAAGTATCCTCGACCCTCCCACAAGTAATTTTGC
AATCAGCCCAGTTCCCACTCATACATCATCTCACCCATTCTTTATAGGCAGTTTGACGTAC
TACACAGATTCATCCACACATTTCATATTTCCCACCACTCAGTCAATTATTTTCCTCTCTTC
TCCCCAACCAACGACATCTCAAACAGAAAACGCCTACATATGTTTGATTTCTTCTAACCG
GAAATACTTGTTGCTTATTATTCCGGGTATCTTATAAAACGCGGTCCAGTCAGAATCAAA
CACGAACGAGACCTCTCCAATACGCATGCGCATTACGAAACGGGCAGGCTTCCTAGATG
CCACGTTCCAAAGGCGAGAGGTGAAATGTAATGGAGGAAGAGATAGACTCCGTTTAAGC
TTTCACCGAGCAACCAATCAAAGCCGGTTGAACCAGTGAACGAGAACGGCGCTGTTGTC
CAATCGCAGCCAACAAAGAAGTCTGACAAACCAATCCTAGTTGACGGAACGTA 
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